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Postnatal growth and regeneration of skeletal muscles depend on the activity of satellite 
cells, resident muscle stem cells defined by their location between the basal lamina and the 
muscle fibre plasma membrane. In response to injury or disease satellite cells activate, 
proliferate and eventually differentiate and fuse to one another to form new muscle fibres, or 
to existing damaged fibres to repair them. The microenvironment surrounding satellite cells, 
called the satellite cell niche, plays a crucial role in muscle regeneration. Heparan sulfate 
(HS) is a highly negatively charged, sulfated polysaccharide present on the surface of almost 
all mammalian cells or residing in the extracellular matrix. HS is usually bound to a core 
protein termed heparan sulfate proteoglycans (HSPGs). The HS component of the HSPG 
exhibits a high level of structural variability since it can vary in chain length and notably, in 
the pattern of sulfation along the length of the HS chain, leading to distinct chemical 
properties. As a consequence, HS is able to interact with numerous proteins, and thus plays 
a key role in the regulation of multiple cell processes. A number of HSPGs are expressed in 
muscle precursors during embryonic development and in satellite cells during postnatal life. 
However, the changes that muscle HS undergoes during satellite cell differentiation are 
unknown. In this project, it is shown that the sulfation levels of HS increase during satellite 
cell-derived myoblast differentiation. Interestingly, a specific increase in 6-O sulfation is also 
observed in HS from ageing muscle, which is shown to lead to promotion of FGF2 signalling 
and satellite cell proliferation, suggesting a role for HS in age-associated loss of satellite cell 
quiescence. Addition of chemically modified heparins (referred to as HS mimetics) to 
differentiating satellite cell derived-myoblast cultures results in differential effects depending 
on the pattern and level of sulfation: an oversulfated HS mimetic inhibits FGF2 signalling, a 
known major promoter of myoblast proliferation and inhibitor of differentiation. In contrast, 
FGF2 signalling is promoted by an N-acetylated HS mimetic, which inhibits differentiation 
and promotes satellite cell-derived myoblast expansion. The effects of a new class of fully 
synthetic HS mimetics (referred to as HS mimetic clusters), has been investigated on 
differentiating satellite cell derived-myoblast cultures. Finally, a new HS mimetic cluster has 
been synthesised and tested for its effects on differentiating satellite cell-derived myoblast 
cultures. Overall, these HS mimetic clusters have differential effects on myoblast 
differentiation. Thus, it can be concluded that the HS complement of the satellite cell niche is 
dynamically regulated during muscle differentiation and ageing, and that such changes might 
account for some of the phenotypes and signalling events that are associated with these 
processes. Furthermore, a novel class of HS mimetic clusters may offer promising 
therapeutic candidates for HS-mediated signalling events in muscle ageing and disease. 
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Chapter 1 
 
 
 
1 Introduction 
1.1 The Big Picture 
 
Skeletal muscle wasting is a significant problem within the ageing population. During ageing 
skeletal muscle becomes weaker, smaller and muscle regeneration becomes impaired. 
Overall, loss of muscle leads to frailty, lack of independence and increased risk of mortality. 
A similar process also occurs in muscle wasting diseases such as muscular dystrophy, 
characterised by progressive skeletal muscle degeneration, loss of muscle mass, muscle 
weakness and extensive fibrosis. Considerable research is focused on understanding the 
mechanisms involved in skeletal muscle degeneration and regeneration, however, 
information is still lacking regarding the components of the extracellular matrix that play 
critical roles in skeletal muscle maintenance. This thesis aims to better understand the 
dynamic expression of heparan sulfate, with differing sugar sequences, a major component 
of the muscle stem cell niche, in an attempt to increase knowledge of how muscle growth 
and regeneration are controlled and the molecular mechanisms that are involved. The 
results presented in this thesis have the potential to open up promising new therapeutic 
avenues for the treatment of muscle wasting in ageing and in muscle degenerative diseases.  
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1.2 Introduction Outline  
 
This introduction is presented in four parts; 
 
1. Skeletal Muscle, Myogenesis and Muscle Ageing: I will introduce skeletal muscle 
anatomy and biology, and the molecular mechanisms that are involved in muscle 
growth and regeneration.  
2. Heparan Sulfate Proteoglycans (HSPGs): I will introduce HSPGs, with a focus on 
the heparan sulfate (HS) component discussing its biosynthesis, structural 
importance and biological roles.  
3. Heparan Sulfate and Heparan Sulfate Proteoglycans in Myogenesis: I will discuss 
the involvement of HSPGs in myogenesis and will review the current literature.  
4. Structural Analysis of Heparan Sulfate: I will review the current methods for 
analysing the structure of HS and methods for determining structure-function 
relationships as well as the use of HS mimetics to interfere with HS-regulated 
biological processes.   
 
 
1.3 Skeletal Muscle and Myogenesis 
 
1.3.1 Structure of Skeletal Muscle  
 
Skeletal muscle, also known as striated muscle, is anchored to the bone by tendons and 
functions under conscious control to move the skeleton, control breathing and maintain 
posture. Skeletal muscle consists of bundles of muscle fibres, known as myofibres, which 
are elongated, nearly cylindrical, multinucleated cells (Figure 1.1). In healthy myofibres the 
nuclei are located at the periphery of the cell under the plasma membrane termed the 
sarcolemma. Each myofibre is packed with myofibrils, which extend the length of the cell. 
The myofibrils are further subdivided into alternating light bands termed I bands and dark 
bands, termed the A bands. A segment containing one half of an I band and one half of an A 
band is termed a sarcomere, which is the structural and functional unit of skeletal muscle. 
Each sarcomere contains thick filaments composed of myosin II protein and thin filaments 
containing actin protein. It is the interaction between actin filaments and myosin that allows 
the contraction of muscle cells. Myosin acts as the ‘motor’, the actin filaments are the tracks 
along which myosin moves and adenine triphosphate (ATP) is the fuel that powers 
movement. The endomysium, the connective tissue that surrounds the individual muscle 
fibres, includes the basal lamina produced by the myofibre and extracellular matrix produced 
by surrounding fibroblasts. The endomysium provides the chemical environment for the 
exchange of ions required for myofibre excitation.  
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Figure 1.1 The Structure of Skeletel Muscle. 
Simplified view of the relationship of the anatomic structure of skeletal muscle consisting of 
bundles of myofibres. Each myofibre is packed with myofibrils, which comprise dark A bands and 
light I bands. These form the structural and functional unit of skeletal muscle; the sarcomere. 
Each sarcormere conatins thick filaments, made up of myosin, and thin filaments, made up of 
actin. It is the interaction between actin and myosin that allows for muscle contraction. (Image 
adapted from optistem.org) 
 
1.3.2 The Muscle Stem Cell: Satellite Cells  
 
Skeletal muscle satellite cells are myogenic stem cells responsible for muscle development, 
growth and regeneration, defined anatomically by their location between the basal lamina 
and the sarcolemma of terminally differentiated myofibres (Mauro, 1961) (Figure 1.2). 
Satellite cells represent less than 2% of the nuclear content of myofibres and are present in 
a quiescent state (G0 of the cell cycle) in adult muscle (Allbrook et al., 1971).   
 
 
 
 
 
 
 
Figure 1.2 The Satellite Cell. 
A) Electron micrography showing a satellite cell between the basal lamina and sarcolemma first 
discovered in 1961 in frog muscle (Mauro, 1961). B) A myofibre where myonuclei are stained with 
DAPI. The satellite cell is in green detected with an anti-syndecan-3 antibody where the scale bar 
= 50 µm (Pisconti, unpublished). 
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1.3.3 Myogenesis 
 
Quiescent satellite cells are the only cell type expressing the paired box transcription factor, 
Pax7. In skeletal muscle Pax7+ satellite cells are indispensable for muscle regeneration 
(Lepper et al., 2011; Murphy et al., 2011; Sambasivan et al., 2011). Satellite cells become 
activated in response to a stress such as injury or exercise, enter the cell cycle and convert 
into muscle progenitor cells known as myoblasts (Figure 1.3) (Reznik, 1969). Myoblasts 
then undergo terminal differentiation, withdrawing from the cell cycle, and fusion either with 
one another to form multinucleated myotubes, or with damaged myofibres (Morgan and 
Partridge, 2003; Reznik, 1969). A proportion of satellite cells self-renew, generating an 
identical, undifferentiated cell that can return to a quiescent state in order to maintain full 
muscle regenerative capacity (Charge and Rudnicki, 2004). A wide variety of signalling 
molecules in the microenvironment surrounding the satellite cell, known as the satellite cell 
niche, control satellite cell fate regulation and thus the process of skeletal muscle growth and 
regeneration (Bentzinger et al., 2012). 
 
1.3.4 Molecular Regulation of Myogenesis 
 
Many signalling pathways are involved in the regulation of skeletal muscle growth and 
regeneration, which are governed by the satellite cell itself or the satellite cell niche. These 
pathways affect the expression of the myogenic regulatory factors (MRFs), a family of 
transcription factors that are exclusively expressed in myogenic cells and activate the 
expression of muscle specific genes (Londhe and Davie, 2011). The MRFs consist of the 
basic helix-loop-helix transcription factors MyoD (Davis et al., 1987), Myf-5 (Braun et al., 
1989), myogenin (Edmondson and Olson, 1990) and MRF4 (Rhodes and Konieczny, 1989). 
The expression of the MRFs changes depending on the stage of myogenesis reflecting 
distinct roles of the MRFs in the regulation of satellite cell commitment and differentiation 
(Sabourin and Rudnicki, 2000). Quiescent satellite cells express Paired box 7 (Pax7) at the 
mRNA and the protein level and Myf5 and MyoD mRNAs, which are not translated (Crist et 
al., 2012; Hausburg et al., 2015; Montarras et al., 2013). Upon activation, Myf5 is translated 
and MyoD expression is induced, thus activated satellite cells co-express Pax7 with MyoD 
and Myf5 (Cooper et al., 1999; Zammit et al., 2004). The majority of satellite cells proliferate, 
down-regulate Pax7 and up-regulate Myf5 and MyoD which then in turn drive myogenic 
differentiation. After one or more rounds of proliferation, the majority of myoblasts will 
withdraw from the cell cycle indicating commitment to terminal differentiation by the 
expression of myogenin (Edmondson and Olson, 1990) and MRF4 (Figure 1.3). 
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Figure 1.3 Scheme of Satellite Cell Myogenesis.
Satellite cells become activated in response to a stress such as injury, enter the cell cycle and 
convert into myoblasts (Reznik, 1969) expressing MyoD, Myf5 and replicating DNA (detectable 
via BrdU incorporation). Myoblasts undergo terminal differentiation, withdrawing from the cell 
cycle and fusing either with one another to form multinucleated myotubes, or with damaged 
myofibres (Morgan and Partridge, 2003; Reznik, 1969) expressing, MyoD, Myf5, myogenin and 
Mrf4. A proportion of SCs self-renew returning to a quiescent state, expressing Pax7, in order to 
maintain full muscle regenerative capacity (Charge and Rudnicki, 2004). 
 
1.3.5 The Satellite Cell Niche: The Extracellular Matrix 
 
The extracellular matrix (ECM) surrounding each individual myofibre is a basement 
membrane consisting of two layers: the basal lamina and the reticular lamina. Satellite cells 
reside between the basal lamina and the myofibre sarcolemma, and therefore interact with 
basal lamina components. Thus, the ECM plays a crucial role in satellite cell regulation, as it 
directs a plethora of signalling pathways involved in cell migration, myotube formation and 
muscle regeneration (Barberi et al., 2013; Conboy and Rando, 2002; Le Grand et al., 2009; 
Urciuolo et al., 2013). Another major role of the ECM is to provide structural integrity to the 
satellite cell niche. The ECM is made up of collagens, which are the major structural proteins 
secreted primarily by muscle fibroblasts (Shea et al., 2010; Zou et al., 2008), laminins, 
fibronectin and glycosaminoglycans (GAGs) (Sanes, 2003). GAGs are long, unbranched 
polysaccharides consisting of repeating disaccharide units of an amino sugar and an uronic 
acid sugar, which are usually bound to a core protein to form proteoglycans, the properties 
of which will be discussed in detail in section 2 of the Introduction. 
 
 
Chapter 1                                                                                                                                 Introduction 
   
 
 
18 
1.3.5.1 Extracellular Matrix Composition 
 
Satellite cells bind directly to the basal lamina through their integrin receptors (Ervasti and 
Campbell, 1993; von der Mark et al., 1991) to collagen type IV and laminin, which are cross-
linked by the ECM glycoprotein nidogen forming the primary constituents of the basal lamina 
(Figure 1.4) (Ervasti, 2003; Sanes, 2003). This matrix complex is then able to bind to 
collagen type VI and many proteoglycans such as perlecan and decorin. Collagen type VI 
integrates the basal lamina with the reticular lamina composed predominantly of collagen 
types I and III and fibronectin (Rao et al., 1985). The myofibre sarcolemma is also linked to 
the basal lamina through the dystroglycan complex, which binds the actin cytoskeleton in the 
myofibre through dystrophin and to laminin in the basal lamina. The dystroglycan complex 
stabilizes the sarcolemma during contraction-induced stress and thus forms the basis for 
basement membrane architecture (Grounds et al., 2005).  
 
 
Figure 1.4 Schematic Diagram of the Satellite Cell Niche 
Satellite cells reside between the myofibre sarcoelmma and the basal lamina where they are able 
to interact with ECM components of the satellite niche through their integrins. Through their 
integrins, satellite cells are able to interact with collagen type IV and laminins, which are 
crosslinked with the glycoprotein nidogen. The matrix formed is then able to interact with 
colllagen type VI and various proteolglycans. Collagen type VI of the basal lamina is also able to 
interact with the reticular lamina via primarily with collagen type I and fibronectin. The myofibre 
sarcolemma also interacts with the basal lamina through the dystroglycan complex.  
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1.3.5.2 Extracellular Matrix Remodelling 
 
As well as providing structural integrity, proteoglycans, such as perlecan, which reside in the 
basal lamina, are able to bind and sequester growth factors and thus serve a significant 
signalling role in the satellite cell niche during muscle growth and regeneration as reviewed 
in (Yin et al., 2013). Myogenesis and muscle regeneration post-injury are associated with 
significant remodelling of the basal lamina, reflecting the differing requirements for growth 
factor signalling (Kovanen, 2002).   
 
1.3.6 Growth Factor Signalling in Myogenesis 
 
A wide variety of signalling molecules in the satellite cell niche inhibit or stimulate the 
expression of the MRFs and thus control satellite cell fate (Bentzinger et al., 2012; Olguín 
and Pisconti, 2012). Some of the key extrinsic regulatory factors that are involved in the 
regulation of myogenesis are: fibroblast growth factors (FGFs), insulin-like growth factors 
(IGFs), hepatocyte growth factor (HGF) and transforming growth factor-β (TGF-β). FGF, and 
HGF activate myoblast proliferation and are potent inhibitors of myogenic differentiation and 
thus repress MRF activity (Clegg et al., 1987; Evinger-Hodges et al., 1982; Schabort et al., 
2009; Sheehan and Allen, 1999; Tatsumi and Allen, 2004). IGF on the other hand promotes 
both proliferation and subsequently differentiation (Jennische and Hansson, 1987).  
1.3.6.1 FGF signalling  
 
One of the most well studied growth factor families that regulate self-renewal, proliferation 
and differentiation of multiple cell types, including the regulation of satellite cell fate, are the 
fibroblast growth factors (FGFs) (Coutu and Galipeau, 2011; Hannon et al., 1996; Lanner et 
al., 2010; Olwin et al., 1994).  The FGFs are a family of 22 structurally related members, 
which signal via a family of 4 transmembrane tyrosine kinase high affinity receptors (FGFR1, 
FGFR2, FGFR3 and FGFR4), (Eswarakumar et al., 2005). FGF signalling is also reliant on 
the presence of heparan sulfate, a structurally complex glycosaminoglycan (GAG) that acts 
as a low affinity co-receptor. The structural importance of HS and its regulatory properties in 
FGF signalling will be discussed in detail in section 2 of the Introduction.  
 
1.3.6.2 FGF Signalling in Myogenesis 
 
FGF signalling plays an important role in skeletal muscle development (Clegg et al., 1987; 
Olwin et al., 1994; Seed and Hauschka, 1988) mostly by controlling muscle differentiation 
(Clegg et al., 1987). Previous studies have demonstrated that distinct FGF pathways are 
involved in the regulation of myogenesis (Kudla et al., 1998), which cannot be recapitulated 
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by stimulation of other growth factor receptors (Hannon et al., 1996; Lim and Hauschka, 
1984; Linkhart et al., 1980). Specifically, FGF signalling activates mitogen-activated protein 
kinase (MAPK) pathways (Campbell et al., 1995; Milasincic et al., 1996; Mourey et al., 
1996).  Proliferating MM14 myoblasts, a satellite cell-derived cell line, express FGF1, FGF2, 
FGF6 and FGF7 mRNA (Clegg et al., 1987; Fedorov et al., 1998; Hannon et al., 1996; Kudla 
et al., 1998). Myofibre cultures exposed to FGF2 have a twofold increase in the number of 
proliferating myoblasts by 48 hours in culture (Yablonka-Reuveni and Rivera, 1997). In vivo 
FGF2 is believed to enhance myogenic proliferation by facilitating the recruitment of 
additional satellite cells from the quiescent state thus effectively being an activating factor 
(Yablonka-Reuveni et al., 1999). FGFR1 is the only FGF receptor detected in MM14 
myoblasts (Kudla et al., 1998; Templeton and Hauschka, 1992). Genetic ablation of FGFR1 
results in significantly reduced satellite cell mitogenic response to FGF2 in isolated fibres 
suggesting an important role for FGFR1 in FGF2 signalling (Yablonka-Reuveni et al., 2015). 
However, FGFR1 ablation does not supress subsequent myogenic differentiation or have 
significant effects on muscle regeneration (Yablonka-Reuveni et al., 2015). 
 
 
1.3.7 Skeletal Muscle Ageing 
 
Ageing is often associated with sarcopenia, defined as the loss of muscle mass, strength 
and function during ageing in the absence of a specific disease (Morley et al., 2001). In the 
development of sarcopenia, the loss of muscle mass appears to be irrecoverable 
(Roubenoff, 2001). Since satellite cells are responsible for muscle regeneration and 
maintenance, it is reasonable to speculate that there is a decline in the number of satellite 
cells and/or that they become dysfunctional during ageing leading to reduced regenerative 
potential.  
1.3.7.1 Satellite Cell Decline During Ageing 
 
There have been several reports supporting the hypothesis that the number of satellite cells 
declines during ageing (Brack et al., 2005; Collins et al., 2007; Dedkov et al., 2003; Gibson 
and Schultz, 1983; Neal et al., 2012; Shefer et al., 2006). Although, in some cases the 
significant decline in satellite cell numbers only becomes apparent in geriatric (>26 months) 
mice (Brack and Rando, 2007; García-Prat et al., 2013). However, other studies have shown 
contradictory findings, suggesting that there are no significant differences in the number of 
satellite cells between young and aged muscle (Nnodim, 2000; Schäfer et al., 2005). 
Furthermore, the ablation of satellite cells in young mice does not cause sarcopenia with 
ageing, suggesting that the development of sarcopenia is not dependent on the number of 
satellite cells in the absence of injury (Fry et al., 2015). However, it has previously been 
demonstrated that there is a subpopulation of satellite cells that maintains a healthy 
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phenotype during ageing, and these cells are primarily responsible for muscle regeneration 
in aged mice (Collins et al., 2007). Thus, it is possible that in the ablation model (Fry et al., 
2015), the number of satellite cells is not entirely eliminated and a progeny of healthy 
satellite cells remain, thereby providing the basis for extensive self-renewal and regenerative 
capacity. The number of satellite cells, does however, become a limiting factor for 
regenerative capacity after injury (Boldrin et al., 2012; Chakkalakal et al., 2012; Neal et al., 
2012). Furthermore, satellite cell depletion in young mice leads with ageing to ECM 
accumulation as measured by an increase in collagens and specifically an increase in the 
level of N-acetyl-glucosamine residues (Fry et al., 2015). 
1.3.7.2 Intrinsic Defects in Satellite Cells During Ageing  
 
There have been many studies suggesting that satellite cells become dysfunctional during 
ageing, as they display a reduction in their ability to self-renew and thus lose their 
regenerative capacity (Bernet et al., 2014; Chakkalakal et al., 2012; Conboy et al., 2003; 
Cosgrove et al., 2014; Day et al., 2010; Sousa-Victor et al., 2014a). So far, evidence 
suggests that loss of satellite cell regenerative capacity in ageing is due to both intrinsic 
impairment and changes in molecular signalling that occur in the satellite cell niche. 
 
Through the transplantation of aged satellite cells and young satellite cells in equivalent in 
vivo models, it has been demonstrated that the age-dependent dysfunction of satellite cells 
is in part due to intrinsic defects including both defects in self-renewal and defects in satellite 
cell contribution to myofibre formation (Bernet et al., 2014; Chakkalakal et al., 2012; 
Cosgrove et al., 2014; Price et al., 2014; Sousa-Victor et al., 2014b). These intrinsic defects 
arise from a combination of altered activation of signal transductions, such as: altered 
p38α/β mitogen-activated protein kinase (MAPK) signalling (Bernet et al., 2014) and FGFR-
Sprouty1 signalling (Chakkalakal et al., 2012). However, it has been demonstrated that a 
small portion of satellite cells maintain the regenerative capacity of young satellite cells, and 
are capable of robust regeneration after engraftment into an ‘injury setting,’ indicating that a 
progeny of satellite cells does not become intrinsically defective during ageing (Collins et al., 
2007).  
 
1.3.7.3 Extrinsic Influences on Satellite cell Function During Ageing  
 
In contrast to findings that intrinsic defects persist in engraftment studies, there is evidence 
from experiments of parabiosis that the extracellular environment significantly contributes to 
satellite cell function. Indeed the myogenic potential of aged satellite cells is restored through 
exposure to a young environment via parabiosis (Conboy et al., 2005). The discrepancies in 
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findings are likely to be due to differences in the procedures used to assess satellite cell 
engraftment, such as the recipient mouse age, which might strongly influence regenerative 
capacity as reviewed in (Brack and Muñoz-Cánoves, 2016). Moreover, more recent studies 
have implied that, although older cells maintain regenerative capacity when transplanted into 
a young environment, they nonetheless delay the onset of regeneration upon engraftment 
(Shavlakadze et al., 2010; Smythe et al., 2008). These results suggest that a combination of 
both the intrinsic defects and considerable extrinsic influences on satellite cell regenerative 
capacity is likely to be responsible for muscle regeneration impairment during ageing. In 
support of this hypothesis, satellite cells from aged and young muscle have similar 
proliferative rates ex vivo, indicating that the aged muscle environment plays a crucial role in 
satellite cell fate (Alsharidah et al., 2013; George et al., 2010; Verdijk et al., 2014).  
 
Additionally, the levels of local and systemic inflammatory cytokines and growth factors 
significantly change with ageing (Chakkalakal et al., 2012). Myofibres are progressively 
replaced by fibrotic (Brack et al., 2007) and adipose tissue leading to an increase in the 
levels of TGF-β in the satellite cell niche (Carlson et al., 2008; Zacks and Sheff, 1982). 
Systemic attenuation of TGF-β signalling leads to muscle regeneration improvement in older 
mice (Yousef et al., 2015). Furthermore, it has been reported that the FGF signalling is 
increased in the satellite cell niche during ageing leading to an increase in satellite cell 
activation and proliferation which eventually leads to satellite cell exhaustion (Chakkalakal et 
al., 2012). Consistently, reducing FGF activity through inhibition of FGFR1 signalling 
diminishes satellite cell depletion in ageing muscle (Chakkalakal et al., 2012) as fewer 
satellite cells are stimulated to break quiescence.  
 
Overall, the data strongly support the contention that ageing is associated with changes both 
within satellite cells and their niche leading to quiescent satellite cell depletion and reduced 
regenerative capacity. However, it is still in question which factors are dominant in 
contributing to the ageing phenotype. Understanding the sources of dysregulated cytokine 
and growth factor signalling during ageing may identify new therapeutic targets in muscle for 
the treatment of defective regeneration and sarcopenia.  
 
1.4 Heparan Sulfate  
 
Heparan sulfate proteoglycans are biomolecules composed by a core protein harbouring 
covalently linked complex carbohydrate chains of the HS class (Sarrazin et al., 2011). 
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1.4.1 Carbohydrates 
 
Carbohydrates are a large class of biomolecules, which includes monosaccharides and their 
derivatives, oligosaccharides and polysaccharides. Generation of a polysaccharide chain 
starts with two monosaccharides being linked together by the glycosylation reaction, leading 
to either: 1) equatorial bond formation, where the bond makes a small angle compared with 
the plane of the ring or 2) axial bond formation, where the bond makes an angle of about 90° 
with the plane of the ring (Figure 1.5). The glycosidic bond involves at least one anomeric 
carbon (carbon 1), which are stereocentres of the monosaccharide. The resulting 
disaccharide contains a free anomeric carbon, which can be involved in further glycosylation 
reactions increasing the length of the polysaccharide chain. The anomeric end of sugar, 
which is involved in the glycosylation reaction, is termed the ‘reducing end.’ The non-
anomeric side of the polysaccharide is termed the ‘non-reducing end’. Polysaccharides 
contain large numbers of hydroxyl groups, which can be further functionalised (Figure 1.5).  
 
 
 
Figure 1.5 Scheme showing the glycosylation reaction. 
A general scheme showing the glycosylation reaction linking two monosaccharides of glucose 
together at the anomeric carbon (carbon 1) and carbon 4 to form a) equatorial glycosidic linkage 
and c) axial glycosidic linkages between the disaccharide maltose.  
 
1.4.2 Glycosaminoglycans 
 
HS is a member of the glycosaminoglycan (GAG) family, consisting of large linear 
polysaccharides with a repeating disaccharide unit of; a) an amino sugar, N-acetyl 
glucosamine (GlcN) for HS and b) an uronic acid residue, either iduronic acid (IdoA) or 
glucuronic acid (GlcA) (Figure 1.6). The GAG is defined by the specific disaccharide unit 
and the stereochemistry of the O-glycosidic linkage (Table 1.1). The structural complexity of 
the GAG chains is determined by the fact that they contain large numbers of hydroxyl 
groups, which are differentially functionalized with sulfate groups, giving rise to a highly 
negatively charged macromolecule capable of multiple electrostatic and other interactions. 
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The position and level of sulfation varies depending on the GAG species and its origin. The 
position of sulfation is identified by the carbon that the sulfate group is attached to on the 
monosaccharide ring, starting from the anomeric carbon, carbon 1, as depicted in Figure 
1.4.  
 
HS is present on the cell surfaces of nearly all mammalian cells, and is characterized by a 
linear chain of 10-200 disaccharide units of N-acetyl-D-glucosamine (GlcNAc) linked to D-
glucuronic acid (GlcA) with an average molecular weight of 25-100kDa. It has the most 
variable structure in the GAG family and, as a consequence, HS has the highest potential for 
functional diversity within the GAG family (Turnbull et al., 2001). Indeed, the different 
biological roles played by HS depend mostly on its structural composition, which arise from 
the different levels and patterns of sulfation and is termed the “heparanome” (Turnbull et al., 
2001). Structural analyses of HS indicate cell and tissue-specific HS compositions, 
highlighting the importance of specific structure-function activities (Lawrence et al., 2008; 
Ledin et al., 2004; Maccarana et al., 1996). 
 
 
 
Figure 1.6 Main monosaccharide units of the GAG family. 
The two amino sugars: a) glucosamine (GlcN) and b) galactosamine (GalN). The two uronic 
acids: c) glucuronic acid (GlcA) and d) iduronic acid (IdoA). e) The main disaccharide unit of HS. 
The monosaccharides  contain differing functional groups along the chain (R1, R2 and R3 
substitutions as indicated). 
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Table 1.1 GAG chains with corresponding major disaccharide units.
 The GAG chains with the corresponding main disaccharide unit and main glycosidic linkage 
between the disaccharide units throughout the GAG chain. 
 
GAG chain Major Disaccharide Glycosidic Linkage 
heparan sulfate D-GlcNAc - D-GlcA β(1—4) and α(1—4) 
heparin D-GlcNAc - L-IdoA β(1—4) 
chondroitin sulfate D-GalNAc - D-GlcA β(1—4) 
dermatan sulfate D-GalNAc - L-IdoA β(1—3) 
keratan sulfate D-Gal- D-GlcNAc β(1—4) 
 
 
1.4.3 Heparan Sulfate Biosynthesis 
1.4.3.1 Conventional HS Biosynthetic pathway 
 
HS is synthesized in a dynamic manner with extensive structural modifications throughout 
and thus HS should be considered a heterogeneous family of structurally related molecules 
each with distinct functional properties. Families of HS biosynthetic enzymes are responsible 
for HS synthesis, which occurs in the Golgi apparatus following a non-templated scheme. 
The action of each enzyme does not go to completion throughout the entire HS chain 
(Turnbull et al., 2001) resulting in a high degree of structural diversity (Figure 1.7). Although 
the biosynthetic pathway remains a topic of controversy, the conventional pathway is 
perceived to follow a standard order, in which the HS biosynthetic enzymes function 
consecutively and irreversibly (Lander and Selleck, 2000; Lindahl et al., 1989; Perrimon and 
Bernfield, 2000; Selleck, 2000). HS synthesis starts with the formation of a tetrasaccharide 
linker region, attaching the HS chain to the protein core via a serine (Ser) residue, consisting 
of xylose-galactose-galactose-glucuronic acid (Esko and Zhang, 1996; Zhang et al., 1995). 
Xylosyl-transferase-1 (XylT1) catalyses the addition of the xylose to the serine residue of the 
protein core (Zhang et al., 1995). Two galactosyltransferases (GalT1 and GalT2) catalyse 
the addition of two galactose residues on to the xylose residue respectively followed by the 
addition of a glucuronic acid residue by glucuronic acid transferase 1 (GlcAT1). 
Polymerization of the chain is then initiated by exostosin-like-3 (EXTL3), which catalyses the 
addition of a glucosamine on to the glucuronic acid residue of the tetrasaccharide linkage 
region (Kim et al., 2001). Polymerization continues through the action of HS polymerases, 
the exostosin glycosyltransferases, EXT1 and EXT2 (Lind et al., 1998), which add (in an 
alternating pattern) glucuronic acid and glucosamine to the non-reducing end of the growing 
HS chain. Structural modification of the HS chains occurs concomitantly with chain 
elongation. The conventional route starts with the activity of the bifunctional enzymes N-
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deacetylase-N-sulfotransferases (NDSTs), which catalyse the removal of an N-acetyl group 
and the addition of a sulfate group, producing N-sulfated domains along the HS chain 
(Aikawa and Esko, 1999). Subsequently, C-5 epimerization of a small proportion of D-
glucuronic acid residues to L-iduronic acid occurs through the activity of C-5 epimerase 
(GCE) (Li et al., 1997).  Further modifications include: firstly, 2-O-sulfation of uronic acid by 
2-O-sulfotransferase (HS2ST) (Kobayashi et al., 1997). Secondly, 6-O-sulfation by the 6-O-
sulfotransferases (HS6STs) occurs on N-acetylated and N-sulfated glucosamine residues 
(Habuchi et al., 2000). Thirdly, but rarely, 3-O-sulfation can occur on glucosamine residues 
catalysed by the 3-O-sulfotransferases (HS3STs) (Shworak et al., 1999). These structural 
modifications lead to regions containing a high level of sulfation, termed S-domains, and 
regions containing a low level of sulfation or non-sulfated domains, termed NA-domains. 
Intermediate domains (NA/NS) are also present flanking the NS domains.  
 
1.4.3.2 HS Post-Synthetic Modification 
 
Structural modifications of HS can occur also after the chains have been deposited on the 
cell surface or in the extracellular matrix, by two sets of enzymes: a) the 6-O-endosulfatases 
(Sulf1 and Sulf2) and b) heparanase (HPSE). Firstly, the 6-O-endosulfatases, which are 
extracelluarly targeted, catalyse the removal of 6-O-sulfate groups from glucosamine 
(Habuchi et al., 2003). Evidence suggests that both SULFs are able to act on both heavily 
sulfated domains of HS and also less-sulfated domains (Ai et al., 2006). Secondly, 
heparanase, an endo-β glucuronidase, cleaves HS within the chains yielding HS fragments 
of 10-20 disaccharide units and modifying the activity of the HS chains (Gong et al., 2003). 
Although evidence suggests that there is a preference for a trisaccharide sequence 
containing N-sulfation and 6-O-sulfation, the precise structure of HS substrate required for 
heparanase activity is still under investigation (Okada et al., 2002; Peterson and Liu, 2010; 
Wu et al., 2016).  
 
Chapter 1                                                                                                                                 Introduction 
   
 
 
27 
 
 
Figure 1.7 Schematic showing conventional view of the HS biosynthetic pathway. 
Schematic of HS biosynthetic pathways showing the activity of the HS biosynthetic enzymes 
depicted following a standard order. HS synthesis takes place in the Golgi apparatus following 
formation of the tetrasaccharide linker on the core protein of xylose-galactose-galactose-
glucuronic acid. Chain elongation is initiated with EXTL3 which catalyses the addition of a 
glucosamine, followed by EXT1/2 which catalyse the addition of glucosamine and glucuronic acid 
units alternatively. This occurs concomitantly with chain modification starting with the NDSTS, 
which are dual action enzymes, catalysing the removal of an acetyl group from the amino sugar 
and the addition of an sulfate group. Chain modification continues with the 2-O-sulfotransferases, 
catalysing the addition of a sulfate group of the uronic acid residue and the 6-O- and 3-O-
sulfotransferases catalysing the addition of sulfate groups on the amino sugar. These structural 
modifications lead to regions along the chain of high sulfation, termed S-domains interspersed 
with regions of lower sulfation, termed NA-domains. Intermediate domains (NA/NS) are also 
present flanking the NS domains.  
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1.4.3.3 Biosynthetic Ambiguity  
 
With the exception of C5-epimerase and HS 2-O-sulfotransferase, the HS biosynthetic 
enzymes, represent a multi-isomer family of enzymes. Despite sharing a high degree of 
structural similarity, each family of enzymes displays differences in substrate affinities and 
activity (Aikawa and Esko, 1999; Habuchi et al., 2000; Liu et al., 1999). This presumably 
gives rise to high levels of structural diversity of HS, depending on which isoforms are 
expressed and their level of expression. Despite significant advances in the characterization 
of the biosynthetic process, the precise pathway remains a subject of debate. Following the 
conventional pathway, there are restrictions in the order of activity of the HS biosynthetic 
enzymes and therefore restrictions in the structural output of HS. In reality, some of the basic 
disaccharide structural units that are found naturally in HS are not accounted for by the 
restrictive order of the conventional biosynthetic pathway (Rudd and Yates, 2012). In 
contrast, a biosynthetic pathway of a highly symmetrical tree structure provides an 
explanation for the biosynthesis of all possible structural disaccharide units of HS (Rudd and 
Yates, 2012). According to this alternative biosynthetic pathway and experimental evidence, 
epimerisation can occur both before and after N-sulfation leading to a major branch 
consisting of the most common disaccharides and a minor route, consisting of the more rare 
disaccharide structural units. It also suggests that some of the biosynthetic enzymes can 
operate as complexes, adding further complexity to the structural composition of the chain 
depending on the composition of the enzyme complex and thus its activity (Pinhal et al., 
2001; Victor et al., 2009). Despite many advances in the understanding of the HS 
biosynthetic machinery, the precise mechanisms regulating HS biosynthesis, remain poorly 
understood.  
 
1.4.4 Heparan Sulfate Proteoglycans  
 
HS chains are usually covalently bound to a core protein via a serine residue to form 
heparan sulfate proteoglycans (HSPGs). There are three subfamilies of HSPGs: 
 
(I) transmembrane HSPGs: the 4 syndecans, betaglycan and CD44  
(II) glycophosphatidylinositol (GPI)-linked HSPGs: the 6 gyplicans  
(III) extracellular matrix HSPGs: perlecan, agrin, type XVIII collagen and the 3 
testicans.  
 
The length and number of HS chains attached may also vary between different protein cores 
(Turnbull et al., 2001). Furthermore, it has been shown that domains on the protein core 
other that the GAG binding site may also have regulatory functions for HS biosynthesis 
(Chen and Lander, 2001; Shworak et al., 1994) affecting the structural composition of the HS 
chain bound.  
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1.4.5 The Biological Role of HS  
 
The complexity of the HS biosynthetic pathway leads to an exceptionally structurally diverse 
macromolecule, which is able to interact with a plethora of proteins such as plasma proteins, 
cell surface proteins, enzymes and growth factors termed the HS “interactome”. There is 
increasing evidence suggesting that the structure of HS is critical for correct protein 
interaction and thus plays an important role in regulating biological function (Bernfield et al., 
1999; Gao et al., 2016; Hileman et al., 1998; Lindahl et al., 1998; Takemura and Nakato, 
2017; Thacker et al., 2016; Zhao et al., 2015). Thus far, 100s of HS binding proteins have 
been identified (Meneghetti et al., 2015; Ori et al., 2008, 2011). As a consequence, HSPGs 
play multiple roles in cells and tissues, specifically in: a) cell adhesion, which depends on the 
heparin binding domain of matrix proteins such as fibronectin and the laminins (Bernfield et 
al., 1999; Oh and Couchman, 2004; Saoncella et al., 1999; Woods et al., 2000); b) cell 
migration, which involves the recruitment of growth factors via interactions with HS 
(Arrington and Yost, 2009; Mitsi et al., 2006; Smith et al., 2009); and c) co-receptor 
signalling, which can facilitate the formation of ligand-receptor complexes (Rapraeger et al., 
1991; Yayon et al., 1991). Figure 1.8 highlights some of the key biological functions in which 
HSPGs participate. Since HS is involved in multiple cellular processes, HS is crucial in the 
regulation of many biological processes such as in development and stem cell differentiation, 
and in disease pathogenesis (such as in cancer (Knelson et al., 2014), Alzehimer’s disease 
(Scholefield et al., 2003; Zhang et al., 2014),  and HIV and influenza infection  (Connell and 
Lortat-Jacob, 2013; Patel et al., 1993) ). In an attempt to better understand the role of HS in 
regulation of biological processes, several studies involving mutations in the core proteins or 
the HS biosynthetic enzymes have highlighted the critical role played by HPSGs as 
regulators of multiple biological functions (Sarrazin et al., 2011). In addition, mouse mutants 
for the HS biosynthetic enzymes display more severe phenotypic effects than proteoglycan 
mutants, with many of the knockouts studied to date being embryonically or perinatally 
lethal, highlighting the importance of the HS structural composition as reviewed in Sarrazin 
et al., 2011. 
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Figure 1.8 HSPGS participate in key biological functions. 
Owing to the high structural complexity of HS determined by; the length of chain, number of 
chains, pattern/level of sulfation, localisation or the protein core to which it is attached, 
HS/HSPGs are involved in the regulation of multiple biological processes. Some of the key 
processes which HS is involved in are depicted in the diagram; a) cell-cell cross talk and cell 
adhesion b) growth factor sequestering in the ECM c) as a co-receptor in ligand/receptor 
clustering and signalling on the cell surface d) endocytosis and lysosaml degradation e) Cell 
adhesion and motility based on their interaction with laminins, integrins and matrix proteins f) the 
structrual role the play in ECM and basement membrane organisation. (Adapted from (Bishop et 
al., 2007) ) 
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1.4.6 HS Structural Specificity  
 
Although it is clear that the structure of HS is crucial in numerous biological functions, in the 
vast majority of cases strong levels of a specific structural sequence of HS are not required 
for its biological activity (Mulloy, 2005). The most well investigated case, in which a specific 
sulfation pattern is vital for biological activity, is the interaction of heparin with antithrombin III 
(Björk and Olson, 1997; Jin et al., 1997; Olson et al., 1992). Each of the sulfate groups 
present on a specific pentasaccharide sequence in heparin is critical for binding to 
antithrombin and its anticoagulant activity. In the majority of cases however, there is some 
redundancy in HS sequences that support binding and activity, whereby an intermediate 
level of specificity of HS is required. In these cases, if a minimal specific motif of sulfate 
substitution is present, different substitutions can be present in the same binding site 
(Mulloy, 2005). Thus, this feature of HS allows for complex differential affinities between 
proteins (Ashikari-Hada et al., 2004). Primarily, intermediate levels of HS structural 
specificity are involved with binding to morphogens and growth factors and thus 
accommodate for multi-dynamic signalling.  
 
1.4.7 Heparin Binding Growth Factors  
 
As mentioned previously, a key function HS has is to bind and interact with growth factors. 
HS binding to growth factors can have either a positive or a negative downstream effect on 
signalling. HS can sequester growth factors away from their receptors and, as a 
consequence, protect them against proteolysis or prevent them from signalling 
(Gospodarowicz and Cheng, 1986; Vlodavsky et al., 1991; Vlodavsky et al., 1996). Then, 
selective degradation of HSPGs, can liberate growth factors thus playing an important role in 
regulating growth factor release in the extracellular environment and establishing growth 
factor gradients (Bernfield et al., 1999; Manon-Jensen et al., 2010). However, HS can also 
serve as a cell-surface receptor by facilitating ligand-receptor interactions, lowering their 
activation threshold or modulating the extent of signalling (Rapraeger et al., 1991; Yayon et 
al., 1991) (Figure 1.9). Growth factors, which contain a heparin-binding domain are termed 
heparin binding growth factors (HBGFs) (Olwin, 1989). These include several fibroblast 
growth factors (FGFs), bone morphogenetic proteins (BMPs), epidermal growth factor 
(EGF), vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), insulin-
like growth factor (IGF) and platelet derived growth factor (PDGF) (reviewed by (Ori et al., 
2008; Zhang, 2010).  
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Figure 1.9 Role of HS and Heparin Binding Growth factors. 
a) HS in the extracellular matrix is able to interact with heparin-binding growth factors (e.g. FGF) 
sequestering growth factors away from the cell surface and reducing signalling and/or protecting 
them from proteolysis and thus permiting growth factor signallling. b)  HS present on the cell 
surface can act as a co-recepor prompting ligand-receptor clustering and promoting growth factor 
signalling. 
 
1.4.8 Heparan Sulfate as a co-receptor for FGF2 signalling  
 
Cell surface HSPGs facilitate the formation of FGF2 and FGF receptor complexes by acting 
as a high affinity co-receptor (Burgess and Maciag, 1989; Rapraeger et al., 1991; Yayon et 
al., 1991). The HS-FGF-FGFR interaction has been shown to signal through the mitogen-
activated protein kinase/extracellular regulated signalling kinase (MAPK/ERK) pathway 
(Chua et al., 2004; Delehedde et al., 2000). The HS-FGF-FGFR interaction is the most 
extensively studied of the heparin-binding growth factors where FGFR1 activation and 
downstream signal transduction is dependent on the formation of a ternary complex 
determined by its crystal structure (Schlessinger et al., 2000). Distinct structural sequences, 
the position and level of HS sulfation are crucial for FGF ligand and receptor binding 
(Brickman et al., 1998a; Brickman et al., 1998b; Guimond and Turnbull, 1999; Lundin et al., 
2000) and thus the formation of the ternary complex (Jastrebova et al., 2006). Specifically, 
evidence suggests that HS 2-O-sulfation is required for the binding to FGF2 (Turnbull et al., 
1992), whereas 6-O-sulfation is important for binding to FGF receptor and the subsequent 
formation of the ternary complex (Figure 1.10) (Guimond et al., 1993; Pye et al., 1998). 6-O-
desulfation of HS reduces the formation of the ternary complex specifically via inhibition of 
the FGFR1 and FGF2 interaction and thus inhibition of FGF signalling (Wang et al., 2004). 
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However, it must be noted that even analogous non-GAG structures are able to promote 
FGF2 signalling and exhibit inhibitory activity (Rudd et al., 2010).  
 
 
 
Figure 1.10 Heparan Sulfate as a co-receptor in FGF signalling. 
Diagram depicts the mechanisms by which HS serves as a co-receptor in FGF2 signalling, for 
example. A depicts the formation of the ternary complex of HS-FGF2-FGFR1 (2:2:2) on the cell 
surface permitting signalling to take place. B depicts the key sulfation positions of HS important 
for the formation of the ternary complex. 2-O, and N-sulfation is important for interacting with 
FGF2 wherease 6-O-sulfation is important for interacting with the FGFR. 
 
1.4.9 Heparan Sulfate in Stem Cell Differentiation  
 
Many groups have demonstrated that specific GAGs, including HS, regulates stem cell 
differentiation through their ability to interact with multiple proteins (Dombrowski et al., 2009; 
Lanner et al., 2010; Smith et al., 2011) and that the structure of HS changes during 
embryonic stem cell (ESC) differentiation into different lineages (Baldwin et al., 2008; 
Johnson et al., 2007). For example, HS from ESCs undergoing differentiation shows 
increasing sulfation (Johnson, 2007; Nairn et al 2007; Hirano 2012) and specifically, an 
increase in N- 2- and 6-O-sulfation. To study the effects of HS structure on stem cell 
regulation, mouse ESCs harbouring mutations in the HS biosynthetic enzymes have been 
used (Jakobsson et al., 2006). Mouse ESCs lacking NDST1/2 are unresponsive to VEGF 
and subsequently their differentiation into blood capillary structures is blocked (Jakobsson et 
al., 2006). Similarly, ESCs lacking NDST1/2 are unable to differentiate into different lineages 
in response to FGF4 (Kraushaar et al., 2010; Lanner et al., 2010), and more recent findings 
show genetic targeting of NDST2, inhibits ESC adipogenic and neural differentiation 
(Forsberg et al., 2012). These findings highlight the importance of the structural composition 
of the heparanome of the stem cell niche and its role in regulating differentiation.  
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1.4.10 Heparan Sulfate in Ageing  
 
Ageing is associated with progressive changes in stem cell number and function, and altered 
expression levels of growth factors leading to age-related stem cell dysregulation and 
reduced tissue regenerative capacity (Baumann, 2012; Oh et al., 2014). Since HS is 
involved in the regulation of growth factor signalling, it is not surprising that the structure and 
amount of HS is also altered in several tissues during ageing. Firstly, it has been 
demonstrated that HS on the cell surface of human diploid fibroblasts accumulates during in 
vitro ageing (Aizawa et al., 1980). Secondly, the structure of human aorta HS is gradually 
modulated during ageing, specifically showing an increase in 6-O-sulfation and thus 
enhanced binding to platelet-derived growth factor (PDGF) (Feyzi et al., 1998). HS binding to 
FGF2 is also increased but to a lesser extent (Feyzi et al., 1998). Furthermore, human 
osteoblast HS structure changes during ageing (Grzesik et al., 2002). Additionally, studies in 
the rat myocardium found an age-dependent increase in GAG levels and specifically an 
increase in the amount of HS (Huynh et al., 2012a). Furthermore, during ageing in the 
myocardium, there is an increase in the level of HS 6-O-sulfation (Huynh et al., 2012a). The 
aged HS also shows an increase in the potentiating effect of VEGF and decreased 
capacities to potentiate FGF2-dependent mitogenic activity (Huynh et al., 2012a). Finally, 
recent studies have found an age-dependent decrease in the amount of HS in Bruch’s 
membrane of the eye. This is accompanied by a decrease in HS sulfation in the aged 
Bruch’s membrane and an increase in heparanase leading to altered binding capacities in 
the ageing HS (Keenan et al., 2014). These studies highlight the importance of HS during 
ageing, suggesting that the change in structure of HS is specific to the tissue of origin 
leading to different biological consequences.  
 
1.5 Heparan Sulfate and Heparan Sulfate Proteoglycans in 
Myogenesis  
 
1.5.1 Heparan Sulfate Proteoglycans in Myogenesis 
 
During skeletal muscle development, regeneration and degeneration, HSPGs are 
dynamically expressed and differentially located suggesting different functional roles for HS 
during myogenesis (Brandan and Gutierrez, 2013; Jenniskens et al., 2002; Liu et al., 2002). 
However, the HS composition during myogenesis has remained largely unexplored.  
1.5.1.1 Heparan Sulfate Proteoglycans in Muscle Development 
 
It has been demonstrated that HSPGs play an essential role during muscle development due 
to their ability to regulate important signalling pathways (Asundi et al., 1997; Lin, 2004; 
Poulain and Yost, 2015). During human skeletal muscle formation, syndecan-1 is 
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upregulated at week 13 of gestation whereas perlecan is undetectable (Sogos et al., 1998). 
In the development of mouse limb muscles, syndecan-1 and glypican-1 are detectable at 
day 10.5, while syndecan-3, syndecan-4 and perlecan are up regulated from day 12.5 
(Olguin and Brandan, 2001). Syndecan-2, however, is undetectable in muscle cells during 
mouse embryonic development (David et al., 1993). In turkey pectoral muscle development, 
syndecan-1 and glypican-1 are also up regulated between days 18 and 20, respectively (Liu 
et al., 2004). Finally, HS 6-O-sulfation specifically has been found to be essential for muscle 
development in zebrafish (Bink et al., 2003). Morpholino-mediated functional knockdowns of 
HS6ST, led to a specific inhibition of 6-O-sulfation and impaired muscle growth during 
development (Bink et al., 2003). Morphant zebra-fish displayed disrupted somitic muscle 
development and later defects in muscle differentiation, which eventually led to severe 
muscle degeneration (Bink et al., 2003).  
 
1.5.1.2 Heparan Sulfate Proteoglycans in Muscle Differentiation and Regeneration 
 
Certain aspects of the process of muscle regeneration recapitulate the process of muscle 
development and therefore it is not surprising that the expression levels and localisation of 
several HSPGs change during muscle regeneration. Amongst the HSPGs, syndecans seem 
to have significant importance in satellite cell regulation. All four syndecans are down 
regulated during skeletal muscle differentiation (Fuentealba et al., 1999; Gutierrez et al., 
2006; Larraín et al., 1997b). Syndecan-3 and syndecan-4 expression is restricted to satellite 
cells and thus serve as useful markers (Cornelison et al., 2001). Both syndecan-1 and 3 are 
important in the regulation of FGF2 activity (Fuentealba et al., 1999; Larraín et al., 1998) with 
syndecan-1 likely promoting FGF2 signalling and syndecan-3 inhibiting FGF2 signalling 
which is upregulated at the onset of differentiation (Cornelison et al., 2001; Cornelison et al., 
2004). With the exception of syndecan-3, syndecans are down regulated during myogenesis 
and thus allow differentiation to take place due to reduced sensitivity to FGF2 (Fuentealba et 
al., 1999; Larraín et al., 1998; Larraín et al., 1997b). In vivo syndecan-4 knockout (Sdc4-/-) 
satellite cells fail to regenerate damaged muscle with low levels of activation, proliferation, 
myotube fusion and differentiation (Cornelison et al., 2004). In contrast, syndecan-3 
knockout (Sdc3-/-) mice successfully regenerate damaged muscle with satellite cells 
exhibiting impaired quiescence maintenance and self-renewal, and slower proliferation than 
wild type cells (Pisconti et al., 2010). In addition, Sdc3-/- regenerating muscle shows an 
increase in the number of myonuclei and myofibre size indicating enhanced myoblast fusion 
(Pisconti et al., 2010). Perlecan, a component of the basal lamina which surrounds 
myofibres, is also downregulated during terminal muscle differentiation (Larraín et al., 
1997a). Unlike the syndecans and perlecan, which are downregulated during myogenesis, 
glypican expression remains constant throughout myogenesis (Jen et al., 2009). 
Interestingly, glypican-1 is the only HSPG localized in lipid raft domains in myoblasts 
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sequestering FGF2 away from its receptor and thus decreasing FGF2 signalling (Brandan et 
al., 1996; Gutiérrez and Brandan, 2010). Glypican deficient mice exhibit increased FGF2 
signalling, reduced myogenin and muscle myosin expression, and decreased myoblast 
fusion (Brandan et al., 1996; Gutiérrez and Brandan, 2010).  
 
1.5.2 Heparan Sulfate Biosynthetic Enzyme Regulation in Myogenesis 
 
Studies focusing on the role of the HS biosynthetic enzymes in myogenic regulation provide 
a useful indication of the importance of HS structure during myogenesis. The role of the 
heparan sulfate 6-O-sulfatases (Sulfs), in skeletal muscle has been described. Sulf 1 and 2 
affect several extracellular signals involved in skeletal muscle regeneration (Gill et al., 2010; 
Langsdorf et al., 2007). Since Sulfs modify sulfated HS moieties after HS biosynthesis by 
removing 6-O-sulfate groups from tri-sulfated IdoA2S-GlcNS6S and di-sulfated UA-
GlcNS6S, the removal the 6-O-sulfate group on HS disrupts the FGF2 ternary complex, 
repressing FGF signalling (Tran et al., 2012). As myogenic differentiation is inhibited by FGF 
signalling, Sulf double mutant mice exhibit delayed myogenic differentiation and prolonged 
Pax7 expression upon muscle injury (Langsdorf et al., 2007). More recent studies suggest 
that the heparanome composition is important for maintaining satellite cell quiescence, since 
satellite cells activated in vivo in response to injury, led to the majority of biosynthetic 
enzymes being significantly downregulated (Pisconti et al., 2012). This is with exception of 
EXTL2 and HS3ST3b1, a 3-O-sulfotransferase, which are up-regulated during satellite cell 
activation (Pisconti et al., 2012).  
 
1.5.3 Heparan Sulfate in Myogenesis 
 
With regards to the specific structure of HS itself, epitope analysis via phage display 
technology has demonstrated that different specific HS epitopes exist in skeletal muscle, and 
their abundance changes in developing muscle in vitro and in vivo (Jenniskens et al., 2002; 
Jenniskens et al., 2000). This suggests a role for specific structural moieties of the HS 
chains in regulating skeletal muscle growth and regeneration. Total sulfated GAG amounts 
(including HS and chondroitin sulfate) have been found to increase in the C2.7 myoblast cell 
line (derived from the C2 mouse myoblast cell line) when myoblasts are differentiated to 
myotubes (Barbosa et al., 2003). Leading on from this, it was discovered that the amount of 
HS specifically increases during differentiation of the C2.7 myoblast cell line (Barbosa et al., 
2005).  
1.5.3.1 Structure of Heparan Sulfate in Muscle Regeneration 
 
It has been well reported that GAG levels increase in several tissues during regeneration 
(DiMicco et al., 2004; Ghatak et al., 2015; Papakonstantinou and Karakiulakis, 2009). During 
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muscle regeneration, total sulfated GAG content increases compared to intact muscle and 
this increase is enhanced in the presence of TGF-β (Barbosa et al., 2003; Zimowska et al., 
2009). Furthermore, when male rats are subjected to ischaemic-injury the expression levels 
of HS biosynthetic enzymes change significantly, correlating with structural changes in HS 
and CS (Chevalier et al., 2015). Specifically, HS from muscle post ischaemic-injury has 
increased chain length, increased sulfation and different sulfation patterns compared to HS 
from intact muscle (Chevalier et al., 2015). Moreover, HS from regenerating muscle post 
ischaemic injury display differential binding affinities towards FGF2 and IL8 depending on 
the stage of regeneration (Chevalier et al., 2015). Total GAG content from regenerating 
muscle from day 8-post injury potentiates FGF2 mitogenic activity with an increasing effect 
up to 21 days post injury (Chevalier et al., 2015). 
1.5.3.2 Structure of Heparan Sulfate in Muscular Dystrophy 
 
Muscular dystrophy is a family of genetic disorders characterised by progressive skeletal 
muscle degeneration (Emery, 2002). A feature of the disease is extensive fibrosis due to an 
accumulation of ECM around muscle fibres leading to a hostile environment and 
compromised satellite cell function (Morgan and Zammit, 2010). Myoblasts from dystrophic 
(mdx) mice have been shown to synthesise 10 times the normal amount of sulfated GAGs, 
both HS and chondroitin sulfate (Crisona et al., 1998), correlating with the increase in ECM. 
Further investigations into the role of sulfated GAGs in Duchenne muscular dystrophy (DMD) 
demonstrated an increase and differential localisation of three HSPGs: gylpican-1, perlecan 
and syndecan-3 (Alvarez et al., 2002). In dystrophic (mdx) mice, syndecan-3 loss leads to 
improved muscle regeneration, with decreased muscle fibrosis and enhanced muscle 
function, shown by the ability of the mice to run longer when tested for endurance training 
performance (Pisconti et al., 2016). With regards to structural changes in sulfated GAGs, a 
modification of the sulfation pattern of chondroitin sulfate and dermatan sulfate in DMD 
muscles has been described, whereas the structure of HS appears comparable to wild type 
muscle (Negroni et al., 2014) despite there being significant changes in the structure of HS 
during post-ischaemic injury (Chevalier et al., 2015). 
 
1.6 Structural Analysis of Heparan Sulfate  
 
Since the structure of HS is critical in multiple biological processes, efficient and accurate 
methods are crucial for determining the structure of HS. Unlike DNA and protein synthesis, 
HS biosynthesis is not template driven, and the mechanisms of regulation are poorly 
understood. Therefore, it is not possible to determine structural sequences of HS chains 
based on expression levels of HS biosynthetic enzymes alone.  
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1.6.1 Heparan Sulfate Antibodies 
 
One method for determining HS distribution in tissues and cells is by using antibodies that 
recognise specific HS epitopes. The first monoclonal HS-specific antibodies, 10E4 and 
3G10, were developed in 1992 (David et al., 1992).  3G10 recognises the epitope produced 
after HSPGs have been treated with an HS degrading enzyme, heparinase III, thereby 
removing the HS chain from the protein core, providing a quantitative method of detection of 
HS chains present on a protein core (David et al., 1992). 10E4 on the other hand, 
recognises mainly N-sulfated domains on the HS chain (David et al., 1992). Later JM403 
(van den Born et al., 2005) and NAH46 (Suzuki et al., 2008) antibodies were developed 
which recognise N-unsubstituted glucosamine residues and disaccharide residues 
containing N-acetyl glucosamine respectively. Thus, these antibodies are useful for the 
localization of specific HS epitopes in tissues. However, they still remain relatively limited 
compared to antibodies available for other GAG species and do not provide information on 
fine structural entities of HS. 
 
1.6.2 Heparan Sulfate Phage Display Antibodies 
 
An alternative technique for detecting different structural entities of HS involves the use of 
HS-specific single chain variable fragment antibodies that have been generated by phage 
display technology (van Kuppevelt et al., 1998). However, it must be considered that when 
cations bind to polysaccharides, both to HS analogues and HS on a cell surface, phage 
display antibody binding is often altered (Solari et al., 2015). This suggests that phage 
display antibodies do not bind to single specific structural sequences on the polysaccharide 
chain but that their binding depends rather on the overall conformation, the charge 
distribution and the flexibility of the HS chain (Thompson et al., 2009). Although phage 
display antibodies may be useful for determining general differences in the structure of HS, it 
must be considered that this is an overall interaction of the antibody to the polysaccharide 
and the surrounding environment, and therefore is not a sufficient technique alone for 
deciphering HS sequences. Furthermore, the epitopes for the antibodies are often 
insufficiently defined, and low abundance HS epitopes may not be detected.  
 
1.6.3 Heparan Sulfate Isolation 
 
For a more inherently accurate method of HS structural analysis, HS can be structurally 
analysed post isolation from tissues or cells. HS can be extracted from tissues or cells 
because of the high anionic nature of the sulfated HS chain, which binds to positively 
charged species via strong electrostatic attractions. Various enzymes can be employed to 
depolymerise HS chains from their protein core, bound DNA or from other GAG chains that 
are isolated in the process (Guimond et al., 2009a).  
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1.6.4 HS Quantification 
 
One of the most common methods for HS quantification is the 1,9-dimethylmethylene Blue 
(DMMB) assay (Farndale et al., 1986; Farndale et al., 1982). DMMB is a cationic dye that 
can bind sulfated GAGs. The blue of the dye shifts to a violet tone when the dye binds to the 
polyanionic sulfate groups of the HS chain (Templeton, 1988). The HS-dye complex can 
then be isolated and the optical density measured for HS quantification. This measures the 
amount of sulfated HS isolated but does not account for non-sulfated HS species. Therefore 
the results may be skewed if the proportion of non-sulfated HS varies between samples. An 
alternative method for HS quantification is by exploiting the double bond, formed post 
heparinase digestion. Bacterially derived enzymes heparinase I, II and III digest the HS into 
its constituent disaccharide units (Ernst et al. 1995) resulting in a double bond per 
disaccharide (Figure 1.10). The double bond absorbs UV light strongly and thus can be 
used for HS quantification for sulfated and non-sulfated regions. Other quantification 
methods that do not include heparinase are destructive and also require larger quantities of 
HS.  
 
1.6.5 Analytical Techniques for Heparan Sulfate Structural Analysis 
 
Nuclear magnetic resonance (NMR) spectroscopy can be used to determine the structure of 
heparin as an intact polymer, without the requirement of cleaving the chain providing 
information on the monosaccharide composition, sulfation states and the uronic acid 
neighbouring linkages (Mulloy and Johnson, 1987; Rudd et al., 2011; Yates et al., 1996). 
However, NMR requires milligrams of material, and often it is difficult to isolate enough HS 
material from cells or tissues for NMR analysis as a single species (Venkataraman et al., 
1999). Mass spectrometry on the other hand, requires much less material for structural 
analysis but is limited in the information it can provide from intact HS chains, as sulfate 
groups are often lost during fragmentation especially with matrix-assisted laser 
desorption/ionisation mass spectrometry (MALDI-MS) (Venkataraman et al., 1999). 
Recently, mass spectrometry has allowed for more detailed analysis, including identification 
of the epimeric forms of the uronic acid residues (Leary et al., 2015; Miller et al., 2016b). 
More commonly, initial HS structural analysis is achieved via HS degradation into its 
constituent disaccharide units, followed by separation using SAX-HPLC in reference to 
authentic HS standards. This method requires little material and allows for the detection of 
specific disaccharide units and their relative abundance.  
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1.6.6 Heparan Sulfation Depolymerisation  
1.6.6.1 Nitrous Acid Depolymerisation  
 
The most common form of chemical degradation of HS into its constituent disaccharide units 
is the use of nitrous acid oxidative depolymerisation, resulting in the selective cleavage of 
the acid sensitive N-sulfated residues leading to 2,5-anyhdromannose terminal units (Figure 
1.10). N-acetylated domains are preserved and O-sulfated domains remain unmodified 
(Turnbull, 2001). The benefit of using this method is that the uronic acid is maintained in its 
authentic epimeric state and the method is overall relatively cheap. A downside to this 
method is that since nitrous acid degradation reacts at N-sulfated domains, N-acetylated 
domains will not be depolymerized and thus important structural information may be lost 
(Turnbull, 2001). This may be overcome by sulfating N-acetylated domains prior to 
depolymerisation. Furthermore, the non-reducing end of the sugar, which is converted into 
anhydromannose, is modified leading to further loss of information. Finally, the disaccharides 
produced from nitrous acid degradation lack a chromophore and so further labelling at the 
reducing end of the sugar is required for detection (Shriver et al., 2012).  
 
1.6.6.2 Heparinase Depolymerisation  
An alternative approach for HS depolymerisation is the use of HS degrading enzymes.  As 
mentioned briefly, bacterially derived enzymes heparinase I, II and III digest HS into its 
constituent disaccharide units (Ernst et al. 1995) at pH 7 (Figure 1.11). Each enzyme has a 
distinct substrate specificity, some of which are overlapping and thus results in complete (or 
near complete) HS depolymerisation (Desai et al., 1993; Linhardt et al., 1988; Linhardt et al., 
1990; Nader et al., 1999). Cleavage of the HS chain results in the formation of a Δ 4,5 
double bond on the uronic acid, which absorbs UV light strongly at 232 nm (with a molar 
extinction coefficient of 5500 M-1cm-1) and thus represents a method for disaccharide 
detection. However, one downside of enzymatic degradation is that the uronic acid identity is 
lost in the formation of the double bond, as both GlcA and IdoA degrade to a common 
structure. The reducing end of the sugar, which is highly reactive, is left unmodified, and thus 
an available site for labelling with chromophores for alternative methods of detection with 
increased sensitivity.  
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Figure 1.11 Nitrous acid and heparinase depolymerisation.
 a) Nitrous acid depolymerisation results in oligosaccharides with 2,5-anyhdromannose terminal 
units.  b) Heparinase I/II/II enzymes lead to HS depolymerisation resulting in disaccharides with a 
Δ 4,5 double bond on the uronic acid at the non-reducing end.  
 
1.6.7 Remodelling Endogenous Heparan Sulfate  
 
The methods described above are useful for determining the structure of HS from a pure 
sample, however, further studies exploring the functional role of the HS analysed can be 
difficult due to the high structural complexity, the dynamic turnover and low abundance of 
HS. An alternative approach for studying structure-function relationships of HS is to use 
exogenous HS of well-defined structures. In this way the biological effect of specific 
structures can be investigated. Naturally occurring HS, which is highly heterogeneous, can 
be separated based on fragment size and charge to produce better-defined structures with 
less variability for testing (Powell et al., 2010). However, HS is produced in minute quantities 
and as a consequence, it is often difficult to obtain enough material for structural 
determination and bioassays.  
 
Alternatively, many groups have investigated the complex chemical synthesis of HS 
oligosaccharides and recent advances have been made (Arungundram et al., 2009; 
Schwörer et al., 2013). However, despite several modifications and improvements, the 
synthesis of HS remains a multi-step and costly process. A new chemoenzymatic approach 
as emerged using recombinant HS biosynthetic enzymes combined with unnatural uridine 
diphosphate monosaccharide donors (Liu and Linhardt, 2014; Liu et al., 2010; Xu et al., 
2012). Although, chemoenzymatic approaches provide a general method for preparing 
different HS sequences, the target selection is restricted by the substrate specificities of the 
enzymes and thus synthetic selectivity remains a challenge (Xu et al,. 2012).  
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1.7 HS Mimetics 
 
1.7.1 Chemically Modified Natural Products 
 
To combat the difficulties of chemical synthesis of HS, a common method for developing HS 
mimetics is to chemically modify naturally occurring non-GAG polysaccharides by 
introducing functional sulfated groups along the chain to mimic the biological function of HS 
or other GAG species (Christman et al., 2008; Ikeda et al., 2011; Lee et al., 2010; Meddahi 
et al., 1996a; Roy et al., 2014; Ziebell et al., 2001).  
 
1.7.2 Chemically Modified Heparin 
 
Heparin, a more highly sulfated, close structural analogue of HS, can also be used for 
producing HS mimetics and studying structure-function relationships. However, it should be 
noted that the uronic acid residue of heparin is predominantly L-iduronic acid rather than the 
majority of glucuronic acid in HS. Additionally, heparin is more highly sulfated than HS and 
therefore less structurally diverse. Nonetheless heparin shows a broad molecular weight 
distribution, giving rise to a highly heterogeneous mixture of oligosaccharides. Heparin is 
produced by mast cells, it is more abundant than HS and thus commercially available at 
relatively low cost. Heparin can then be chemically modified, by selective de-sulfation at 
different positions (N-, 2-O- and 6-O-sulfation), producing more well-defined and simpler 
polysaccharides than parent heparin. The modified heparins can then be further separated 
based on fragment size after cleavage, allowing for more specific structural studies in which 
structural modifications are correlated to changes in activity or binding (Yates et al., 1996).  
 
1.7.3 Glycomimetics in Muscle Regeneration 
 
As discussed earlier, HS is implicated in skeletal muscle disease and muscle repair (Alvarez 
et al., 2002; Chevalier et al., 2015; Crisona et al., 1998). For this reason, evidence suggests 
that controlling the GAG composition of the ECM might represent a promising therapeutic 
approach to enhance muscle regeneration. One hypothesis postulates that GAG mimetics 
are resistant to enzymatic degradation and thus reside in the ECM longer than naturally 
occurring HS, permitting further growth factor regulation and subsequently, promoting 
muscle regeneration (Meddahi et al., 2002b; Meddahi et al., 1996b). Thus far, experiments 
involving GAG mimetics in muscle regeneration have largely focused around the use of so-
called regenerating agents (RGTAs). These are matrix-based therapies, synthesised from 
natural dextran derivatives to contain defined amounts of various modifications 
(carboxymethyl, benzylamide and sulfonate groups). RGTAs serve to recreate the ECM 
microenvironment lost in degeneration and are able to interact with and protect several 
heparin-binding growth factors from proteolysis (Meddahi et al., 2002b; Meddahi et al., 
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1995), preserving the natural endogenous cytokine signalling of the ECM. RGTAs 
successfully stimulate tissue repair when applied at a site of injury in several tissues 
(Blanquaert et al., 1995; Meddahi et al., 2002a; Meddahi et al., 1996a) including skeletal 
muscle (Aamiri et al., 1995; Gautron et al., 1995; Yamauchi et al., 2000).  In EDL muscle of 
mice, RGTA protects muscle fibres from degeneration and preserves a differentiated state of 
fibres in ischaemic muscle (Desgranges et al., 1999). Further experiments have shown that 
RGTAs promote satellite cell proliferation and fusion in vitro (Papy-Garcia et al., 2002; 
Zimowska et al., 2005; Zimowska et al., 2001) and also change the GAG species during 
myogenesis of the C2.7 myoblast cell line (Barbosa et al., 2005). Thus they provide a good 
proof-of-concept for the activity of GAGs and GAG mimetics in muscle function.  
 
1.7.4 Chemical Synthesis of HS mimetics 
 
RGTAs have shown to be promising in the development of matrix-based therapies for tissue 
regeneration. Since they are based on dextran, which is a polysaccharide consisting of 
glucose residues, structural specificity can be a limitation.  Furthermore, RGTAs are able to 
interact with numerous growth factors(Meddahi et al., 1996b), and if added in excess at a 
site of injury, in which all heparin-binding sites are occupied, heparin-binding growth factors 
can compete for sites on the matrix bound RGTAs. In this case, it might be beneficial to use 
a more highly selective compound, with fewer off-target effects.  
 
1.8 Overall Project Aims 
 
The central aim of this project was to investigate the structure-function relationship of HS in 
myogenesis. Although it has been previously demonstrated that HSPGs are dynamically 
regulated during myogenesis, in the majority of cases the focus was on the protein core, 
leaving the structural composition of the HS component largely unexplored. There has been 
no investigation to our knowledge, into the HS structural composition of primary myoblasts, 
nor investigations into the effects of ageing on the HS structural component of skeletal 
muscle. Alongside the main aim of this project, was the plan to investigate the use of 
chemically modified and fully synthetic HS mimetics as potential indications for therapeutic 
intervention to enhance muscle regeneration in ageing or in disease.  
 
Thus, the aims of this project were to: 
 
1) Determine the structure of HS during myogenic differentiation and assess the affects 
on signalling in the satellite cell niche  
2) Determine the structure of HS during ageing in skeletal muscle  
3) Investigate the structural importance of HS on myogenesis with the use of 
chemically modified HS mimetics 
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4) Investigate the effects of fully synthetic HS mimetics on myogenesis and potential 
use as novel therapeutic agents 
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2 Materials and Methods 
 
 
2.1 Mice 
 
Young (11-13 weeks) and old (1 year and 2 years) C57Bl/6J female mice were obtained 
from Charles River, housed in a pathogen-free facility at the University of Liverpool, UK and 
used in accordance with the Animals (Scientific Procedures) Act 1986 and the EU Directive 
2010/63/EU and after local ethical review and approval by Liverpool University’s Animal 
Welfare and Ethical Review Body (AWERB). 
 
2.1.1 Skeletal Muscle Dissection 
 
Mice were euthanized by cervical dislocation. Before dissection, the mouse was sprayed 
with 70% ethanol. The skin was lifted on the back and a small incision was made with 
scissors. The incision was extended and the skin was retracted to the ankle to expose the 
hindlimb muscles. Forceps were used to remove the fascia coating the exterior muscles. The 
tibialis anterior (TA), extensor digitorum longus (EDL), gastrocnemius and soleus muscles 
were detached from the tibia and fibula. The quadriceps, hamstrings and remaining muscle 
were detached from the femur. Visible fat and hair were removed. For heparan sulfate 
extraction or RNA extraction, the individual muscles were placed in a cryovial and snap 
frozen in liquid nitrogen before being stored at -80 °C. For satellite cell-derived myoblast 
isolation, all muscles were collected in ice-cold F12-C + 0.4 mM CaCl2 in a 50 ml falcon tube.  
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2.2 Cell Culture  
 
2.2.1 Cell Culture Materials  
 
2.2.1.1 Primary Myoblast Media 
Primary myoblasts were isolated from the hindlimb muscles of 3-month-old female mice. 
 
Primary Myoblast Growth Medium: F12 + 0.4 mM CaCl2 (F12C)+ 15% horse serum + 1% 
penicillin/streptomycin + 2 mM glutamine (supplemented with 2 nM FGF2) 
Primary Myoblast Differentiation Medium: F12 + 0.4 mM CaCl2 + 3% horse serum + 1% 
penicillin/streptomycin + 2 mM glutamine 
2.2.1.2 C2C12 Myoblast Medium  
C2C12 myoblasts are a subclone (produced by Blau, et al) of the mouse myoblast cell line 
established by D. Yaffe and O. Saxel(Yaffe and Saxel, 1977).  
 
C2C12 Myoblast Growth Medium: Dulbecco’s Modified Eagle Medium (DMEM), Gibco + 
10% foetal bovine serum (FBS, Gibco) + 1% penicillin/streptomycin + 2 mM glutamine 
C2C12 Myoblast Differentiation Medium: Dulbecco’s Modified Eagle Medium (DMEM), 
Gibco + 2% horse serum, + 1% penicillin/streptomycin + 2 mM glutamine 
2.2.1.3 BaF3 Cell Medium 
BaF3 cells are interleukin-3 dependent mouse pro B lymphocytes established from 
peripheral blood. 
 
BaF3 Cell Growth Medium: RPMI-1640 supplemented + 10% FCS + 100 Units/ml penicillin 
G + 100 µg/ml streptomycin sulfate (all from ThermoFisher, UK) and 1 ng/ml murine 
interleukin-3 (R&D Systems, UK) 
 
2.2.2 Cell Culture Methods  
2.2.2.1 Isolation of Satellite Cell Derived Myoblasts: Differential Plating Protocol  
 
Muscles were dissected from mouse hindlimbs as described above, transferred to a Petri 
dish and minced with scissors for approximately 5 minutes until the muscles were reduced to 
a homogeneous slurry. Minced muscles were then transferred to a 50 ml conical tube 
containing 15 ml of 400 units/mg collagenase type I (Worthington Biochemical Corporation) 
+ F12C (F12 + 0.4 mM CaCl2) for 1.5 hour at 37°C with agitation every 15 minutes. The 
homogenate was spun down by centrifugation at 30 x g for 4 minutes. The supernatant was 
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collected and diluted with double the volume of growth media medium (F12C+ 15% horse 
serum + 1% penicillin/streptomycin + 2 mM glutamine). A pellet was obtained after 
centrifugation at 500 x g for 10 minutes. The pellet was resuspended in growth medium and 
filtered through a 40 μM cell strainer (BD Falcon®). The filtrate was spun down by 
centrifugation at 500 x g for 10 minutes. The pellet was resuspended in medium and plated 
on two gelatin-coated 10 cm plates per mouse for pre-plating 1 (PP1) under a humidified 
atmosphere of 5% CO2 for two hours. The plates were then washed gently with their own 
medium and collected for re-plating on to two new gelatin-coated 10 cm plates for one hour; 
this was pre-plating 2 (PP2). PP2 were again washed gently with their own medium and 
collected for final plating (PO) on two gelatin-coated 10 cm plates per mouse. FGF2 was 
added at a final concentration of 2nM and satellite cell-derived myoblasts were expanded in 
growth medium (F12 + 0.4 mM CaCl2 + 15% horse serum + 1% penicillin/streptomycin + 2 
mM glutamine + 2 nM FGF2) under a humidified atmosphere of 5% CO2 for two days. 
Recombinant FGF2 was prepared in house and kindly donated by Dr Dave Fernig, 
University of Liverpool.  
2.2.2.2 Pre-plating Method Validation 
 
In order to validate primary myoblast separation from contaminating fibroblast through the 
pre-plating technique, fresh growth medium (primary myoblast growth medium + 2nM FGF2) 
was added to PP1 and PP2 adhered cells and expanded for 2 days. After 2 days of 
expansion cells from PP1, PP2 and PO were fixed with 4% paraformaldehyde prepared in 
phosphate buffered saline (PBS) for 10 minutes at room temperature and then washed 3 
times with PBS. Fixed cells were stored in PBS at 4°C until immunostaining was performed. 
 
2.2.2.3 Preparation of Gelatin-Coated Culture Dishes 
 
0.6 % (w/v) gelatin solution was boiled for 2 minutes prior to addition on to either; 
a) 12 multi-well culture dishes and incubated at RT for 30 minutes. The excess gelatin was 
removed before being air-dried for a further 30 minutes at RT.  
b) 10 cm culture dish in which the gelatin was spread with a sterilised glass spreader and 
air-dried at RT for 30 minutes. 
 
2.2.2.4 Routine Culture of Primary Myoblasts  
 
Primary myoblasts were obtained as described above from 11-13 week old female mice 
(Charles River) and plated on gelatin-coated 10 cm plates. Satellite cell-derived myoblasts 
were expanded in growth medium (F12C + 15% horse serum + 1% penicillin/streptomycin + 
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2 mM glutamine + 2 nM FGF2) under a humidified atmosphere of 5% CO2 at 37°C for two 
days then either used as proliferating cells or passaged, using 40 units/ml of collagenase I in 
F12C, onto 12 multi-well culture dishes at a density of 800 cells/cm2. Primary myoblasts 
could then be expanded for a further day in growth medium and then fixed as proliferating 
cells or be induced to differentiate by replacing the growth medium with differentiation 
medium (F12C + 3% horse serum + 1% penicillin/streptomycin + 2 mM glutamine). Primary 
myoblasts were differentiated for 3 days for differentiation assays.  
 
2.2.2.5 Routine Culture of C2C12 Myoblast Cell Line  
 
C2C12 myoblasts at passage number 3 were kindly donated by Prof Bradley Olwin 
(University of Colorado, USA) and grown in growth medium (Dulbecco’s Modified Eagle 
Medium, Gibco) + 10% foetal bovine serum (FBS, Gibco) + 1% penicillin/streptomycin + 2 
mM glutamine) under a humidified atmosphere of 5% CO2 at 37°C. Cells were maintained at 
40-70% confluence on uncoated plastic dishes for proliferating cells. Confluent cultures were 
switched to differentiation medium (Dulbecco’s Modified Eagle Medium, Gibco + 2% horse 
serum, + 1% penicillin/streptomycin + 2 mM glutamine) and differentiated for 5 days for 
biological assays.  
2.2.2.6 Routine Culture of BaF3 Cells  
 
Murine BaF3 lymphocytes stably expressing murine FGFR1IIIc were a gift from Professor 
David Ornitz (Washington University, St. Louis, USA). They were grown in RPMI-1640 
supplemented + 10% FCS + 100 Units/ml penicillin G + 100 µg/ml streptomycin sulfate (all 
from ThermoFisher, UK) with 1 ng/ml murine interleukin-3 (R&D Systems, UK) under a 
humidified atmosphere of 5% CO2 at 37°C. Cells were maintained in suspension 105 to 106 
cells/ml in uncoated plastic flasks.  
 
2.3 Immunochemistry 
 
2.3.1 General Fixation of cells  
 
For general fixation of cells, medium was removed with aspiration and 4% paraformaldehyde 
(PFA, Sigma Aldrich) prepared in PBS, was added to the cells. Cells were incubated at RT 
for 5 minutes, before removing PFA and washing cells three times in PBS (5 minutes each). 
Cells were stored for a maximum of 2 days at 4 °C until immunostaining.  
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2.3.2 Fixation of cells for 5-bromo-2'-deoxyuridin Detection  
 
For proliferation assays, 10 μM BrdU 5-bromo-2'-deoxyuridin (BrdU, Sigma Aldrich) was 
added to cells for 2 hours prior to fixation. For immunostaining of BrdU, cells were fixed with 
ice-cold 20% methanol and incubated for 10 minutes at -20°C, before removing methanol 
and washing cells three times in PBS (5 minutes each). Cells were stored for a maximum of 
2 days at 4 °C until immunostaining. 
 
2.3.3 Immunostaining of Cells 
2.3.3.1 General Antibody Immunostaining 
 
For detection of Tcf4, Myf5, myosin heavy chain (MyHC), myogenin (MyoG) and Pax7, fixed 
cells were permeabilized with PBS + 0.2% TritonX100 for 20 minutes at RT and then 
blocked with 3% bovine serum albumin (BSA, Sigma Aldrich) for 1 hour before incubation 
with primary antibodies over night in PBS + 1% BSA at 4 °C. Primary antibodies used were: 
mouse anti-MyHC (Developmental Studies Hybridoma Bank at Iowa University, MF20 clone) 
at 1:200, mouse monoclonal anti-Pax7 (Developmental Studies Hybridoma Bank at Iowa 
University) at 1:100, rabbit anti-Tcf4 (Cell Signalling), 1:200, rabbit anti-Myf5 (Santa Cruz) 
1:500, rabbit anti-MyoG and rabbit anti-GFP (Thermo Fisher Scientific), 1:200. Cells were 
then washed 3 times with PBS + 0.2% TritonX100 and incubated for 1 hour at RT with PBS 
+ 1% BSA + secondary antibodies conjugated with AlexaFluor 488, 555 or 647 (Invitrogen), 
at 1:500 followed by incubation with 2 µg/mL DAPI (Life Technologies) in PBS for 5 minutes 
at RT. Cells were then washed 3 times with PBS + 0.2% TritonX100 then stored at 4 °C in 
PBS until imaging. 
2.3.3.2 BrdU Immunostaining 
 
For detection of BrdU fixed cells were permeabilized with PBS + 0.2% TritonX100 + 1% BSA 
for 10 minutes at RT. Cells were quickly washed with 3N HCl and then DNA was denatured 
with 3N HCl for 20 minutes at RT. Cells were quickly washed with 0.1 M sodium-borate, pH 
8.5 and then incubated in 0.1 M sodium-borate, pH 8.5 for 10 minutes at RT. Cells were 
washed 3 times with PBS and then blocked with PBS + 3% BSA for 30 minutes at RT before 
incubation with primary antibody rat anti-BrdU (Serotec) at 1:100 over night in PBS + 1% 
BSA at 4 °C. In some cases where stated, rabbit anti-GFP (Thermo Fisher Scientific), 1:200 
or mouse anti-MyHC (Developmental Studies Hybridoma Bank at Iowa University, MF20 
clone) at 1:200 were included in the incubation. Cells were then washed 3 times with PBS + 
0.2% TritonX100 and incubated for 1 hour at RT with PBS + 1% BSA + secondary 
antibodies conjugated with AlexaFluor 555 (Invitrogen) at 1:500 followed by incubation with 2 
µg/mL DAPI (Life Technologies) in PBS for 5 minutes at RT. Cells were then washed 3 times 
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with PBS + 0.2% TritonX100 then stored at 4 °C in PBS until imaging.  
 
 
2.4 Microscopy, Image Processing and Quantification 
 
2.4.1 Microscopy and Image Processing 
 
Fixed cells were imaged on an epifluorescence microscope (EVOS-FL, Life Technologies), 
10 X objectives were used for all images unless otherwise stated. Images were composed 
using Photoshop 7.0 (Adobe Systems). Background was linearly reduced using contrast and 
brightness adjustments, and all modifications were applied to the whole image.  
 
2.4.2 Manual Quantification of Immunostaining 
 
Quantification of immunostaining was achieved by manually counting cells with positive 
immunofluorescence. Conducted for 10 random images per dish, repeated over at least 
three technical replicates. All experiments were conducted at least three independent times.  
 
2.4.3 Automated Quantification of Immunostaining 
 
In some cases, images were analysed using a bespoke macro written for Fiji (available at 
[http://fiji.sc]). Assistance in analysis was provided by the Liverpool Centre for Cell Imaging, 
University of Liverpool.  Bespoke macros were written to calculate: 
 
a) The Differentiation Index;  
 𝑀𝑦𝐻𝐶  𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒  𝑛𝑢𝑐𝑙𝑒𝑖𝑡𝑜𝑡𝑎𝑙  𝑛𝑢𝑐𝑙𝑒𝑖 ×  100 
 
 
b) The Fusion Index; 
 𝑀𝑦𝐻𝐶  𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒  𝑐𝑒𝑙𝑙𝑠  𝑤𝑖𝑡ℎ  𝑎𝑡  𝑙𝑒𝑎𝑠𝑡  𝑡𝑤𝑜  𝑛𝑢𝑐𝑙𝑒𝑖𝑡𝑜𝑡𝑎𝑙  𝑛𝑢𝑐𝑙𝑒𝑖  𝑖𝑛  𝑎𝑙𝑙  𝑀𝑦𝐻𝐶  𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒  𝑐𝑒𝑙𝑙𝑠 ×  100 
 
 
c) The number of proliferating cells; 
 𝐵𝑟𝑑𝑈  𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒  𝑛𝑢𝑐𝑙𝑒𝑖𝑡𝑜𝑡𝑎𝑙  𝑛𝑢𝑐𝑙𝑒𝑖 ×  100 
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2.5 Heparan Sulfate Compositional Analysis 
 
2.5.1 Heparan Sulfate Proteoglycan Extraction  
 
2.5.1.1 Heparan Sulfate Proteoglycan Extraction from Cells  
 
Proliferating or differentiating primary myoblasts or C2C12 myoblasts, were washed twice 
with ice-cold PBS and solubilized in 1 ml TUT buffer (8 M urea, 1 % Triton X100, 10 mM 
Trizma Base, 0.1 mM Na2SO4, pH 8.0), per 10 cm2 culture dish followed by sonication to 
disrupt DNA. Samples were stored at 4 °C for a maximum of 2 days.  
2.5.1.2 Heparan Sulfate Proteoglycan Extraction from Muscle 
 
Quadricep, gastrocnemius or tibialis anterior muscles were homogenized with a blade 
homogenizer and solubilized in 1 ml of TUT buffer (8 M urea, 1 % Triton X100, 10 mM 
Trizma Base, 0.1 mM Na2SO4, pH 8.0), then cleared by centrifugation at 13,000 x g for 10 
minutes, followed by sonication to disrupt DNA. Samples were stored at 4 °C for a maximum 
2 days. 
 
 
2.5.2 Heparan Sulfate Disaccharide Preparation  
2.5.2.1 DEAE Partial Purification of HSPGs  
 
Cell or muscle homogenates were added to diethylaminoethyl (DEAE) Sephacel beads (GE 
healthcare) and incubated over night at 4°C with gentle mixing. The DEAE beads were 
washed with 10 volumes of PBS, pH 7.4 followed by 10 volumes of PBS + 0.3 M NaCl, pH 
7.4 and then eluted with 10 volumes of PBS + 2 M NaCl, pH 7.4. Eluted fractions were 
desalted on HiTrap Desalting Columns (GE healthcare) and freeze-dried.  
2.5.2.2 Heparinase Depolymerisation 
 
Freeze-dried samples were resuspended in 100 mM sodium acetate, 0.1 mM calcium 
acetate, pH 7.0 and digestion by sequential addition at 37 °C of 2.5 mU of heparinase I (2 
hours, 37 °C) followed by 2.5 mU of heparinase III (2 hours, 37 °C) and finally with 2.5 mU of 
heparinase II (2 hours, 37 °C). All three enzymes were then added together at 2.5 mU each 
(16 hour, 37 °C), to ensure full depolymerisation of HS. The cleavage specificities for the 
heparinase enzymes are shown in Table 2.1. The enzymes and core proteins were removed 
using Pierce C18 Spin Columns (Life Technologies) and the salt removed using Pierce 
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Graphite Spin Columns (Life Technologies). The samples were then freeze-dried before 
labelling. 
 
Table 2.1 Cleavage specificity of the HS chain required for the corresponding heparinase 
enzymes. 
Treatment of HS with the three heparinase enzymes at 37 °C leads to complete depolymerisation 
of the chain into its constituent disaccharide units. 
 
Enzyme Sequence Specificity 
Heparinase I -GlcNS(±6S)-α (1-4) IdoA(2S)- 
Heparinase II -GlcNR(±6S)-α (1-4) GlcA/IdoA- 
Heparinase III -GlcNR(±6S)-α (1-4) GlcA- 
 
2.5.2.3 BODIPY Labelling for Fluorescence Detection 
 
Freeze-dried samples were resuspended in BODIPY hydrazide (5 mg/ml in methanol). 
Methanol was removed by centrifugation under vacuum, and samples were resuspended in 
dimethyl sulfoxide (DMSO): acetic acid (17:3 v/v) prior to incubation for 4 h at room 
temperature in the dark. Samples were snap frozen and freeze dried. Excess free BODIPY 
tag was removed by thin layer chromatography (TLC plates, Sigma Aldrich). Bound labelled 
disaccharides were eluted from the silica scrapings with deionized water (3 x 4 ml) and then 
freeze-dried. 800 µl of saturated ethanol solution (sodium acetate in molecular biology grade 
ethanol) was added to lyophilised samples, incubated on ice for 15 minutes and then 
centrifuged at 13000 x g for 5 minutes. The supernatant was collected and dried by 
centrifugation under vacuum.  
2.5.2.4 Strong Anion Exchange-High Liquid Performance Chromatography  (SAX-HPLC) 
 
The fluorescently labelled disaccharides were resuspended in H2O (700 µl) prior to loading 
onto a Propac PA-1 column and eluted using a linear gradient of 0 – 1 M sodium chloride 
(prepared in 150 mM NaOH) over 30 minutes at a flow rate of 1 ml/minute on a Shimadzu 
HPLC system. Peaks were detected using inline fluorescence detection at excitation 
wavelength of 488 nm and an emission wavelength of 520 nm using a Shimadzu RF-551 
detector. The column was reconditioned by washing with 2 M NaCl (in 300 mM NaOH) 
before equilibrating in 150 mM NaOH. Disaccharides were identified with reference to 
authentic heparin unsaturated disaccharide standards (Table 2.2) (Dextra Labs). Previously 
calculated correction factors were applied to quantify the observed disaccharides (Table 2.2) 
(Skidmore et al., 2010).  
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Table 2.2 BODIPY Labelled HS Disaccharide Standards. 
HS disaccharides purchased from Sigma with the corresponding structure prior to BODIPY 
labelling. The typical elution times by SAX-HPLC correspond to the BODIPY labelled 
disaccharides. Correction factors were used in the calculation of peak area based on the labelling 
efficiency of each standard disaccharide.  
Sigma 
Ref Standard structure 
Elution 
time 
Correction 
Factor 
IV-A Δ-UA-GlcNAc 12.784 1.3 
IV-S Δ-UA-GlcNS 18.594 1.7 
II-A Δ-UA-GlcNAc(6S) 21.257 1.2 
III-A Δ-UA(2S)-GlcNAc 23.906 1.2 
II-S Δ-UA-GlcNS(6S) 27.661 1.0 
III-S Δ-UA(2S)-GlcNS 31.138 1.1 
I-A Δ-UA(2S)-GlcNAc(6S) 37.507 1.4 
I-S Δ-UA(2S)-GlcNS(6S) 46.079 1.1 
 
2.6 Heparan Sulfate Activity Assays 
 
2.6.1 Isolation of HS for activity assays 
 
Muscle or C2C12 myoblast homogenates (from HSPG extraction using TUT buffer) were 
added to diethylaminoethyl (DEAE) Sephacel beads (GE healthcare) and incubated over-
night at 4°C on gentle mixing. The DEAE beads were washed with 10 volumes of PBS, pH 
7.4 followed by 10 volumes of PBS + 0.3 M NaCl, pH 7.4 and then eluted with 10 volumes of 
PBS + 2 M NaCl, pH 7.4. Eluted fractions were desalted on HiTrap Desalting Columns (GE 
healthcare) and freeze-dried. Freeze-dried samples were re-suspended in 1:5 volume of 10x 
DNase solution (200 mM Tris-acetate pH 8.0, 30 mM MgCl2, 50 mM CaCl2 with 1 µg/ml 
DNase was added for 4 hours, 37 °C. 1:5 volume of 5x RNase solution was then added 
(50mM Tris pH 8.0, 25 mMEDTA, 40 mM Na-Acetate) with 0.5 mg/ml RNase was added for 
1 hour, 37 °C. 1:5 volume of 5x Chondroitin ABC lyase (cABCase) solution (500 mM Tris-
acetate pH 8.0) with 1.25U cABCase was added for 4 hours 37 °C. A 1:5 volume of 5x 
Neuraminidase buffer (250 mM Tris Acetate pH 7.5) with 2.5 mU of neuraminidase was 
added for 4 hours, 37 °C. 1:5 volume of 5x keratanase buffer (250 mM Tris Acetate, pH 7.5) 
with 100 mU keratanse was added for 4 hours, 37 °C. A 1:5 volume of 5X Pronase solution 
(500 mM Tris-acetate, 50mM Calcium acetate pH 8.0) with 10 mg/ml Pronase was added for 
16 hours, 37 °C. The samples were then added to (DEAE) Sephacel beads to remove the 
enzymes. The isolated HS chains were eluted from the beads as described previously. 
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Samples were freeze-dried and re-suspended in 100 µl filtered milliQ water. 5 µl was taken 
through for heparinase digestion (described above) for HS quantification. After the enzymes 
were removed the freeze-dried samples were re-suspended in 20 µl of miliQ water for 
quantification on the nano-drop measuring the absorbance of the C4=C5 bond at 232 nm. 
 
2.6.2 BaF3 cell Assays 
 
For assays, BaF3 cells were plated at 105 cells/ml in 96-well, flat-bottomed Costar tissue 
culture plates (Corning, USA) in 100 µl growth medium without interleukin-3 supplemented 
with FGF2 (R&D Systems, UK) and heparan sulfate at the indicated concentrations. Cells 
were incubated for 72 hours at 37°C, 5% CO2. Thiazolyl blue tetrazolium bromide (MTT) 
(Sigma, UK) was then added to a final concentration of 250 µg/ml and the cells were 
incubated a further 4 hours at 37°C, 5% CO2.  The assay was stopped with the addition of 50 
µl 10% SDS, 0.01N HCl and the plates were incubated 4 hours to overnight at 37°C to 
dissolve the formazan products.  Plates were read at 570 nm using a Thermo multiskan EX 
plate reader (ThermoFisher, UK). 
 
2.7 Knockdown of HS6STs 
 
C2C12 myoblasts were seeded in a 12-well plate at a density of 5000 cells/cm2. Cells were 
cultured in growth medium for 24 hours after which the medium was replaced with Optimem 
(Gibco). 250 ng/ml pClover (Addgene) was co transfected with 20 nM of each HS6ST siRNA 
using with Lipofectamine®2000 (Thermo FisherScientific) according to manufactures 
instructions. siRNA sequences were obtained from Sigma Aldrich (HS6ST1, 
SASI_Mm01_00066864; HS6ST2, SASI_Mm02_00292422; HS6ST1, 
SASI_Mm01_00105592; universal negative control. Following knockdown:  
 
1) To assess the extent of knockdown by quantitative real time PCR (qPCR) using 
RNA purified from siRNA-treated cells 24 hours post transfection was performed. 
2)  To assess proliferation of siRNA-treated cells, 22 hours post transfection a BrdU 
proliferation assay was performed on myoblasts in the 12-well plates 
3) To assess differentiation of siRNA-treated cells, 24 hours post transfection 
myoblasts in the 12-well plates were fixed and immunostained to detect myogenin. 
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2.8 Real Time Polymerase Chain Reaction  
 
2.8.1 RNA Isolation 
2.8.1.1 RNA Isolation from C2C12 Myoblasts 
 
RNA was isolated using a Qiagen RNeasy Mini Kit (Qiagen) following manufacturer’s 
instructions. RNA quality and integrity were checked using a Nanodrop®1000 (Thermo 
Fisher Scientific).  
2.8.1.2 RNA Isolation from Skeletal Muscle  
 
Whole TA muscle, which had been snap frozen in liquid nitrogen and stored at -80°C, was 
ground by pestle and mortar in liquid nitrogen to a fine powder. The powdered muscle was 
added to 1 ml of cold Invitrogen™TRIzol™ (Thermo Fisher Scientific). 200 µl of chloroform 
was added and the mixture was then vortexed until a homogenous mixture was obtained. 
The homogenate was centrifuged at 12,000 x g for 20 minutes. After centrifugation, the top, 
aqueous, clear layer was carefully collected and transferred into a new eppendorf tube. 500 
µl of ice-cold isopropanol was added and then thoroughly vortexed. The mixture was 
incubated for 30 minutes at RT before centrifugation at 12,000 x g for 20 minutes. The 
supernatant was carefully removed to expose a clear pellet. 200 µl of 80% ethanol was 
added and was immediately centrifuged for at 12,000 x g for 20 minutes. The supernatant 
was removed carefully avoiding the pellet. The pellet was air-dried before being 
resuspended in 20 µl of RNase-free water and stored at -80°C. RNA quality and 
concentration were checked using a Nanodrop®1000 (Thermo Fisher Scientific). 
 
 
2.8.2 cDNA Synthesis 
2.8.2.1 cDNA Synthesis for Manual RT-PCR 
 
Following RNA extraction from C2C12 myoblasts, cDNA was synthesised from a maximum 
of 5 µg of RNA using the Tetro cDNA Synthesis Kit (Bioline).  
2.8.2.2 cDNA Synthesis for Automated RT-PCR 
 
Following RNA extraction from whole muscle RNA was taken to Oxford on dry ice. cDNA 
was synthesised using the Applied Biosystems™ High-Capacity cDNA Reverse Transcription 
Kit (Thermo Fisher Scientific) carried out by Dr Anastasios Chanalaris in Dr Linda Troeberg’s 
laboratory (Kennedy Institute of Rheumatology, University of Oxford).  
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2.8.2.3 Manual RT-PCR 
 
Gene expression was quantified by qPCR using the LightCycler 460 SYBR Green I Master 
kit (Roche) with 5 µl cDNA corresponding to 20 ng total RNA in a 20 µl final volume and 0.4 
µM of each primer. Experiments were performed in duplicate for each sample in a 96-well 
plate (Roche). The PCR programme contained: 95°C for 5 minutes followed by 45 cycles at 
95°C for 12 seconds, at the annealing temperature of 57°C for 10 seconds, and the 
extension at 72°C for 10 seconds. Amplification specificity was assessed using a melting 
curve following the manufacturer’s instructions. Primers were designed using the NCBI 
Primer-BLAST software to have a melting temperature of 60°C and an amplicon size 
between 100-200 base pairs (Table 2.3). Primers were purchased from Eurofins Genomics. 
Results were analysed with the LightCycler software (Roche) using the second derivative 
maximum method to set the threshold cycle (CT). The relative quantitative analysis was 
carried out using the comparative CT method (2-ΔΔCT) method such that expression levels of 
all three HS6STs were first normalised to the reference gene glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) and then the normalised HS6ST/GAPDH values obtained from 
cells transfected with HS6ST siRNAs where expressed as percentage of the HS6ST/GAPDH 
values obtained from cells transfected with control (scrambled) siRNA. 
 
Table 2.3 Sequences of Primers used in Manual RT-PCR 
Gene Forward Primer Reverse Primer Size 
GAPDH CCCCTTCATTGACCTCAACTAC TCCACGACATACTCAGCACC 182 
HS6ST1 CGTTCGCCCAGAAAGTTCTAC CACACATGTGCAAGGAGGTC 118 
HS6ST2 CCCTTGGCCAGCGTCG GCACACGTATTGGACGA 102 
HS6ST2 GGCAAGAAGGAGACCTGGCT GTAGAAATTCCTGGTGTGGCTGTG 150 
 
2.8.2.4 Taqman® Low Density Array Microfluidic cards 
 
Taqman® Low Density Array (TLDA) microfluidic cards were used to study the transcript 
expression levels of the HS biosynthetic enzymes in the tibialis anterior muscles of 3 month 
and 2 year-old mice. TLDA experiments were carried out by Dr Anastasios Chanalaris in Dr 
Linda Troeberg’s laboratory (Kennedy Institute of Rheumatology, University of Oxford). 
TLDA microfluidic cards were custom designed to contain pre-selected Taqman gene probes 
and carry out 384 real time PCR reactions simultaneously. A total of 8 samples were run on 
one card (four from 3 month old muscle and four from 2 year old muscle). For each sample 
48 HS-related genes were analysed, including the endogenous control, GAPDH. Cards were 
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prepared with a total reaction mixture for each sample of 100 µl containing 50 µl 2X 
Universal PCR mix (Applied Biosystems, USA) and 50 µl cDNA template (200 ng starting 
RNA) in nuclease-free water. Prior to loading, the reaction mixture of each sample was 
vortexed and briefly centrifuged. Once loaded the card was centrifuged twice (1 minute at 
12,000 rpm) and sealed with the microfluidic card sealer. The cards were run on the 7900HT 
ABI thermocycler (Applied Biosystems, USA). The thermocycling conditions were as follows: 
held at 50°C for 2 minutes, denatured at 94.5°C for 10 minutes, followed by 40 cycles of 
denaturing at 97°C for 30 seconds, and lastly annealing/extending for 1 minute at 60°C.  
 
2.9 Treatment With Modified Heparins  
 
Chemically modified heparins were prepared and kindly donated by Dr Ed Yates, University 
of Liverpool (Yates et al., 1996).  
 
2.9.1 Differentiation Assay  
 
Primary satellite-cell derived myoblasts were induced to differentiate in the 
presence/absence of modified heparins for 3 days prior to fixation with 4% PFA was 
prepared in PBS for 10 minutes at room temperature and then washed 3 times with PBS. 
Fixed cells were stored in PBS at 4°C until immunostaining was performed. 
 
2.9.2 Proliferation Assay in High Serum  
 
Primary satellite-cell derived myoblasts were grown under proliferating conditions in the 
presence/absence of modified heparins for 24 hours prior to a BrdU assay.  
 
2.9.3 Proliferation Assay in the Absence of Serum 
 
Primary satellite-cell derived myoblasts were serum-starved for 12 h to induce cell cycle exit 
followed by treatment with FGF2 with or without the modified heparin over night. To assess 
proliferation of treated cells in the absence of serum, a BrdU assay was then performed on 
myoblasts in the 12-well plates. 
 
 
 
2.9.4 Western Blotting 
 
Whole cell extracts were obtained by incubating C2C12 cells in modified RIPA buffer (50 mM 
Tris-HCl, pH 7.4, 1% NP-40, 0.25% sodium-deoxycholate, 150 mM NaCl, and 1 mM 
ethylenediaminetetraacetic acid (EDTA)) supplemented with a protease inhibitor cocktail 
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(Complete, Roche) and phosphatase inhibitors (2 mM Na3VO4 and 2 mM NaF) for 30 
minutes on ice, then cleared by centrifugation at 13,000 x g for 10 minutes at 4°C. Protein 
was quantified with a bicinchoninic acid (BCA)-based kit (Pierce) according to the 
manufacturer’s instructions. Total protein content (10–30 µg) was separated on a 10% SDS-
PAGE gels and transferred onto nitrocellulose membranes (Hybond, GE Healthcare) for 
Western blotting. Primary antibodies were incubated overnight at 4 °C in PBS + 5% BSA and 
were: rabbit anti-p44/42 MAPK (Erk1/2, Cell Signalling Technology) used at 1:1,000, rabbit 
anti-Phospho-p44/42 MAPK (Erk1/2, Thr202/Tyr204, Cell Signalling Technology) used at 
1:1,000. Anti–rabbit horseradish peroxidase (HRP)-conjugated secondary antibodies (Santa 
Cruz Biotechnology) were used at 1:10,000 in PBS + 5% BSA for 1 hour at room 
temperature, and HRP activity was visualized using the ECL Plus system (BioRad). Images 
were quantified using the “Analyze Gel” function of ImageJ.  
 
2.10 Statistical Analysis 
 
All statistical analyses were carried out using Microsoft Exel or GraphPad Prism. Each 
experiment consisted of at least three technical replicates, where statistical significance was 
determined using an unpaired Student’s t-test or a one-way ANOVA. Data were plotted as 
the mean ±	 standard error of the mean (SEM) for normally distributed data. Data were 
deemed statistically significant when p < 0.05.  
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Chapter 3  
 
 
 
 
 
3 The Structure of HS Changes During Myogenic 
Differentiation 
 
 
3.1 General Introduction 
 
3.1.1 Myogenic Cultures 
 
To study myogenesis in vitro, satellite cell derived-myoblasts can be isolated from skeletal 
muscle and expanded ex vivo. Isolation requires satellite cells to be liberated from their 
niche, by manual muscle mincing followed by enzymatic digestion to break-up connective 
tissue and the myofibres to which the satellite cells adhere. Several murine myoblast cell 
lines have been developed from isolated myoblasts whose behaviour corresponds to that of 
progenitor lineage. C2C12 myoblasts, the most commonly used myoblast cell line (Blau et 
al., 1983b), are a sub-clone of C2 myoblasts (Yaffe and Saxel, 1977), which differentiate 
spontaneously after serum withdrawal (Blau et al., 1983a). The C2C12 myoblast cell line 
requires standard culture conditions with no extra growth factor supplements, is highly robust 
and thus can be readily expanded at low cost. An alternative cell line is the MM14 myoblast 
cell line, which is less widely used than the C2C12 myoblast cell line but retain more similar 
morphological and molecular characteristics of primary satellite cells (Linkhart et al., 1980). 
Furthermore a conditionally immortal satellite cell-derived cell-line, H2K 2B4 has been 
generated, which display no tumorogenic tendency in vivo unlike the C2C12 myoblast cell 
line (Morgan et al., 1994). Although myoblast cell lines provide consistency and convenience 
for studying biochemical and molecular mechanisms of myogenesis in vitro, they lack some 
critical features of satellite cells. For example, primary satellite cells display significantly 
differential adhesion and motility on extracellular matrix substrates than both C2C12 and 
MM14 myoblasts (Siegel et al., 2009). Primary satellite cell-derived myoblast cultures are 
therefore a better representation of an in vivo system (Cornelison, 2008), effectively 
mimicking most of the molecular mechanisms involved in satellite cell self-renewal, 
proliferation and differentiation. Thus, efficient purification protocols are essential for isolating 
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satellite cell-derived myoblasts dissociated from whole skeletal muscle. A method based on 
fluorescence-activated cell sorting (FACS) has been recently developed for purifying satellite 
cell derived myoblasts, by using antibodies directed against specific satellite cell surface 
antigens (Liu et al., 2015; Pasut et al., 2012).  However, antibodies and FACS are highly 
expensive and laser exposure can induce cell death during the purification process, leading 
to loss of material (Mollet et al., 2007). Alternatively, satellite cells can be separated from 
fibroblasts and myofibril debris by a series of pre-plating steps based on differences in 
adhesion characteristics (Goetsch et al., 2015; Qu-Petersen et al., 2002; Rando and Blau, 
1994; Richler and Yaffe, 1970). Since fibroblasts are more adhesive than quiescent and 
early activated satellite cells, they adhere to the dish in the first series of pre-plating steps, 
while satellite cell-derived myoblasts remain in suspension and after pre-plating can be 
collected for culturing and expansion.  
 
3.1.2 HS Structural Analysis During Muscle Differentiation 
 
As discussed previously, many heparin-binding growth factors are involved in the regulation 
of myogenesis, and depend heavily on the structure of HS. Currently, however, there is little 
information available with regards to the structural composition of HS during myogenesis. 
There has been one study, which reported an increase in the amount of HS during 
differentiation of the C2.7 myoblast cell line (Barbosa et al., 2005). Modest changes in the 
structural composition of HS were also implicated based on antibody expression and the 
expression levels of a small proportion of HS biosynthetic enzymes (Barbosa et al., 2005). 
However, these techniques do not reveal more subtle structural changes in HS, such as 
differences in the abundance of specific HS disaccharide units. Furthermore, studies in vivo 
suggest that structural changes in HS do affect myogenic regulation. Firstly, mutant mice 
lacking the two extracellular sulfatases that remove the sulfate group in 6-O position, mSulf1 
and mSulf2, exhibit delayed myogenic differentiation (Langsdorf et al., 2007; Tran et al., 
2012). Secondly, structural changes in HS have been reported in regenerating muscles post 
ischaemic-injury (Chevalier et al., 2015), suggesting that the structure of HS has a role in 
regulating satellite cell homeostasis. Given this, it would be important to further investigate 
the structural composition of HS during myogenesis in primary cultures of satellite cell-
derived myoblasts in an attempt to better understand the structure-function relationships of 
HS during myogenesis. 
 
3.1.3 HS Structural Analysis Background  
 
Efficient protocols are crucial for purifying and analysing HS from tissues and cells. HS 
purification involves the initial release of HS by the homogenisation of cells or tissues in a 
manner that leads to disruption of cell membranes. Although HS is a highly stable 
macromolecule in most physiological conditions, caution must be taken with the method of 
extraction, since extreme conditions, such as low pH and high temperatures, can lead to N-
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desulfation and other modifications (Drummond et al., 2001; Inoue and Nagasawa, 1976; 
Yates et al., 1996). More commonly, methods for HS extraction from cells and tissues 
involve the use of detergent for cell membrane disruption. Following on from HS extraction, 
an efficient approach for the rapid isolation of proteoglycans has been developed (Guimond 
et al., 2009a), which involves little loss of material and is readily scalable. Since HS is highly 
negatively charged, ion exchange is used for HS partial purification. HS binds to gel matrix 
beads derivatised with a positively charged molecule, such as diethylaminoethanol (DEAE) 
and is released from the matrix with an increasing salt gradient. Contaminating 
macromolecules can also be removed at this step by single-pot sequential enzymatic digests 
and a second ion exchange and desalting procedure for preparing highly purified HS suitable 
for bioassays. For structural analysis, due to the structural complexity, depolymerisation of 
the HS chain for subsequent disaccharide compositional analysis is commonly used. HS 
disaccharide units harbour different levels and positions of sulfation and consequently, will 
bind with different affinities to a strong anion exchange (SAX) column, allowing for 
separation and detection by high performance liquid chromatography (HPLC). The 
heparinase enzymes are lyases that, acting together, catalyse complete depolymerisation of 
the HS chain into its constituent disaccharide units, harbouring a 4,5 unsaturated bond at the 
newly introduced non-reducing end allowing for its detection at 232 nm; ε = 5500 M−1cm−1. 
HS disaccharide abundance can be determined by reference to the elution times of a set of 
commercially available HS disaccharides. Additionally, the introduction of the unsaturated 
bond allows for HS quantification via absorption at 232 nm. This is more advantageous than 
other methods of HS quantification, which often require complete disruption of HS, such as 
the cationic dye 1,9-dimtehylmethylene blue (DMMB), which covalently binds to sulfated 
GAGs and thus the HS cannot be used for further structural analysis.  
 
However, since it is difficult to isolate HS in sufficient quantities from primary cells and 
tissues, UV absorption is often not sensitive enough for individual disaccharide detection and 
therefore an alternative method of detection is important. The reducing end of the 
disaccharide allows for labelling with a fluorescent tag. The fluorophore 4,4-difluoro-5,7-
dimethyl-4-bora-3a,4a-diaza-s-indacene-3-propionic acid, hydrazide (BODIPY) (Figure 3.1), 
has been found to produce improved yields and sensitivity compared to other more widely 
used fluorescent tags (Skidmore et al., 2006; Skidmore et al., 2010), permitting structural 
analyses of HS approximately 1000-fold higher sensitivity than UV detection (Lohse and 
Linhardt, 1992) and 10-100-fold higher sensitivity than previous fluorescence detection 
methods (Deakin and Lyon, 2008; Kinoshita and Sugahara, 1999; Kitagawa et al., 1995; 
Toyoda et al., 1997). Owing to its higher reactivity, BODIPY labelling also requires less 
harsh chemical conditions, which can often be problematic when dealing with the acid 
sensitive N-sulfate groups of HS. Furthermore, unlike many other fluorescent labels, which 
are charged, BODIPY is a neutral compound and therefore does not interact strongly with 
anion exchange columns. The resulting labelled HS disaccharides can then be passed over 
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a SAX-HPLC column eluted with a salt gradient and detected at λexc = 488 nm and λemm = 
520 nm. 
 
 
Figure 3.1 Structure of BODIPY fluorophore. 
Structure of the BODIPY fluorescent tag used for derivatisation of the HS disaccharide at the 
reducing end of the disaccharide after HS digestion with heparinase I/II/III. 
 
3.2 General Hypothesis 
 
Given that HS controls many signalling pathways that are involved in the regulation of 
myogenesis, it was hypothesized that the structural composition of HS changes during 
satellite cell differentiation and thus is a contributory factor for regulating the balance 
between proliferation and differentiation.   
 
In this chapter it will be shown that: 
 
1. Pure populations of myoblasts can be isolated from murine skeletal muscle using a 
quick and economical differential plating protocol 
2. The level of sulfation of the primary myoblast heparanome increases with 
differentiation  
3. The level of sulfation of the C2C12 myoblast heparanome increases with 
differentiation  
4. HS from proliferating myoblasts but not that from differentiating myoblasts promote 
FGF2 signalling 
 
3.3 Results  
 
3.3.1 Isolating Satellite cell-derived Myoblasts  
3.3.1.1 Differential Adhesion Protocol for the Isolation of Satellite Cell-Derived Myoblasts  
 
Since HS controls many of the protein functions that are involved in the regulation of 
myogenesis (as reviewed in Turnbull et al, 2001;Bishop et al, 2007), it was hypothesized that 
the structure of HS changes during muscle progenitor differentiation, and thus may be a 
contributory factor that regulates the balance between myoblast proliferation and 
N
B
N
CH2CH2F F C
O
NHNH2
Chapter 3                                                                                            Structure of HS During Myogenesis 
   
 
 
63 
differentiation. To explore this hypothesis, primary myoblast cultures were initially used for 
HS extraction, since primary myoblasts are generally more representative of an in vivo 
system than myoblast cell lines. For satellite cell-derived myoblast purification, a differential 
plating protocol was employed based on an adapted version of the method previously 
described by Rando and Blau (Rando and Blau, 1994) (Figure 3.2). Myoblasts were derived 
from the hind-limb muscles of 3 month-old female mice following the protocol outlined in 
Figure 3.2. Firstly, muscles were minced into a fine slurry and cells were then enzymatically 
dissociated with collagenase type I. The slurry was filtered before centrifugation to pellet 
cells, resuspended and plated onto gelatin-coated plates, which was referred to as pre-
plating 1 (PP1). After two hours of incubation, the supernatant containing non-adherent cells 
was transferred to a second pre-plating, again onto gelatin-coated plates, which was referred 
to as pre-plating 2 (PP2). After a further one hour incubation on PP2, the supernatant 
containing non-adherent cells was transferred to a final plating onto gelatin-coated plates, 
labelled as passage 0 (P0). Adherent cells from PP1 and PP2 were also supplied with fresh 
medium. To ensure fibroblasts were successfully removed in the initial pre-platings (PP1 and 
PP2) that the final plating (P0) was enriched for myoblasts, 48 hours post isolation, cells 
were fixed and immunostained to detect transcription like-7 2 factor (Tcf4), a fibroblast 
marker (Mathew et al., 2011), myogenic regulatory factor, Myf5 and paired box transcription 
factor, Pax7.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 Schematic showing differential plating protocol for myoblast isolation.
 The hindlimb muscles of 3 month-old female mice were minced and incubated at 37°C with 
collagenese type I for 1 h to release cells. Myoblasts were isolated through a series of two pre-
plating steps: PP1 and PP2. The differential plating protocol is based on the shorter adhesion 
time of fibroblasts compared to myoblasts. After 2 h on PP1, the supernatant containing non-
adherent cells was transferred to PP2. Then, after 1 h on PP2, the supernatant containing non-
adherent cells was transferred to passage 0 (P0).  Adhered cells were cultured for a further 48 h 
before fixing and immunostaining to detect the fibroblast marker, Tcf4 and myogenic markers; 
MyoD, Myf5 and Pax7. Cells were supplemented with FGF2 daily and grown on plates coated 
with gelatin. 
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3.3.1.2 Myoblast Enrichment Validation 
 
After 48 hours in culture, the majority of cell populations present in PP1 and PP2 displayed 
distinct fibroblast-like morphological features (Figure 3.3), exhibiting diverse, elongated 
shapes. The majority of cells present at passage 0 (P0) were more homogeneous in shape, 
smaller and rounder, which is highly characteristic of satellite cell-derived primary myoblasts 
plated on gelatin (Motohashi et al., 2014). Cells present in PP1 stained positively for Tcf4 but 
did not co-express Pax7 or Myf5 (Figure 3.4 + Figure 3.5). At PP2, cells labelled positively 
for Tcf4 or Myf5. Cells present at PP2 did not express Pax7. At P0 only 1.49 (± 0.97) % of 
cells stained positively for Tcf4. Lastly, at P0, 48 hours after isolation, 80.9 (± 4.4) % of cells 
stained positively for Pax7 and 85.9 (3.1) % cells stained positively for Myf5. Thus this 
provided a clear indication that PP1 consisted of predominantly fibroblasts and P0 consisted 
predominantly of myoblasts, with few contaminating fibroblasts.  
 
Figure 3.3 Morphological validation of 
fibroblasts and myoblasts. 
Firstly, a representative image of adhered 
fibroblast at PP1, showing elongated shape 
with large nuclei (left image). Representative 
image of adhered myoblast at P0, which are 
rounder and smaller (right image).  Images 
taken at 40 X magnification. Scale bar = 20 
µm 
 
Figure 3.4
Representative 
images of cell 
populations from 
PP1, PP2 and P0 
immuno-labelled 
with anti-Tcf4 
(red) antibody. 
Cells were fixed 
and 
immunostained 48 
h after the initial 
isolation. Nuclei 
are detected with 
the DNA stain 
DAPI (blue). A 
minimum of 5 
random fields 
were taken to 
calculate the 
percentage of 
Tcf4+. Scale bar = 
100 µm across all 
images. 
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Figure 3.5 Representative images of cell populations from PP1, PP2 and P0 immuno-
labelled with anti-Myf5 (red) and anti-Pax7 (green) antibodies. 
Cells were fixed and immunostained 48 h after the initial isolation. Nuclei are detected with 
the nuclear stain DAPI (blue). A minimum of 5 random fields was taken to calculate the 
percentage of Myf5+ and Pax7+ over the total number of DAPI+ cells. Scale bar = 100 µm 
across all images. 
 
 
3.3.2 The Structure of HS from Satellite Cell-Derived Myoblasts 
3.3.2.1 Proliferating and Differentiating Satellite Cell-Derived Myoblasts 
 
After purifying satellite cell-derived myoblasts in culture, HS was extracted from proliferating 
myoblasts 48 hours after plating of Passage 0. HS was extracted from differentiating 
myoblasts, which had been induced to differentiate with reduced serum medium for a further 
72 hours. Incorporation of the cell cycle marker 5-Bromo-2′-deoxyuridine (BrdU) was used as 
an indication of myoblasts proliferating, in particular of cells in S-phase of the cell cycle, 
(Figure 3.6) and thus is nearly absent in differentiating myoblast cultures (Figure 3.6). 
Myosin heavy chain (MyHC), a muscle myosin protein, is found only in differentiating 
myoblasts and thus was used as a marker of myoblast differentiation (Figure 3.6). To further 
investigate the level of myoblast proliferation 3 days after culture in low serum-medium, Ki-
67, a nuclear protein involved in cell cycle regulation (Gerdes et al., 1983), was used as a 
marker of myoblast proliferation since it is found only in proliferating cells and is absent from 
quiescent and differentiating cells, which are both in G0 phase of the cell cycle. In 
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differentiating myoblast cultures only 0.29 (± 0.2) % of cells stained positively for Ki-67 
strongly indicating that nearly all cells in these cultures had left the cell cycle (Figure 3.7). It 
has been shown that upon serum deprivation, a sub-population of both satellite cell-derived 
myoblasts and C2C12 myoblasts exits the cell cycle but does not differentiate. These cells, 
named ‘reserve cells’, do not express differentiation markers, express Pax7 and enter a 
temporary G0 phase, thus effectively representing an in vitro model of satellite cell self-
renewal (Yoshida et al., 1998). Under the conditions of the experiments shown here, since 
only a negligible percentage of non-differentiated cells expressed proliferation markers after 
3 days in low serum medium, we concluded that nearly all the non-differentiated cells that 
expressed Pax7 were bona fide reserve cells. 
 
Figure 3.6 Representative images of proliferating and differentiating satellite cell-derived 
myoblasts. Satellite cell-derived myoblasts were isolated from the hind-limb muscles of 3 month 
old female mice. Proliferating myoblasts were grown in culture for 72 h post isolation with growth 
medium supplemented with 2 nM FGF2. Differentiating myoblasts were differentiated for another 
72 h in culture with differetiating medium. Proliferation was detected via BrdU incorporation and 
immunostaining (red) whilst differentiation is detected via myosin heavy chain (MyHC, green) 
immunostaining. Nuclei were detected with the DNA stain DAPI (blue). Scale bar = 100 μm 
(Ghadiali et al., 2016). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7 Representative images of the number of Ki-67 positive cells in differentiating 
conditions. Satellite cell-derived myoblasts were isolated from the hind-limb muscles of 3 month 
old female mice. Differentiating myoblasts were differentiated for 72 h in culture with differetiating 
medium. Myoblasts were fixed with 4% PFA before immunostaining. Proliferating myoblasts were 
detected via Ki-67 immunostaining (red) whilst differentiation was detected via myosin heavy 
chain (MyHC, green) immunostaining. Nuclei were detected with the DNA stain DAPI (blue). 
Scale bar = 100 μm. 
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3.3.2.2 HS Extraction from Proliferating and Differentiating Satellite Cell-Derived 
Myoblasts 
 
For HS extraction, proliferating and differentiating satellite cell-derived myoblasts were 
homogenised to extract HS with a strong homogenisation buffer. The homogenate was 
applied to DEAE beads to partly purify HS, desalted and then the HS was digested into its 
constituent disaccharide units with heparinase I, II and III. The resulting disaccharides were 
labelled with the fluorophore BODIPY, separated and detected by strong anion exchange 
high performance liquid chromatography (SAX-HPLC) relative to a set of 8 commercially 
available HS disaccharide standards. Figure 3.8 shows the main steps involved in the 
process of HS extraction and disaccharide compositional analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8 Main steps involved in the process of  HS extraction and disaccharide 
compositional analysis.
 Cells were homogenised with TUT buffer (8 M urea, 1 % Triton X100, 10 mM Trizma Base, 0.1 
mM Na2SO4, pH 8.0) to release the HS from a) proliferating satellite cell-derived myoblasts which 
had been grown in culture for 72 h post isolation and b) differentiating satellite cell-derived 
myoblasts which had been differentiated in culture for a further 72 h. HS chains were isolated 
using DEAE beads and eluted with a high salt gradient. HS was digested into its constituent 
disaccharides, with heparinase I, II and III enzymes. Disaccharides were purified and labelled 
with the fluorescent tag BODIPY at the reducing end of the disaccharides. Disaccharides (in red) 
were profiled via SAX-HPLC relative to a set of 8 HS authentic disaccharides (in black). 
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HS disaccharides from proliferating and differentiating myoblasts were identified relative to 
the elution times of a set of commercially available, 8 most common authentic HS 
disaccharides (Figure 3.9 and Table 3.1), which were also derivatised with the BODIPY 
fluorophore. The most highly sulfated disaccharides, and thus the most negatively charged, 
interact most strongly with the SAX column and therefore had the highest elution times. The 
fluorescence intensity was measured by the λexc = 488 nm and λemm = 520 nm of the 
BODIPY fluorophore. The peak areas of the individual disaccharides were then used to 
calculate their abundance relative to the total peak area of the 8 disaccharides. 
 
 
 
 
 
 
 
Figure 3.9 Common HS disaccharide units derived by heparinase digestion.
The general HS disaccharide unit post heparinase digestion. The 8 most common disaccharide 
structural units are displayed in Table 3.1 where R1 = COCH3 or SO3- and R2, R3 = H or SO3-. 
Disaccharides are labelled with BODIPY for fluorescence detection. 
 
 
Table 3.1 HS disaccharide reference standards structure and elution times. 
The structure of the 8 commonly occurring HS disaccharides (in reference to Figure 3.8) derived 
from heparinase digestion before derivitisation with BODIPY and the elution times of the 
commercially available (Sigma) HS disaccharide standards from SAX-HPLC post derivitisation 
with BODIPY. Elution times were used to identify HS disaccharides. On the general disaccharide 
structural unit shown in Figure 3.9: R1 corresponds to position N (Pos. N), R2 corresponds to 
position 6 (Pos. 6) and R3 corresponds to position 2 (Pos. 2). 
 
Sigma 
Ref Standard structure 
Elution 
time 
(Pos. N) 
R1 
(Pos. 6) 
R2 
(Pos. 2) 
R3 
IV-A Δ-UA-GlcNAc 12.784 COCH3 H H 
IV-S Δ-UA-GlcNS 18.594 SO3- H H 
II-A Δ-UA-GlcNAc(6S) 21.257 COCH3 SO3- H 
III-A Δ-UA(2S)-GlcNAc 23.906 COCH3 H SO3- 
II-S Δ-UA-GlcNS(6S) 27.661 SO3- SO3- H 
III-S Δ-UA(2S)-GlcNS 31.138 SO3- H SO3- 
I-A Δ-UA(2S)-GlcNAc(6S) 37.507 COCH3 SO3- SO3- 
I-S Δ-UA(2S)-GlcNS(6S) 46.079 SO3- SO3- SO3- 
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3.3.2.3 The Level of Sulfation of the Muscle Stem Cell Heparanome Increases with 
Differentiation 
 
Since the level of sulfation in HS has been reported to increase in embryonic stem cell 
differentiation (Hirano et al., 2012; Johnson et al., 2007; Nairn et al., 2007), it was 
hypothesised that the level of sulfation of HS may change during myogenic differentiation of 
muscle stem cells. To investigate this, the proportion of unsulfated disaccharides (Δ-UA-
GlcNAc) and sulfated disaccharides (the seven remaining sulfated disaccharides) was 
calculated as a percentage of the total disaccharide content. In proliferating myoblasts there 
was an equal distribution between unsulfated and sulfated disaccharides (Figure 3.10). In 
differentiating myoblasts however, there was a higher proportion of sulfated disaccharides 
compared to non-sulfated disaccharides (Figure 3.10).  
 
 
Figure 3.10 HS is more sulfated in differentiating myoblast cultures compared to 
proliferating myoblast cultures. HS was extracted and anlaysed via the process shown in 
Figure 3.8. The relative proportion of each disaccharide was calculated as the percentage peak 
area of the total peak of the 8 HS disaccharide units. The percentage of non-sulfated 
disaccharides (Δ-UA-GlcNAc, unsulfated, black bars) and sulfated (sum of all remaining 
disaccharides which are sulfated, grey bars) disaccharides is plotted as averages of four 
independent experiments ± S.E.M. * = p < 0.05 (Pro; N=4, Diff; N=4) (Ghadiali et al., 2016). 
 
3.3.2.4 Specific Changes in the Disaccharide Composition During Satellite Cell-Derived 
Myoblast Differentiation 
 
To investigate the increase in HS sulfation during differentiation, the relative abundance of 
mono-sulfated, di-sulfated and tri-sulfated disaccharides was quantified. There was a 
statistically significant increase in the abundance of mono-sulfated disaccharides in 
differentiating myoblasts compared to proliferating myoblasts (Figure 3.11). This was 
accompanied by a marked decrease in the abundance of non-sulfated disaccharides and a 
slight decrease in tri-sulfated disaccharides in differentiating myoblast cultures although 
these did not reach statistical significance (Figure 3.11). Specifically, there was an increase 
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in the two mono-sulfated disaccharides: Δ-UA-GlcNAc(6S) and Δ-UA(2S)-GlcNAc in 
differentiating myoblasts (Figure 3.12). There was also a decrease in the abundance of the 
non-sulfated disaccharide Δ-UA-GlcNAc although this did not reach statistical significance 
(Figure 3.12). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11 The proportion of mono-sulfated disaccharides in differentiating satellite cell-
derived myoblast cultures is increased compared to proliferating satellite cell-derived 
myoblast cultures. HS was extracted and anlaysed via the process shown in Figure 3.8. The 
relative proportion of each disaccharide was calculated as the percetage peak ratio of the 8 HS 
disaccharide units. The percentage of non-sulfated Δ-UA-GlcNAc disaccharides (no-S) and the 
sum of the percentages of all mono-sulfated (mono-S), di-sulfated (di-S) and tri-sulfated (tri-S) 
disaccharides in proliferating (black) and differentiating (grey) cells was calculated. Plots show 
averages of four independent experiments ± S.E.M. * = p < 0.05 (Pro; N=4, Diff; N=4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12 HS has increased levels of specific mono-sulfated disaccharides in 
differentiating compared to proliferating satellite cell-derived myblasts. HS was extracted 
and anlaysed for proliferating (black) and differentiating (grey) satellite cell-derived myoblasts. 
The peak ratios of the individual HS disaccharides are plotted as the averages of four 
independent experiments ± S.E.M.  * = p < 0.05. (Pro; N=4, Diff; N=4) (Ghadiali et al., 2016). 
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3.3.2.5 Average Level of Sulfation at Specific Positions of the Primary Myoblast 
Heparanome Remains Unchanged During Differentiation 
 
After observing that the overall level of sulfation is altered during myogenic differentiation, it 
was reasoned that the pattern of sulfation might also change, since the position of sulfation 
of HS is an important factor in determining its bioactivity. The three positions of the 
disaccharide unit, which are differentially functionalised in the 8 most common HS 
disaccharides are at position N, position 6-O and position 2-O. Thus, to assess the overall 
position of HS sulfation, the proportion of HS disaccharides containing 2-O-sulfation, 6-O-
sulfation and N-sulfation was calculated. There were no statistically significant differences 
between the global positions of sulfation in HS from proliferating satellite cell-derived 
myoblasts compared with HS from differentiating myoblasts (Figure 3.13). There was a 
slight decrease in the level of 6-O- and 2-O-sulfation, and a slight increase in N-sulfation 
although these did not reach statistical significance.  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.13 Average level of sulfation at specific positions is not altered between HS from 
proliferating and differentiating satellite cell-derived myoblasts. Analysis of the abundance 
of disaccharides containing specific sulfate groups: 6-O-sulfation, N-sulfation and 2-O-sulfation 
reveals no statistically significant differences in proliferating (black) and differentiating (grey) 
satellite cell-derived myoblasts. The abundance of specific sulfate groups are plotted as the 
averages of four independent experiments ± S.E.M. * = p < 0.05 (Pro; N=4, Diff; N=4) (Ghadiali et 
al., 2016). 
 
3.3.3 The heparanome of the Myoblast C2C12 Cell Line Changes During Myogenic 
Differentiation 
 
Since the structure of HS changes during differentiation of primary myoblasts and FGF2 is a 
potent inhibitor of myogenic differentiation, it was hypothesised that the HS from proliferating 
myoblasts would promote FGF2 signalling more than the HS from differentiating myoblasts. 
Thus we sought to test the effect on FGF2 signalling exerted by HS extracted from 
proliferating or differentiating cells. Since the quantities of HS necessary for cell biology 
experiments are large and difficult to obtain from primary cells, it is more advantageous to 
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use cell lines, which are more readily expandable compared to primary cultures. Thus, 
before investigating the effect of HS from proliferating and differentiating cells on FGF2 
activity, we characterised the HS present in proliferating and differentiating C2C12 
myoblasts to verify that it was comparable to that of primary myoblasts. 
3.3.3.1 Differentiating C2C12 Myoblasts Show an Increase in the Level of HS Sulfation 
 
HS was isolated from proliferating C2C12 myoblasts or from C2C12 myoblasts that were 
induced to differentiate for five days by serum reduction. Overall, the structural changes in 
HS observed in differentiating C2C12 myoblasts followed a similar trend compared to the 
changes observed in satellite cell-derived myoblast cultures. Importantly, a statistically 
significant increase in the proportion of sulfated disaccharides in differentiating C2C12 
myoblasts compared to proliferating myoblasts was observed (Figure 3.14).  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.14 HS is more sulfated in differentiating C2C12 myoblast cultures compared to 
proliferating cultures. HS was extracted from proliferating and differentiatiatin C2C12 myoblasts 
and anlaysed via the process shown in Figure 3.8. The relative proportion of each disaccharide 
was calculated as the percentage peak area of the total peak area of the 8 HS disaccharide units. 
The percentage of non-sulfated disaccharides (Δ-UA-GlcNAc, unsulfated, black bars) and 
sulfated (sum of all sulfated, grey bars) disaccharides are plotted as the average of 4 
independent experiments. ± S.E.M.   * = p < 0.05 (Pro; N=4, Diff; N=4). 
 
3.3.3.2 Specific Changes in Disaccharide Composition Are Observed During C2C12 
Myoblast Differentiation   
 
As in the case of primary satellite cell-derived myoblasts, the increase in sulfation associated 
with differentiation was primarily due to an increase in the proportions of mono-sulfated 
disaccharides and a decrease in the proportion of the unsulfated disaccharide, although the 
latter did not reach statistical significance in C2C12 myoblast cultures (Figure 3.10). 
However, C2C12 myoblasts also showed a statistically significant decrease in the proportion 
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of tri-sulfated disaccharides in differentiating cells compared to proliferating cells (Figure 
3.15). The increase in the abundance of mono-sulfated disaccharides during myogenic 
differentiation was due to a statistically significant increase in: Δ-UA-GlcNAc(6S), Δ-UA(2S)-
GlcNAc and Δ-UA-GlcNS (Figure 3.16). In addition to these, there was also a significantly 
higher proportion of the di-sulfated disaccharide Δ-UA(2S)-GlcNS in differentiating C2C12 
myoblasts compared to proliferating C2C12 myoblasts. The tri-sulfated disaccharide Δ-
UA(2S)-GlcNS(6S) was also significantly reduced in differentiating C2C12 myoblasts. 
 
Figure 3.15 Mono-sulfated disaccharides are increased and non-sulfated and tri-sulfated 
disaccharides are decreased in differentiating C2C12 myoblasts compared to proliferating 
C2C12 myoblasts. The percentage of non-sulfated Δ-UA-GlcNAc disaccharides (no-S) and the 
sum of the percentages of all mono-sulfated (mono-S), di-sulfated (di-S) and tri-sulfated (tri-S) 
disaccharides in proliferating (black) and differentiating (grey) C2C12 myoblasts are plotted as 
averages of four independent experiments ± S.E.M. * = p < 0.05 (Pro; N=4, Diff; N=4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.16 Specific HS disaccharide levels are different between proliferating and 
differentiating C2C12 myoblasts. HS was extracted and anlaysed via the process shown in 
Figure 3.8 from proliferating (black) and differentiating  (grey) C2C12 myoblasts. HS disaccharide 
peak ratios are plotted as averages of four independent experiments ± S.E.M.   * = p < 0.05 
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3.3.3.3 The Average Position of Sulfation of the C2C12 Myoblast Heparanome Remains 
Unchanged During Differentiation 
 
Since the overall position of sulfation remained unchanged during primary myoblast 
differentiation (Figure 3.13), it was hypothesised that there would be no significant changes 
in the level of 6-O-sulfation, N-sulfation and 2-O-sulfation during differentiation of the C2C12 
myoblast cell line. As predicted, there were no statistically significant changes in the global 
position of sulfation in differentiating C2C12 myoblasts compared to proliferating C2C12 
myoblasts (Figure 3.17). There appeared to be a modest decrease in 6-O-sulfation in 
differentiating myoblasts accompanied by a modest increase in N-sulfation and 2-O-sulfation 
but these did not reach statistical significance. 
 
 
 
 
 
 
 
 
 
 
Figure 3.17 Average levels of sulfation at specific positions in HS are not changed 
bewteen proliferating and differentiating C2C12 myoblasts. Analysis of the abundance of 
specific sulfate groups: 6-O-sulfation, N-sulfation and 2-O-sulfation reveals no statistically 
significant differences in proliferating (black) and differentiating (grey) C2C12 myoblasts. The 
abundance of specific sulfate groups are plotted as the averages of four independent 
experiments ± S.E.M. * = p < 0.05 (Pro; N=4, Diff; N=4).  
 
 
3.3.4 HS from proliferating C2C12 myoblasts is more effective at promoting FGF2 
mitogenic activity than HS from differentiating C2C12 myoblasts  
 
After determining that the level of HS sulfation increases in differentiating C2C12 myoblasts 
in similar way to that observed during primary myoblast differentiation, it was reasoned that 
the C2C12 myoblast cell line could be used as a proxy for studying the effects of myogenic 
differentiation on HS-mediated regulation of FGF2 mitogenic activity as a measure of FGF2 
signalling. Since FGF2 signalling is a potent inhibitor of myogenic differentiation and requires 
HS as a co-receptor, it was hypothesised that the HS from proliferating myoblasts would 
promote FGF2 signalling more than the HS from differentiating myoblasts. One way of 
investigating the effects of HS on FGF2 mitogenic activity is to use a BaF3 mitogenic cell 
assay. BaF3 lymphoid cell cultures produce no endogenous HS and thus require an 
exogenous source of HS and FGF in order to promote FGF signalling for survival and 
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proliferation (Guimond and Turnbull, 1999; Ornitz et al., 1996). Since FGF receptor 1 
(FGFR1) is the main FGF receptor expressed in myoblasts, and the receptor for FGF2, 
BaF3 cells stably transfected with FGFR1 were utilised for studying the effects of HS 
extracted from proliferating and differentiating cells on FGF2 mitogenic activity. HS from 
proliferating and differentiating C2C12 myoblasts was isolated and, subsequently put 
through a series of enzymatic digests to remove protein, DNA and other GAG impurities and 
thus produce a highly pure HS species. A proportion of the fully purified HS was digested 
with heparinases I, II and III for quantification via absorption at 232 nm of the double bond. 
BaF3 cells were then treated with FGF2 and the purified, non-digested HS at various 
concentrations for 72 hours and the extent of cell proliferation analysed with an MTT assay. 
BaF3 cells treated with HS from proliferating myoblasts showed a dose-dependent increase 
in FGF2-induced mitogenic activity compared to cells treated with FGF2 alone (Figure 3.18), 
with a dose of 10 μg/ml producing a statistically significant difference. In contrast, BaF3 cells 
treated with HS from differentiating myoblasts showed no increase in FGF2-induced 
mitogenic activity at any dose compared to cells treated with FGF2 alone (Figure 3.18). 
Indeed, the FGF2 mitogenic activity in BaF3 cells treated with HS from differentiating 
myoblasts was significantly lower than that in cells treated with HS from proliferating 
myoblasts at 10 μg/ml HS (Figure 3.18).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.18 FGF2 mitogenic activity is promoted by HS extracted from proliferating 
myoblasts but not by HS extracted from differentiating myoblasts. BaF3 cell assay where 
the mitogenic activity of FGF2 on BaF3 cells was measured in response to FGF2 alone or in the 
presence of FGF2 and HS extracted from the proliferating (black) and differentiating (grey) 
C2C12 myoblasts. Data from 3 independent experiments with 3 technical replicates each were 
analysed and plotted as averages ± S.E.M. * = p < 0.05 (Pro; N=3, n =3 Diff; N=3, n=3). 
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3.4 Discussion  
 
The work described in this chapter has demonstrated that: (1) the structure of HS changes 
during myogenic differentiation; (2) HS from proliferating and differentiating cells, which have 
different structures, also have different functional properties. To explore the hypothesis that 
the structural composition of HS changes during myogenic differentiation, HS was initially 
analysed from primary satellite cell-derived myoblasts, which better reflect the in vivo 
situation than any myogenic cell line. In addition, we also characterised the structural 
composition of C2C12 myoblasts, which we later used in bioassays that require amounts of 
starting material that are difficult to obtain from primary cells. Indeed C2C12 myoblasts are 
commonly used in biochemical assays, since they are financially more favourable, they 
bypass ethical concerns associated with the use of animal tissue, are more robust and have 
a higher expansion capacity than primary myoblasts, and thus yields higher amounts of 
material. In order to isolate pure populations of satellite cell-derived myoblasts, a differential 
plating protocol was employed based on an adapted protocol previously developed by 
Rando and Blau (Rando and Blau, 1994). By assessing a combination of fibrogenic and 
myogenic cell markers, and marked morphological differences, fibroblasts and myoblasts 
were readily distinguished. Overall, the procedure led to little loss of myoblasts in pre-plating 
cultures and produced highly pure cultures of myoblasts at passage 0, with few 
contaminating fibroblasts. Overall, this procedure is cost- and time-effective, with the whole 
isolation process being completed in one day.  
 
After successfully obtaining pure populations of satellite cell-derived myoblasts, HS was 
extracted and analysed from proliferating and differentiating myoblasts. Previously, general 
trends have been observed during embryonic stem cell differentiation (ESC), displaying an 
overall increase in the amount of HS and level of sulfation, irrespective of the ESC lineage 
fate (Hirano et al., 2012; Johnson et al., 2007; Nairn et al., 2007). The findings from this 
chapter reveal that satellite cells are an additional stem cell type displaying an increase in 
HS sulfation during differentiation. The same phenomenon was observed in C2C12 myoblast 
differentiation; taken together these results are consistent with the idea that the level of HS 
sulfation is an important factor in the satellite cell niche supporting myogenic differentiation.  
 
Although the overall positions of sulfation were not significantly altered during differentiation 
in both primary myoblasts and C2C12 myoblasts, it is possible that the increase in specific 
disaccharides leads to changes in specific sequences and/or alterations in conformation of 
HS chains, which might support reduced activation and even inhibition of pro-proliferative 
factors, such as FGF2, and thus permitting myogenic differentiation. For example it has been 
demonstrated that two isomeric heparin oligosaccharides with differences in just one position 
of sulfation (either 6-O-sulfation of glucosamine or 2-O-sulfation of the uronic acid), exhibit 
significantly different binding affinities to the oligomeric chemokine Monocyte 
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Chemoattractant Protein-1 (MCP-1)/CCL2 (Miller et al., 2016a). It has also well established 
that 2-O-sulfation on iduronic acid has a significant effect on the conformation of the ring, 
whereas glucuronic acid remains rigid regardless of 2-O-sulfation (de Paz et al., 2001; Ferro 
et al., 1990; Hsieh et al., 2014). This is a reflection of the conformational flexibility of iduronic 
acid, which can equilibrate between two forms: the 2S0 (skew boat) and 1C4 (chair) 
conformers, whereas the glucuronic acid residue remains rigid in the 4C1 conformer (Ferro et 
al., 1990; Sattelle et al., 2010). In turn, the conformation can have significant effects on the 
spatial orientation of the sulfate groups and thus the chemical environment (Canales et al., 
2005; Faham et al., 1996). 
 
Interestingly, during differentiation there is a significant increase in the proportion of 
ΔUA(2S)-GlcNAc in both satellite cell-derived myoblasts and C2C12 myoblasts tested. In 
HS, the uronic acid residue is made up of approximately 20 % iduronic acid residues (Höök 
et al., 1974). Therefore, depending on the uronic acid epimer present in the HS disaccharide 
unit, the increase in 2-O-sulfation on the uronic acid residue may lead to significant 
conformational changes reflecting differences in binding affinities and biological activity. For 
example, the binding of antithrombin to the heparin pentasaccharide, the IdoA2S residue is 
crucial since when IdoA2S is replaced with GlcA2S, binding is not permitted (Hsieh et al., 
2014). However, for the HS structural analysis shown here, the HS has been depolymerised 
with heparinase enzymes in order to allow for disaccharide compositional analysis, and as a 
consequence, iduronic acid and glucuronic acid both appear as a common delta-uronic acid 
structure and thus are non-distinguishable. Therefore, in the future, it could be beneficial to 
determine the epimeric form of the uronic acid residues of the HS extracted from myoblasts. 
To do this, nitrous acid could be employed to depolymerise HS, as this process leaves the 
uronic acid residues intact (Conrad, 2001; Turnbull, 2001). It might then be possible to 
determine if there is a specific increase in ΔIdoA(2S)-GlcNAc specifically, which may provide 
more insight into the altered structures and possibly conformations of HS produced in 
differentiating myoblasts, and whether this reflects differences in the biological functions 
exhibited.  
 
Furthermore, we demonstrated a significant increase in the proportion of ΔUA-GlcNAc(6S). 
Although it has been reported that there are no significant changes in conformation due to 6-
O-sulfation alone, the chemical environment of the neighbouring residues is affected by 6-O-
sulfation (Hsieh et al., 2014) which in turn may reflect differences in biological function.  
Interestingly, the most significant changes were noted for the mono-sulfated disaccharides 
ΔUA(2S)-GlcNAc and  ΔUA-GlcNAc(6S), which are disaccharides most commonly found in 
the transition zones of HS (between N-acetylated regions and the more highly sulfated NS-
domains). It is interesting to speculate that these regions may be particularly important for 
regulation of the activity of HS during myogenesis. Overall, these findings suggest that 
alterations in specific HS disaccharides during myogenic differentiation may present regions 
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along the HS chains with altered sequences and different conformations and chemical 
environments, reflecting the ability to modulate distinct biological functions.  
 
Since there are many heparin-binding growth factors that are involved in the regulation of 
myogenesis which are dependent on the structure of HS, it was hypothesised that the 
change in structure of HS during myogenic differentiation would alter growth factor 
signalling. Since FGF2 is a potent inhibitor of myogenic differentiation (Olwin et al., 1994; 
Rapraeger et al., 1991; Yablonka-Reuveni and Rivera, 1997), it was hypothesised that 
altered HS sulfation present in differentiating primary and C2C12 myoblasts would act as a 
repressor of FGF2 signalling or, at least, would not promote FGF2 signalling to the same 
degree as the HS present on proliferating myoblasts. Indeed, HS from differentiating 
myoblasts was less able to promote FGF2 mitogenic activity than HS from proliferating 
myoblasts. This lends strength to the hypothesis that the HS component of the extracellular 
matrix is a contributory factor evolved to repress FGF2 signalling during myogenic 
differentiation.  
 
One way in which more highly sulfated HS from differentiating myoblasts could be ineffective 
at promoting FGF2 signalling is that highly sulfated HS binds more strongly to FGF2 
(Gospodarowicz and Cheng, 1986) thus sequestering FGF2 away from its receptor, since it 
has previously been demonstrated that HS with different patterns and levels of sulfation bind 
FGF2 with different strengths (Uniewicz et al., 2010). This could be reminiscent of the role of 
the HSPG, glypican-1 during myogenesis, which sequesters away FGF2 in vivo thus 
permitting myogenic differentiation (Gutiérrez and Brandan, 2010). Further studies must be 
undertaken to explore this hypothesis. However, it must be noted that there are also some 
significant differences in the heparanome of satellite cell-derived myoblasts and the C2C12 
myoblast cell line. Therefore, caution must be taken when studying HS signalling pathways 
in the C2C12 cell line, which could potentially exclude critical features of the satellite cell 
heparanome. Further investigations could be undertaken to determine whether the 
differences in structure of HS also correspond to significant differences in biological activity 
in both satellite cell-derived myoblast cultures and the C2C12 myoblast cell line. 
 
Earlier investigations into the GAG composition during myogenesis have indicated that the 
structure of HS does not change significantly during differentiation of the C2.7 myoblast cell 
line (Barbosa et al., 2005). However, structural analysis was carried out with HS antibodies, 
which recognise HS sub-domains only, and a small number of the HS biosynthetic enzymes; 
EXT1/2, NDST1, GCE, HS2ST and HS6ST1 (Barbosa et al., 2005). Therefore, more specific 
or subtle changes in HS structure, such as changes in specific disaccharide abundance, 
overall levels and positions of sulfation may have been undetectable using these methods. 
Furthermore, the study used the C2.7 myoblast cell line, which may be less representative of 
the situation in vivo and indeed, there have been other studies in vivo which have detected 
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significant changes in the expression levels of the HS biosynthetic enzymes during 
differentiation (Langsdorf et al., 2007; Pisconti et al., 2012). It has been demonstrated that 
there is a significant down-regulation in the extracellular sulfatases, Sulf1 and Sulf2 during 
satellite cell activation and differentiation in vivo (Olguín and Pisconti, 2012; Pisconti et al., 
2012). In contrast to this finding, mice lacking both Sulf1 and Sulf2 delayed myogenic 
differentiation in vivo upon muscle injury. However, in the HS compositional analysis of 
Sulf1/2-/- satellite cell-derived myoblast cultures, only one out of the three 6-O-sulfated 
disaccharides analysed was increased; the tri-sulfated disaccharide IdoA2S-GlcNS6S 
(Langsdorf et al., 2007), suggesting that expression level analysis of the HS biosynthetic 
enzymes do not directly reflect the final HS structure in a simplistic manner. Indeed, complex 
changes in 6-O-sulfation but also N- and 2-O-sulfation were also observed in mSulf1-/- and 
Sulf2-/- mice brain, suggesting feedback mechanisms and compensation effects when 
changes in sulfation are induced (Kalus et al., 2015). Therefore, we believe that the 
observations from this chapter provide strong evidence that the structural composition of HS 
does indeed change during myogenic differentiation and in turn has an important role in 
regulating myogenesis.  
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Chapter 4 
 
 
 
 
4 The Structure of HS Changes During Ageing in Skeletal 
Muscle 
 
4.1 General Introduction 
 
4.1.1 Structural Changes in HS During Ageing 
 
In the previous chapter, it was demonstrated that the structure of HS is altered during 
myogenic differentiation and that HS from differentiating myoblasts has a reduced capacity 
to promote FGF2 induced mitogenic activity compared to HS from proliferating myoblasts. In 
aged satellite cells many MAPK signalling pathways, which are heavily affected by HS, are 
altered (Bernet et al., 2014; Cosgrove et al., 2014). These include FGF2 signalling 
(Chakkalakal et al., 2012). Yet the muscle heparanome during ageing has not been 
investigated. However, age-related changes in HS have been reported in several other 
tissues (Aizawa et al., 1980; Feyzi et al., 1998; Huynh et al., 2012a; Huynh et al., 2012b). In 
some cases, structural changes in HS have been linked to differences in their abilities to 
potentiate growth factors (Feyzi et al., 1998; Huynh et al., 2012a; Huynh et al., 2012b). The 
age-related changes in HS are tissue-specific, suggesting that the altered structure might 
have specific effects on growth factor signalling during ageing. Since FGF2 signalling is 
altered in ageing satellite cells, it is possible that an altered heparanome may contribute to 
altered FGF2 signalling. Understanding the composition of the heparanome of skeletal 
muscle during ageing would provide new insights into HS-mediated signalling events 
involved in the ageing process. Indeed, changes in HS could be a contributory factor to the 
loss of satellite cell number and/or function observed during ageing. 
 
4.1.2 HS Biosynthetic Enzyme Regulation 
 
The structure of HS is determined largely during biosynthesis by HS biosynthetic enzymes 
and then by post synthetic structural modifications by the sulfatases (SULFS). The 
biochemical role of each biosynthetic enzyme is well determined. Transcript expression 
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analysis acts as a useful complement with HS compositional analysis, providing insights into 
HS regulation and synthesis. Gene expression profiling studies using real-time reverse 
transcription PCR (RT-PCR) are generally rapid and reproducible. However, the HS 
biosynthetic enzymes are made up of over 20 genes, and thus gene expression profiling for 
all the enzymes would be highly labour-intensive. A more time-effective solution is to use 
TaqMan® Low-Density Arrays (TLDA) microfluidic cards (applied biosystems). TLDA 
microfluidic cards act as a medium-throughput technique for real-time RT-PCR as it is 
possible to simultaneously assay the RNA expression levels of up to 384 pre-selected genes 
at a time. Furthermore, only a small amount of RNA is required for screening multiple genes, 
which is highly beneficial when using small muscle biopsies.  
 
For a more in-depth analysis of structure-function relationships of HS, the expression of 
specific HS biosynthetic enzymes can be selectively silenced in vivo or in vitro using RNA 
interference (RNAi) technology (Fire et al., 1998). Commercially available synthetic small 
interfering RNA (siRNA) can be used to silence HS biosynthetic genes and in turn alter the 
structure of the endogenous HS in a selective manner. Biological assays can then be 
employed to analyse the effects of changes in HS biosynthetic gene expression and altered 
HS structure.  
 
4.2 General Hypothesis 
 
Since: 1) Age-associated changes in HS-regulated signalling pathways, such as FGF2 
signalling, have been reported and 2) the structure and amount of HS changes in several 
tissues during ageing, it was hypothesised that changes in the structure of muscle HS occur 
with ageing and may affect satellite cell homeostasis and/or fate. 
 
 
In this chapter it is shown that: 
 
1. The muscle heparanome is altered with ageing. Particularly, there is an increase in 
6-O-sulfation during ageing.  
2. The altered heparanome of ageing muscle is associated with changes in FGF2 
mitogenic activity  
3. A decrease in 6-O-sulfation is associated with reduced myoblast proliferation and 
increased differentiation 
 
 
 
 
 
Chapter 4                                                                      Structure of HS During Ageing in Skeletal Muscle 
 
 
82 
4.3 Results 
 
4.3.1 The Structure of HS During Ageing in Skeletal Muscle  
4.3.1.1 The Amount of Muscle HS Does Not Significantly Change During Ageing 
 
HS was quantified from the gastrocnemius muscles of 3 month and 2 year-old mice relative 
to the wet weight of the muscle. Overall, there was a slight trend for a reduction in the 
amount of HS in aged muscle (2 year-old muscle) compared to young muscle (3 month-old 
muscle). However, this difference did not reach statistical significance (p=0.63) (Figure 4.1).  
 
Figure 4.1 The level of is similar in 3 month and 2 year old mouse muscle. HS was extracted 
from the gastrocnemius muscles (3 month, n = 3, 2 year n = 4) of 3 month and 2 year-old mice. A 
proportion of the HS was digested into its constituent disacchardies with heparinase I, II and III 
enzymes. HS was quantified by measuring the absorbance at 230 nm of the double bond. The 
amount of HS was normalised to the total wet weight of the muscle. The averages ± S.E.M of n = 
3 (3 months) and n = 4 (2 years) biological replicates were plotted. 
 
4.3.1.2 The Level of HS Sulfation Remains Unchanged During Ageing in Muscle 
 
To explore the hypothesis that the structural composition of HS changes during ageing in 
muscle, HS was extracted and characterised from the quadriceps of 3 month, 1 year and 2 
year-old female mice. Firstly, the relative abundance of unsulfated and sulfated 
disaccharides was calculated. Overall, there was no change in the proportions of unsulfated 
and sulfated disaccharides during ageing (Figure 4.2). Furthermore, there was no 
statistically significant change in the abundance of the specific disaccharides during ageing 
(Figure 4.3).  
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Figure 4.2 HS sulfation levels are similar in 3 month, 1 year and 2 year-old mouse 
quadricep muscles. HS was extracted using TUT lysis buffer and a blade homogeniser. HS was 
then profiled as in schematic 1. HS has the same proportion of sulfated and non-sulfated HS in 3 
month, 1 year, and 2 year-old muscles. The percentage of non-sulfated disaccharides (Δ-UA-
GlcNAc, unsulfated, black bars) and sulfated (sum of all sulfated, grey bars) disaccharides is 
plotted as the average of at least 4 independent experiments. ± S.E.M. (n = 4 in 3 months and 1 
year age groups and n = 5 in 2 years age group) * = p < 0.05 (Ghadiali et al., 2016). 
 
 
 
Figure 4.3 HS disaccharide compositions are similar in 3 month, 1 year and 2 year old 
mouse muscle. HS disaccharide peak ratio analysis in 3 month (black), 1 year (grey) and 2 year 
old (dark grey) muscle are plotted as averages of at least 4 independent experiments. ± S.E.M. (n 
= 4 in 3 months and 1 year age groups and n = 5 in 2 years age group) * = p < 0.05 (Ghadiali et 
al., 2016) 
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4.3.1.3 HS 6-O-Sulfation Increases in Skeletal Muscle During Ageing 
 
Although the abundance of individual disaccharides does not significantly change, when the 
relative abundance of disaccharides containing 2-O-sulfation, 6-O-sulfation and N-sulfation 
in the muscles during ageing was calculated, a statistically significant increase in the 
abundance of sulfated HS disaccharides containing 6-O-sulfation was found in the 
quadriceps of old mice (1 year and 2 year-old mice) compared to young mice (3 month-old 
mice) (Figure 4.4). There was also a trend towards a reduction in 2-O-sulfation in the HS 
from old mice compared to young mice, although this did not reach statistical significance. (3 
months compared to 1 year; p=0.27 and 3 months compared to 2 years; p=0.20) 
 
 
Figure 4.4 HS 6-O-sulfation is increased in quadriceps muscle from aged mice. Analysis of 
the abundance of specific sulfate groups (6-O-sulfation, N-sulfation and 2-O-sulfation) reveals a 
statistically significant increase in 6-O-sulfation from 3 month (black) muscle compared to 1 year 
(grey) and 2 year (dark grey) old muscle. The percentages of disaccharides are plotted as 
averages of at least 4 independent experiments. ± S.E.M. (n = 4 in 3 months and 1 year age 
groups and n = 5 in 2 years age group) ** = p < 0.01 (Ghadiali et al., 2016) 
 
These findings on 6-O-sulfation were not specific to the muscle type analysed as similar 
results were obtained when the tibialis anterior (TA) muscles of young and old mice were 
examined. HS was extracted from the TA muscle of 3 month and 2 year-old mice for HS 
compositional analysis. A trend towards an increase in the levels of HS 6-O-sulfation in TA 
muscles of 2 year-old mice compared to TA muscles 3 month-old mice was observed, 
although this result did not reach statistical significance (p=0.26) (Figure 4.5). Intriguingly, 
although in quadriceps muscle the increase in 6-O-sulfation was accompanied by a modest 
decrease in 2-O-sulfation, in TA muscles the increase in 6-O-sulfation was accompanied by 
a marked, though not statistically significant, decrease in N-sulfation (p=0.059). This 
suggests that different muscles might age in different ways, which could lead to different 
effects on the resident satellite cell population. 
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Figure 4.5 HS 6-O-sulfation shows a trend for increasing in aged TA muscle. Analysis of the 
abundance of specific sulfate groups: 6-O-sulfation, N-sulfation and 2-O-sulfation from 3 month 
(black) TA muscle compared to 1 year (grey) and 2 year (dark grey) old TA muscle. The 
percentages of disaccharides are plotted as averages of at least 4 independent experiments. ± 
S.E.M. 
 
4.3.2 HS 6-O-Sulfation Modulates Mitogenic Activity  
4.3.2.1 HS from Ageing Muscle Promotes FGF2 Induced Mitogenic Activity 
 
Since HS 6-O-sulfation is proportionally increased in aged muscle without leading to an 
increase in the overall sulfation levels and since 6-O-sulfation is heavily implicated in FGF2 
signalling (Pye et al., 1998), it was hypothesised that the HS from old (2 year-old) mouse 
muscle may promote FGF2 signalling more than HS from young (3 month-old) muscle. To 
test this hypothesis, the BaF3 assay was employed and the effect of HS from the quadricep 
muscles of 3 month and 2 year-old mice on FGF2 mitogenic activity via FGFR1 was 
measured (Figure 4.6). HS from 3 month-old muscles inhibited FGF2 signalling compared to 
the FGF2 alone and this effect was statistically significant with 10 µg/ml treatment. In 
contrast, FGF2 mitogenic activity in BAF3 cells treated with HS from 2 year-old muscle was 
increased in a dose-dependent manner, and this effect was statistically significant at 10 
µg/ml compared to cells treated with FGF2 alone.  
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Figure 4.6 HS from aged muscle enhances FGF2 mitogenic activity. Murine BaF3 
lymphocytes were stably transfected with FGFR1IIIc to assess the mitogenic activity of FGF2 on 
BaF3 cells measured in plain growth medium (white bar), and in response to either FGF2 alone 
(blue bar) or FGF2 and HS extracted from either 3 month (black bars) or 2 year-old (grey bars) 
muscle. Data from 3 independent experiments with 3 technical replicates were analysed and 
plotted as averages ± S.E.M. * = p < 0.05. 2 of the 3 independent experiments were conducted by 
Dr Scott Guimond (Ghadiali et al., 2016).  
 
4.3.2.2 Reduction in Myoblast HS 6-O-sulfation Reduces Proliferation 
 
Since the increase in HS 6-O-sulfation in aged muscle was also associated with increased 
mitogenic activity of FGF2, it was hypothesised that HS 6-O-sulfation supports myoblast 
proliferation and that a reduction in myoblast HS 6-O-sulfation would reduce myoblast 
proliferation. Mice express three 6-O-sulfotransferases (HS6ST1, HS6ST2 and HS6ST3) 
which catalyse the transfer of a sulfate group to the 6 position of the glucosamine residue in 
HS. RNAi technology was utilised to transiently knockdown all three HS6STs simultaneously 
in C2C12 myoblasts, to reduce endogenous HS 6-O-sulfation. Myoblasts were co-
transfected with a GFP plasmid to aid detection of cells that had been successfully 
transfected (Figure 4.7). The day after transfection gene knockdown was confirmed via RT-
PCR (Appendix 1). Proliferation was then measured using a BrdU incorporation assay. Only 
cells that were GFP positive were scored to ensure that only cells that had been successfully 
transfected were analysed. A significant reduction in myoblast proliferation (BrdU+GFP+ 
cells) by approximately 50% was found in the knockdown cells compared to the negative 
control (Figure 4.8). Therefore, these data strongly support the hypothesis that a reduction 
in endogenous HS 6-O-sulfation leads to a reduction in myoblast proliferation, confirming 
that the three 6-O-sulfotransferases have a positive regulatory role in myoblast proliferation, 
possibly via promotion of FGF2 signalling. 
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Figure 4.7 Representative images showing a reduction in HS 6-O-sulfation leads to a 
reduction in proliferation in C2C12 myoblasts. Representative images of GFP (pClover) and 
siRNA simultaneously to the three HS6STs or control scrambled siRNA were transfected into 
C2C12 myoblasts and 24 h later 10 µM BrdU was added to the culture medium 2 h prior to 
fixation and immunostaining to detect GFP (green) and BrdU (red). Nuclei were detected with the 
nuclear stain DAPI (blue). The proportion of BrdU+GFP+ myoblasts are increased in control cells 
indicated by white arrows. Ten images across two technical replicates for three independent 
experiments were taken. Scale bar = 100 µm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8 A reduction in HS 6-O-sulfation leads to a decrease in proliferation in C2C12 
myoblasts. GFP (pClover) and siRNA simultaneously to all three HS6STs or universal control 
siRNA were transfected into C2C12 myoblasts and 24 h later 10 µM BrdU was added to the 
culture medium 2 h prior to fixation and immunostaining to detect GFP and BrdU. The percentage 
of BrdU+/GFP+ cells was calculated over the total number of GFP+ cells was calulated. 
Simultaneous knockdown of all three HS6STs produces a significant decrease in C2C12 
myoblast proliferation. The averages of ten images across two technical replicates for three 
independent experiments ± S.E.M. are plotted.** = p < 0.01 (Ghadiali et al., 2016) 
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4.3.2.3 Reduction in Myoblast HS 6-O-Sulfation Promotes Myoblast Differentiation 
 
Myoblast proliferation and differentiation are mutually exclusive events. Since proliferation 
was reduced in myoblasts, which had been subjected to simultaneous knock down of all 
three HS6ST enzymes, it was hypothesised that myogenic differentiation would increase. In 
order to investigate the extent of differentiation, the myogenic regulatory factor myogenin, 
which is expressed in terminally differentiated myoblasts, was measured in C2C12 
myoblasts 24 hours post transfection (Figure 4.9). There was a significant increase in 
myoblast differentiation (MyoG+/GFP+ cells) by approximately 50%, in the knockdown cells 
compared with the negative control (Figure 4.10). This further supports the hypothesis that a 
reduction in myoblast HS 6-O-sulfation, has both anti-proliferative and pro-differentiative 
effects.  
 
Figure 4.9. Representative images showing a reduction in HS 6-O-sulfation leads to an 
increase in myogenin expression in the C2C12 myoblast cell line. Representative images of 
GFP (pClover) and siRNA simultaneously to the three HS6STs or universal control siRNA were 
transfected into C2C12 myoblasts and 24 h later cells were fixed and immunostained for 
detection of GFP (green) and myogenin (MyoG, red). Simultaneous knockdown of all three 
HS6STs produces a significant increase in C2C12 myoblast differentiation. Nuclei were detected 
with the nuclear stain DAPI (blue). The proportion of Myogenin+ GFP+ cells was increased in 
myoblasts transfected with HS6ST1,2,3 indicated by the white arrows. Ten images across two 
technical replicates for three independent experiments were taken. Scale bar = 100 µm 
 
Figure 4.10 A reduction in HS 6-O-sulfation leads to an 
increase in myogenin expression in the C2C12 
myoblast cell line. GFP (pClover) and siRNA 
simultaneously to the three HS6STs or universal control 
siRNA were transfected into C2C12 myoblasts and 24 h 
later cells were fixed and immunostained for detection 
detect of GFP and myogenin. Simultaneous knockdown of 
all three HS6STs produces a significant increase in C2C12 
myoblast differentiation. The averages of ten images across 
two technical replicates for three independent experiments 
± S.E.M. plotted  * = p < 0.05. 
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4.3.3 HS Biosynthetic Regulation 
 
Since the structure of HS is altered during ageing in muscle, it was hypothesised that the 
expression levels of the HS biosynthetic enzymes might be differentially regulated during 
ageing in muscle. To test this hypothesis, RNA was extracted from the TA muscles of 3 
month and 2 year-old mice. Taqman Low Density Array (TLDA) microfluidic cards were 
custom designed to contain 25 HS biosynthetic enzyme gene probes, including endogenous 
controls, for simultaneous real time PCR reactions. Out of the 25 HS biosynthetic enzymes 
analysed, 21 were expressed in both 3 month and 2 year-old muscles. To study the relative 
expression levels of the HS enzymes between young and old muscle, gene expression was 
calculated relative to the endogenous control GAPDH, which displayed the lowest variability 
of the endogenous controls present on the TLDA microfluidic card. For the majority of genes, 
there were no statistically significant differences in the transcript levels between the 3-month 
and 2 year-old muscle (Figure 4.12). This might have been a consequence of the high 
biological variability and small sample size. However, two HS enzymes that did show 
statistically significant differences between young and old muscle were: 1) heparan sulfate 3-
O-sulfotransferase 5 (HS3ST5), which displayed a significantly higher expression level in the 
2 year-old muscle compared to the 3 month-old muscle and 2) heparan sulfate 6-O-
sulfotransferase 1 (HS6ST1), which displayed a significantly lower expression level in the 2 
year-old muscle (Figure 4.11).  
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Figure 4.12 Heatmap of 21 HS biosynthetic enzyme transcript levels in 3 month and 2 year-
old muscle. Complementary DNA (cDNA) was generated from RNA extracted from the TA 
muscle of 3 month (left, n=4) and 2 year-old muscle (right, n=4). TDLA microfluidic cards were 
custom designed to contain HS biosynthetic gene probes to carry out 384 real time PCR 
reactions simultaneously and a total of 8 samples were run in one card. The log of the ΔΔCT 
values relative to GAPDH expression levels are plotted using R Studio, where blue is low 
expression and orange is high expression. The two genes that are significantly different between 
young and old muscle are highlighted with black boxes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.11 1D scatter plots of the relative expression levels of HS biosynthetic 
enzymes. The individual transcript expression levels (log ΔΔCT) relative to GAPDH are 
plotted on 1D scatter plots. In 2 year-old muscles there is a significantly higher HS3ST5 
transcript level and a significant downregulation of HS6ST1 compared to 3 month-old muscle 
where * = p<0.05. 
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4.4 Discussion 
 
There have been several reports showing age-related changes in the heparanome in 
different tissues (Aizawa et al., 1980; Huynh et al., 2012a; Keenan et al., 2014) and in this 
chapter, it has been shown for the first time that skeletal muscle is another tissue in which 
the heparanome is altered during ageing. Although no significant differences in the 
abundance of specific HS disaccharides were found, there was an overall increase in the 
levels of HS 6-O-sulfation in the muscles of 1 year and 2 year-old mice compared to 3 
month-old mice. Interestingly, 1 year-old mice display no signs of sarcopenia (Brack et al., 
2005) suggesting that changes at the molecular level are already occurring in the muscle 
before any macroscopic changes at the tissue or functional level are detected. Furthermore, 
HS was extracted from the TA muscles of 3 month and 2 year-old mice. Unfortunately, the 
HS chromatographs from the majority of the HS samples were poorly resolved and thus 
difficult to analyse. This could have been due to a contaminant in the samples or simply a 
lack of material leading to poor resolution. However, a trend towards an increase in 6-O-
sulfation of the ageing TA muscle was still observed. There also appeared to be a marked 
reduction in the level of N-sulfation although this did not reach statistical significance. This 
may be indicative of differences in the structural composition of HS during ageing depending 
on the muscle type. However, further experiments including more replicates and different 
muscle types are required to explore this hypothesis. 
 
Owing to the fibrosis that occurs during ageing in muscle (Brack et al., 2007; Fry et al., 2015; 
Paliwal et al., 2012), it was difficult to obtain pure cultures of myoblasts using the differential 
plating protocol, leading to a heterogeneous mixture of predominantly fibroblasts and thus, it 
was not possible to analyse the structure of HS from satellite cell-derived myoblasts from 
aged muscle. Therefore, it cannot be ruled out that the change in structure of HS in aged 
muscle is a consequence of the increased numbers of fibroblasts. To better understand the 
altered heparanome in ageing muscle, satellite cell-derived myoblasts and fibroblasts 
isolated from aged muscle, could be purified using fluorescence-activated cell sorting 
(FACS) to obtain pure cultures for HS compositional analysis. This would provide an 
indication of the cell type responsible for the structural changes in HS in aged muscle.  
 
In an attempt to elucidate the function of the HS from ageing muscle, and since 6-O-sulfation 
is important in FGF2 signalling and FGF2 signalling is increased in ageing muscle 
(Chakkalakal et al., 2012), it was hypothesised that the HS from aged muscle with an 
increase in 6-O-sulfation might further  promote FGF2 signalling compared to HS from young 
muscle. HS from 2 year-old muscles promoted FGF2 mitogenic activity in BaF3 cells while 
HS from 3 month-old muscles inhibited it. This result strongly supports two important points: 
(1) that the altered heparanome in ageing muscle may be a contributory factor to loss of 
satellite cell quiescence by promoting FGF2 signalling. This spontaneous breaking of 
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quiescence would then lead to satellite cell depletion (Chakkalakal et al., 2012) and 
consequently muscle fibrosis (Fry et al., 2015). (2) That the muscle heparanome in young 
mice is normally inhibitory of FGF2 signalling, thus effectively contributing to maintenance of 
satellite cell quiescence. Future investigations might involve culturing myoblasts ex vivo in 
the presence of HS from either young or old muscle to investigate the effects of an old HS 
extracellular environment on the phenotype of myoblasts. 
 
Next, we sought to better characterise the role of HS 6-O-sulfation in myogenesis by 
knocking down the three 6-O-sulfotransferases in C2C12 myoblast to reduce endogenous 
HS 6-O-sulfation. Myoblasts that had been transfected with HS6ST1, 2 and 3 siRNA 
exhibited a significant reduction in proliferation and a significant increase in differentiation 
compared to myoblasts transfected with scrambled siRNA. Since FGF2 promotes myoblast 
proliferation and is a potent inhibitor of differentiation, this study suggests that the reduction 
in myoblast HS 6-O-sulfation represses FGF2 signalling and thus: (1) reinforces previous 
findings that 6-O-sulfation is important for FGF2 signalling (Guimond et al., 1993; Pye et al., 
1998), (2) supports our hypothesis that a difference in HS 6-O sulfation between young and 
old muscle is responsible for the different effect of young and old muscle HS on FGF2 
mitogenic activity and possibly on the overall control of satellite cell quiescence. Earlier 
evidence suggests that FGF2 binding to HS does not require 6-O-sulfation (Ashikari-Hada et 
al., 2004; Kreuger et al., 1999; Kreuger et al., 2001; Maccarana et al., 1993; Turnbull et al., 
1992) but rather, is important in the formation of the HS:FGF:FGFR ternary complex and 
thus for FGF2 signalling to take place (Allen and Rapraeger, 2003; Powell et al., 2002). 
Interestingly, although the presence or absence of 6-O-sulfation has significant biological 
effects, altered 6-O-sulfation actually has the smallest impact on HS conformation compared 
to changes in 2-O-sulfation and N-sulfation on the other hand (Rudd and Yates, 2010). This 
suggests that HS biological activity is reliant on the patterns of sulfation and distribution of 
charge for biological activity as well as conformations of the iduronate rings. As mentioned 
previously, 6-O-sulfation can have a significant effect on the chemical environment of 
neighbouring residues (Hsieh et al., 2014) and this may also contribute to the altered 
biological function. Future work could investigate the binding affinities of HS from young and 
old muscle to FGF2/FGFR1 and its role in the formation of the ternary complex (FGF2-HS-
FGFR1), which is crucial for signalling to take place (Schlessinger et al., 2000).  
 
It should also be noted that the altered structure of HS present in ageing muscle might affect 
different FGF signalling pathways that are involved in the regulation of myogenesis. Several 
members of the FGF family are expressed in mouse muscle during injury-induced 
regeneration, which display different requirements for the optimal HS sequence for binding 
and signalling (Guimond and Turnbull, 1999; Powell et al., 2002). In consideration of the 
scope of this project, FGF2 signalling was selected as a priority for investigation because: 1) 
FGF2 signalling is a potent inhibitor of myoblast differentiation, 2) FGF2 signalling is 
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increased in ageing muscle (Chakkalakal et al., 2012) and 3) HS 6-O-sulfation is crucial for 
FGF2 signalling (Allen and Rapraeger, 2003; Powell et al., 2002). However, the results 
obtained here provide scope for future research into how other FGFs, or indeed other 
heparin-binding growth factors, are affected by the structural changes in HS during ageing.  
 
To further investigate the age-related regulation of the muscle heparanome, transcript 
expression analysis of the HS biosynthetic enzymes was performed on 3 month and 2 year-
old TA muscles. Although, the biochemical role of the biosynthetic enzymes is well 
determined, how HS biosynthesis is regulated and how the fine structure of HS is produced 
is largely unknown (Kreuger and Kjellén, 2012). Since HS synthesis is non-template driven, 
and a number of the enzymes consist of a multiple family of isoforms with differing levels of 
expression and activity, the expression levels alone may not reflect the resulting structure of 
HS. Thus we sought to test whether analysis of HS biosynthetic and remodelling enzyme 
gene expression could provide a useful complement to HS compositional analysis. Since 
aged muscle displayed a significant increase in the levels of HS 6-O-sulfation, it was 
hypothesised that this was due to either an increase in the expression levels of the HS6STs, 
the enzymes responsible for the addition of 6-O-sulfate group, and/or a decrease in the 
expression levels of the SULFs, the enzymes that are responsible for the removal of 6-O-
sulfate groups. Two out of the 21 HS biosynthetic genes expressed, HS6ST1 and HS3ST5, 
were significantly different between the 3-month and 2-year old mice.  
 
Firstly, HS6ST1 was downregulated in the 2 year-old muscles compared to the 3 month-old 
muscles, which was expected to lead to a reduction in 6-O-sulfation rather than the observed 
increase in 6-O-sulfation. Moreover, the expression levels of HS6ST2, HS6ST3, Sulf1 and 
Sulf2 were not significantly altered during ageing, with only a modest trend for an increase in 
the expression levels of HS6ST3 in the ageing muscle. These data indicate that the gene 
expression levels alone do not reflect enzyme activity and subsequently the level of 6-O-
sulfation. Indeed, it has previously been demonstrated that each HS6ST isoform exhibits 
characteristic substrate preferences (Bink et al., 2003; Habuchi et al., 2000). For example, 
HS6ST2 preferentially catalyses 6-O-sulfation of IdoA(2S)-GlcNS to IdoA(2S)-GlcNS(6S), 
but unfortunately from the compositional analysis, it is not possible to distinguish IdoA from 
GlcA. Furthermore, the HS 6-O-endosulfatses (Sulf1 and Sulf 2), which catalyse the removal 
of sulfate groups of glucosamine from HS, are also crucial regulators of HS 6-O-sulfation. 
From the expression level analysis, there are no significant differences in Sulf1 or Sulf2 
expression levels. However, as in the case of the HS6STs, Sulf1 and Sulf2 recognise distinct 
structural features and enzymatic activities (Ai et al., 2006) and thus expression levels do not 
solely reflect catalytic activity and fractional effects. Therefore, to further assess the origin of 
the increase in 6-O-sulfation observed in ageing muscle, it would be useful to investigate 
protein levels and enzymatic activity of the three HS6STs and the two Sulfs.  
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The second enzyme that was significantly altered during ageing in muscle was HS3ST5, a 3-
O-sulfotransferase, which catalyses the addition of sulfate groups at the 3-O- position of the 
glucosamine residue in HS. HS3ST5 was upregulated in 2 year-old muscles compared to 
the 3 month-old muscles. From the HS disaccharide compositional analysis that was 
performed in this study, only the 8 most abundant HS disaccharide units could be identified 
with the HS standards used, which do not include disaccharides containing 3-O-sulfation. 
Therefore, we were unable to determine the presence or abundance of disaccharides 
containing 3-O-sulfation from the HS compositional analysis. Thus, it is possible that the 
level of 3-O-sulfation is increased in HS during ageing in muscle. Intriguingly, the HS3STs 
make up the largest gene family among all the sulfotransferases (Liu and Pedersen, 2007) 
yet 3-O-sulfation is relatively rare, with few modifications along the chain or absent entirely 
(Thacker et al., 2014). However, it has been demonstrated previously that HS3ST5 is 
expressed in human skeletal muscle (Xia et al., 2002) suggesting that 3-O-sulfation may 
play an important role in skeletal muscle although there have been no Hs3st5 mutants 
reported to date. Furthermore, HS3ST3b1 is significantly up-regulated during satellite cell 
activation which might support the hypothesis that 3-O-sulfation is associated with satellite 
cells breaking quiescence in ageing muscle (Pisconti et al., 2012). However, little information 
on the role of 3-O-sulfation in protein binding is currently available. To date six proteins have 
been identified, including the well-recognised HS binding protein antithrombin, that are 
affected by 3-O-sulfation (Thacker et al., 2014). Interestingly, there is indirect evidence that 
3-O-sulfation might have a role in FGF1 and FGF2 binding to FGFR1 (McKeehan et al., 
1999; Ye et al., 2001) and more recently it has been shown that 3-O-sulfation controls the 
FGFR2b-dependent signalling during organogenesis (Patel et al., 2014). Thus, it is possible 
to postulate that an increase in 3-O-sulfation during ageing in muscle may contribute to 
increased FGF2 signalling, supporting our finding that HS from ageing muscle is more 
effective at promoting FGF2 signalling than HS from younger muscle. Furthermore, in mouse 
embryonic stem cells, overexpression of HS3ST5 induces differentiation (Hirano et al., 
2012), suggesting that altered 3-O-sulfation has a significant effect on the signalling 
properties of HS. However, it must be noted that the data on HS biosynthetic enzyme 
expression shown here are only preliminary, with only a few samples for each age group 
being analysed. Therefore, to investigate this further, transcript expression analyses with 
more replicates is required. Additional investigations would also be necessary to allow for 
the characterisation of HS 3-O-sulfation. This would require the production of defined HS 
disaccharides standards for 3-O-sulfation, that could be identified after heparinase digestion, 
or the use of nitrous acid depolymerisation which has been used to identify disaccharides 
with 3-O-sulfate groups (Turnbull, 2001).  
 
As mentioned above, the majority of enzymes from the same family have different substrate 
affinities, such as a difference in affinity for glucuronic acid over iduronic acid (Hsieh et al., 
2016). Since the compositional analysis does not account for differences in abundance of 
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iduronic acid or glucuronic acid, further investigations may involve nitrous acid degradation 
of HS to retain the epimeric form of the uronic acid residue. Furthermore, other regulatory 
enzymes may alter HS enzyme catalytic activity and thus, cannot be excluded from our data. 
For example, the cofactor, 3'-phosphoadenosine-5'-phosphosulfate (PAPS) is crucial for HS 
sulfotransferase activity (Kurima et al., 1998), which may be differentially regulated during 
ageing in muscle and thus affecting the activity of the HS sulfotransferases.  
 
 
 
 
 
Chapter 5                                                          Effects of Modified Heparin HS Mimetics on Myogenesis 
 
 
 
96 
 
 
Chapter 5 
 
 
 
 
5 Effect of Semi-Synthetic Heparan Sulfate Mimetics on 
Myogenesis 
 
5.1 General Introduction 
 
In the previous chapters it was shown that the structural composition of HS is altered during 
myogenic differentiation and ageing in skeletal muscle, and these changes are associated 
with changes in HS-dependent FGF2 mitogenic activity. In the case of myogenic 
differentiation, a more highly sulfated HS species is associated with reduced FGF2 induced 
mitogenic activity. In the case of muscle ageing, on the other hand, increased levels of 6-O-
sulfation are associated with an increased ability to promote FGF2 mitogenic activity, 
possibly leading to breaking of satellite cell quiescence and eventually loss of satellite cell 
numbers. From these findings it is evident that the biological function of HS is dependent on 
a combination of the overall charge density and the patterns of sulfation. To further 
investigate the structure-function relationships of HS, “HS mimetic” polysaccharides can be 
used to model in a systematic way an altered extracellular heparanome. Thus far, sulfated 
dextran derivatives, known as Regenerating Reagents (RGTAs), have been used to 
investigate the effects of altering the ECM during myogenesis. Firstly, it has been 
demonstrated that satellite cell-derived myoblasts treated with RGTAs exhibit a significant 
increase in proliferation by increasing the potency of FGF2 and scatter factor/hepatocyte 
growth factor (HGF) (Papy-Garcia et al., 2002). It was also shown that RGTAs lead to the 
production of an altered HS species during differentiation of the C2.7 myoblast cell line 
(Barbosa et al., 2005). These investigations provide an important indication of the 
mechanisms by which RGTAs affect myogenesis. However, since RGTAs are produced by 
derivatisation of dextran, which is made of branched chains of glucose monosaccharides, 
structural diversity becomes a limitation for structure-function investigations.  
 
Another method for generating HS mimetics, which are simpler, more readily available and 
low cost, is by chemically modifying heparin, a highly sulfated type of HS, to resemble 
naturally occurring HS species (Yates et al., 1996). Since heparin is readily available, it is 
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possible to produce modified heparins in large quantities. The structure of the HS species 
obtained via this method can then be determined with nuclear magnetic resonance (NMR) 
spectroscopy (Rudd et al., 2011; Yates et al., 1996) and compositional analysis (Patey et al., 
2006). The majority of methods for the production of chemically modified heparins involve 
the chemical de-sulfation from one or more positions, usually to completion, creating 
simplified structures. This approach leads to a library of chemically modified heparins, each 
consisting of one of the 8 most common disaccharide units found in naturally occurring HS, 
containing discrete, specific, structural entities. Thus far, modified heparins produced in this 
way, have proven useful for determining the importance of HS sulfation in different biological 
scenarios. For example, modified heparins have allowed for the elucidation of the 
importance of specific structural entities of HS such as; in the inhibition of Alzheimer’s 
protease BACE-1 (Patey et al., 2006), in the FGF/FGFR tyrosine kinase signalling system 
(Guimond et al., 2006) and in the binding of FGF1 and FGF2 (Uniewicz et al., 2010). 
Furthermore, chemically modified heparins have been used to identify the importance of HS 
sulfation in boundary formation by glial cells (Higginson et al., 2012).  
 
5.2 General Hypothesis 
 
In this chapter it is shown that: 
 
1. HS mimetics harbouring different degrees and patterns of sulfation differentially 
affect expansion, differentiation, fusion and Pax7 expression of satellite cell-derived 
myoblast cell fate decisions 
2. HS mimetics have differential effects on FGF2-induced myoblast proliferation 
through Erk1/2 activation 
 
5.2.1 Modified Heparins: HS mimetics 
 
To model in a systematic way changes in the structure of HS in the satellite cell niche which 
may affect myogenic differentiation, a library of chemically modified heparins was produced 
by Dr Edwin Yates and kindly donated to us. These will be referred to as HS mimetics 
throughout (Figure 5.1 and Table 5.1). Heparin was chemically modified to produce a library 
of 8 diversely sulfated HS mimetics, containing different levels and positions of sulfation. 7 
HS mimetics contain reduced levels of sulfation compared to native heparin, mimicking 
various structures of HS found normally in tissues: HS with sulfation in two positions (HS 
mimetic 2, HS mimetic 3 and HS mimetic 4), HS with sulfation in one position (HS mimetic 5, 
HS mimetic 6 and HS mimetic 7) and completely de-sulfated HS (HS mimetic 8). A more 
highly sulfated HS mimetic was also produced, with sulfation in more than the three most 
common positions (oversulfated heparin, HS mimetic 1) in which additional 3-O-sulfate 
groups are present on glucosamine and uronic acid rings. The structural unit and 
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corresponding HS mimetic label are summarised in Figure 5.1 and Table 5.1.  
 
Figure 5.1 Structural disaccharide units of the 
HS mimetics. Figure of general structural 
disaccharide unit of the HS mimetics which are 
differentially functionalised indicated by the R 
group. Corresponding functional groups for 
specific HS mimetics are displayed in Table 5.1. 
 
 
 
 
Table 5.1 HS mimetics obtained by chemical modification of heparin. The structural 
composition of the HS mimetics with corresponding nomenclature and functionalised R groups. R 
groups are indicated on the disaccharide unit in Figure 5.1.   
Modified Heparin HS mimetic Fig Annotation R1 R2 R3 
Additional 
Modification 
Heparin hep SO3- SO3- SO3-  
Oversulfated Heparin HS mim 1 SO3- SO3- SO3- 
+ SO3- at C3 
of GlcN and 
C3 of  IdoA 
N-Acetylated Heparin HS mim 2 SO3- SO3- COCH3  
2 de-Sulfated-N-Sulfated Heparin HS mim 3 H SO3- SO3-  
6 de-Sulfated-N-Sulfated Heparin HS mim 4 SO3- H SO3-  
2 de-Sulfated-N-Acetylated Heparin HS mim 5 H SO3- COCH3  
6 de-Sulfated-N-Acetylated Heparin HS mim 6 SO3- H COCH3  
2,6 de-Sulfated-N-Sulfated Heparin HS mim 7 H H SO3-  
2,6 de-Sulfated-N-Acetylated Heparin HS mim 8 H H COCH3  
 
 
5.2.2 HS mimetics differentially affect differentiation  
 
Satellite cell-derived myoblasts were isolated using the differential plating protocol as 
described in Chapter 3. Satellite cell-derived myoblasts were treated with heparin and HS 
mimetics at 10 ng/ml, 100 ng/ml or 1 µg/ml concomitant with induction of myogenic 
differentiation by serum reduction for 72 hours. To measure the effect of the HS mimetics on 
myogenic differentiation, the percentage of nuclei contained in cells staining positive for 
myosin heavy chain (MyHC) over the total number of nuclei (DAPI positive cells) was 
calculated, which is defined as the differentiation index (DI) (Figure 5.2). It was found that 
the effect of different HS mimetics on myoblast differentiation was structure-specific and 
concentration-dependent with the lowest doses tested often leading to non-significant 
differences compared to absence of treatment (Figure 5.3). At the highest concentration of 1 
µg/ml, almost all of the HS mimetics showed a significant reduction in differentiation with the 
exception of mimetic 1 (oversulfated heparin), which showed little effect on differentiation. 
Furthermore, myoblasts treated with HS mimetic 1, 3, 5, 6, 7 and 8 at 10 ng/ml displayed a 
significant increase in differentiation compared to myoblasts treated with heparin at the same 
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concentration. However, at 1 µg/ml, HS mimetic 1 was the only HS mimetic to significantly 
increase differentiation compared to myoblasts treated with heparin at 1 µg/ml.  
 
 
Figure 5.2 Representative 
images showing the effects of 
HS mimetics on myoblast 
differentiation. Primary SC-
derived myoblasts were 
cultured for 48 h and then 
induced to differentiate for an 
additional 72 h. Differentiated 
cells, both mono- and multi-
nucleated, were identified via 
immuno-staining to detect 
myosin heavy chain (MyHC, 
green). Nuclei were detected 
with the nuclear stain DAPI 
(blue). Ten images were taken 
across two technical replicates 
for three independent 
experiments for each condition 
shown. Scale bar = 100 µm 
across all images 
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Figure 5.3 HS mimetics differentially effect myoblast differentiation. Primary SC-derived 
myoblasts were cultured for 2 days in growth medium and then induced to differentiate for a 
further 3 days. For each condition shown, the differentiation index was calculated as the 
percentage of nuclei in MyHC+ cells (both mono- and multi-nucleated) over the total number of 
nuclei (DAPI+). The average of ten images across two technical replicates for three independent 
experiments ± S.E.M. was calculated and plotted. Asterisks are p-values for each condition 
compared to non-treated (NT) cells. ** = p < 0.01; * = < b 0.05.  ** = p < 0.01; * = < b 0.05. Hash 
signs are p-values for each condition compared to heparin-treated cells. ## = p < 0.01; # = p < 
0.05 (Ghadiali et al., 2016). 
 
5.2.3 HS Mimetics Differentially Affect Myoblast Cell Numbers 
 
In myoblasts, differentiation and proliferation are mutually exclusive and thus, it was 
hypothesised that the addition of less sulfated HS mimetics in low serum conditions 
increased pro-proliferative and/or anti-differentiative signals, delaying differentiation and 
promoting cell expansion. To measure this, the average nuclei count (DAPI positive cells) 
was calculated. The HS mimetics that decreased differentiation the most (HS mimetic 2, HS 
mimetic 3 and HS mimetic 4), also showed the greatest effect on increasing cell numbers at 
the highest concentration tested (1 µg/ml) (Figure 5.4). HS mimetic 2 was the only HS 
mimetic to increase cell numbers at the lower concentrations tested (10 and 100 ng/ml). 
Furthermore, HS mimetic 2 displayed similar effects on myoblast expansion compared to 
heparin at all concentrations tested. In contrast, myoblasts treated with oversulfated HS (HS 
mimetic 1), which did not reduce differentiation even at the highest concentration of 1 µg/ml, 
showed significantly reduced cell numbers yet there was no notable cell death or detached 
cells. In contrast, HS mimetics tested in high serum conditions on primary myoblasts, had no 
significant effects on proliferation (Appendix 2).  
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Figure 5.4 HS mimetics differentially affect myoblast cell number. Primary SC-derived 
myoblasts were cultured for 2 days in growth medium and then induced to differentiate for a 
further 3 days. For each condition shown, the total number of nuclei was measured and the 
average of ten images across two technical replicates for three independent experiments ± 
S.E.M. plotted. Asterisks are p-values for each condition compared to non-treated (NT) cells. ** = 
p < 0.01; * = < b 0.05. Hash signs are p-values for each condition compared to heparin-treated 
cells. ## = p < 0.01; # = p < 0.05 (Ghadiali et al., 2016). 
 
5.2.4 HS Mimetics Differentially Affect Cell Fusion 
 
The effects of the HS mimetics on myoblast fusion were then investigated. Fusion is the 
process by which differentiated myoblasts fuse together to form myotubes. The extent of 
fusion is defined as the fusion index (FI), which is calculated by dividing the number of 
differentiated cells over the number of nuclei contained in multinuclear MyHC positive cells. 
In general fusion followed a similar pattern to differentiation with fusion decreasing at 
increasing concentrations of HS mimetics (Figure 5.5).  
 
5.2.5 HS mimetics differentially affect Pax7 expression 
 
As shown in chapter 3, after three days in low serum nearly all myoblasts in primary satellite 
cell-derived myoblast cultures have either differentiated or entered a quiescent state, with 
the percentage of proliferating cells being negligible. Whereas differentiated myoblasts 
express myosin heavy chain (MyHC), non-differentiated quiescent cells express the 
transcription factor Paired Box 7 (Pax7) and are bona fide reserve cells. To test whether the 
changes in the extracellular heparanome affected the level of non-differentiated cells, the 
numbers of Pax7+ bona fide reserve cells was quantified in myoblast cultures that had been 
induced to differentiate and treated with the highest concentration (1 µg/ml) of HS mimetics 
previously tested for differentiation and cell expansion (Figure 5.6). 
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Figure 5.5 HS mimetics differentially affect myoblast cell fusion. Primary SC-derived 
myoblasts were cultured for 2 days and then induced to differentiate for a further 3 days. For each 
condition shown, the fusion index was calculated as the percentage of nuclei in multinucleated 
MyHC+ cells (multinucleated) over the total number of nuclei in MyHC+ (mono-nucleated and 
multinucleated) cells. The average of ten images across two technical replicates for three 
independent experiments ± S.E.M. was calculated and plotted. Asterisks are p-values for each 
condition compared to non-treated (NT) cells. ** = p < 0.01; * = < b 0.05. Hash signs are p-values 
for each condition compared to heparin-treated cells. ## = p < 0.01; # = p < 0.05 (Ghadiali et al., 
2016). 
 
 
At this concentration, with exception of HS mimetic 1 (oversulfated heparin), all of the HS 
mimetics produced a reduction in satellite cell-derived myoblast differentiation, however, the 
effects on the number of Pax7+ cells were more variable (Figure 5.7). Myoblasts treated 
with HS mimetics 2, 3 4 and 7 showed a significantly higher proportion of cells expressing 
Pax7 compared to non-treated cells and cells treated with heparin. However, cells treated 
with HS mimetic 1 and 6 presented a modest reduction in cells expressing Pax7 although 
these results did not reach statistical significance. Cells treated with HS mimetic 5 and 8 
showed similar numbers of cells expressing Pax7 compared to non-treated cells despite 
displaying statistically significant differences in the level of differentiation (Figure 5.8). 
Overall this suggests that the HS mimetics are working by different mechanisms on myoblast 
cell fate decision.  
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Figure 5.6 Representative images 
showing that HS mimetics 
differentially affect the numbers of 
Pax 7+ cells. Primary satellite cell-
derived myoblasts were cultured for 
48 h in growth medium and then 
induced to differentiate for an 
additional 72 h. Immunostaining for 
Pax7 (green) and nuclei are detected 
with the nuclear stain DAPI (blue). 
Ten images were taken across two 
technical replicates for three 
independent experiments for each 
condition shown. Scale bar = 100 µm 
across all images. 
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Figure 5.7 HS mimetics differentially affect Pax7 expression. Primary satellite cell-derived 
myoblasts were cultured for 2 days in growth medium and then induced to differentiate for a 
further 3 days. For each condition shown, the percentage of Pax7+ nuclei over the total number 
of nuclei was calculated and plotted as the average of ten images across two technical replicates 
for three independent experiments ± S.E.M. Asterisks are p-values for each condition compared 
to non-treated (NT) cells. ** = p < 0.01; * = < b 0.05. Hash signs are p-values for each condition 
compared to heparin-treated cells. ## = p < 0.01; # = p < 0.05 (Ghadiali et al., 2016).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.2.6 FGF2 signalling via Erk1/2 are differentially affected by different HS structures 
in myoblasts 
 
FGF2 promotes myoblast proliferation and is a potent inhibitor of myogenic differentiation. 
Since FGF2 depends on the presence of HS to signal and is sensitive to the level and 
pattern of HS sulfation (Guimond and Turnbull, 1999), it was hypothesised that the 
differences in myogenic activity observed in myoblasts treated with structurally different HS 
mimetics could be due to differences in their abilities to interact with and promote FGF2 
signalling. In order to explore this hypothesis, the effects of two HS mimetics on FGF2-
induced Erk1/2 activation, were tested, since it is well established that FGF2 induces ErK1/2 
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Figure 5.8 Summary of the effect 
produced by HS mimetics on 
primary satellite cell-derived 
myoblasts. Key: pro = 
proliferation, diff = differentiation, 
res = reserve cell generation 
where the mean values are plotted 
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activation leading to an up-regulation of phospho-Erk1/2, which is critical for myoblast 
proliferation (Rao et al., 1985). Since HS mimetic 1 (oversulfated heparin) was the only HS 
mimetic to significantly reduce cell numbers and had no statistically significant effects on 
myoblast differentiation, it was hypothesised that mimetic 1 could inhibit FGF2 signalling and 
thus lead to reduced myoblast proliferation. HS mimetic 2 on the other hand was the HS 
mimetic which had the strongest effect on increasing cell number and reducing 
differentiation, therefore it was hypothesised that HS mimetic 2 might enhance FGF2 
signalling and thus leads to increased myoblast proliferation. In order to measure the levels 
of ErK1/2 activation in response to FGF2 and/or various HS structures, the C2C12 myoblast 
cell line was utilised. Myoblasts were serum-starved for 6 hours before being treated with 
mimetic 1 with or without FGF2. Myoblasts treated with FGF2 alone increased Erk1/2 
activation at 15 minutes post stimulation (Figure 5.9). Myoblasts treated with FGF2 and 
mimetic 1 on the other hand showed a reduction in Erk1/2 activation suggesting that mimetic 
1 inhibits FGF2 induced Erk1/2 activation. Interestingly, myoblasts treated with HS mimetic 1 
alone showed a decrease in Erk1/2 activation below basal levels 15 minutes post 
stimulation.  
 
 
 
Figure 5.9 FGF2 signalling via Erk1/2 is reduced by HS mimetic 1 A) C2C12 myoblasts were 
serum-starved for 6 h (lane 1) then stimulated with either 2 nM FGF2 alone (lanes 2, 3) or HS 
mimetic 1 alone (lanes 4, 5) or FGF2 + HS mimetic 1 (1 µg/ml) together (lanes 6, 7) for the 
indicated amounts of time. At the end of the stimulus cells were immediately lysed and analysed 
via Western blotting to detect phosphorylated Erk1/2 (P-Erk1/2) and total Erk1/2. One 
representative of three independent experiments is shown. B) Quantification of phospho-Erk1/2 
band intensity normalised to total Erk1/2 intensity. Moreover, all time points were then normalised 
to time zero (end of serum starvation) and the averages of three independent experiments plotted 
± S.E.M., except for the condition “FGF2 alone at 15 and 30 minutes” which were averaged 
across 6 independent experiments (Ghadiali et al., 2016). 
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HS mimetic 2 on the other hand, showed the opposite effect. Although HS mimetic 2 alone 
did not appear to have any significant effect on the levels of Erk1/2 activation, HS mimetic 2 
and FGF2 appeared to increase Erk1/2 activation levels compared to FGF2 alone (Figure 
5.10). Activation also appeared to be sustained for a longer period of time to (60 minutes) 
compared to myoblasts treated with FGF2 alone. This suggests that HS mimetic 2 may 
inhibit differentiation by both increasing and prolonging FGF2 signalling.  
 
 
 
Figure 5.10 FGF2 signalling via Erk1/2 is increased by HS mimetic 2 A) C2C12 myoblasts 
were serum-starved for 6 h (lane 1) then stimulated with either 2 nM FGF2 alone (lanes 2, 3, 4) or 
HS mimetic 2 (1 µg/ml) alone (lanes 5, 6, 7) or FGF2 + HS mimetic 2 (lanes 8, 9, 10) for the 
indicated amounts of time. At the end of the stimulus cells were immediately lysed and analysed 
via Western blotting to detect phosphorylated Erk1/2 (P-Erk1/2) and total Erk1/2. One 
representative of three independent experiments is shown. B) Quantification of phospho-Erk1/2 
band intensity normalised to total Erk1/2 band intensity, moreover all time points were then 
normalised to time zero (end of serum starvation) and the averages of three independent 
experiments plotted ± S.E.M., except for the condition “FGF2 alone at 15 and 30 min” which were 
averaged across 6 independent experiments (Ghadiali et al., 2016). 
 
5.2.7 FGF2 mitogenic activity on myoblasts is differentially affected by different HS 
structures in myoblasts  
 
To investigate if the increase in FGF2-induced Erk1/2 activation also led to increased 
mitogenic activity on the myoblasts, satellite cell-derived myoblasts were grown overnight in 
serum free medium with or without HS mimetic 1 or 2 and FGF2. BrdU incorporation was 
used as a measure of mitogenic activity (Figure 5.11). Myoblasts treated with FGF2 and HS 
mimetic 1 showed a statistically significant reduction in the proportion of BrdU positive cells 
compared to myoblasts treated with FGF2 alone (Figure 5.12). On the other hand, 
myoblasts treated with FGF2 and HS mimetic 2 showed an increase in the proportion of 
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BrdU positive cells compared to myoblasts treated with FGF2 alone, although this result did 
not reach significance. These results suggest that whilst HS mimetic 2 promotes FGF2-
induced proliferation of satellite cell-derived myoblasts, mimetic 1 inhibits FGF2-induced 
proliferation. This is consistent with the result that HS mimetic 1 reduces FGF2-induced 
Erk1/2 activation, which is upstream of myoblast proliferation pathways.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.11 Representative images showing that HS mimetics differentially affect myoblast 
proliferation. Primary satellite cell-derived myoblasts were expanded for two days in growth 
medium then serum-starved for 12 hours to induce cell cycle exit followed by treatment with either 
vehicle (NT), FGF2, FGF2 + HS mimetic 1 or FGF2 + HS mimetic 2 overnight. 10 µM BrdU was 
then added to the culture medium 2 h prior to fixation and immunostaining to detect BrdU (red). 
Nuclei are detected with DAPI (blue). Ten images were taken across two technical replicates for 
three independent experiments for each condition shown. White arrows indicate BrdU postive 
nuclei. Scale bar = 100 µm across all images. 
 
 
 
Figure 5.12 HS mimetics differentially affect 
proliferation of serum-deprived myoblasts. Primary 
satellite cell-derived myoblasts were cultured for 2 days in 
growth medium and then serum-starved for 12 h to induce 
cell cycle exit followed by treatment with either vehicle 
(NT), FGF2, FGF2 + HS mimetic 1 or FGF2 + HS mimetic 
2 overnight. Cells were then treated with BrdU for 2 hours 
before fixing and immunostaining. For each condition 
shown, the percentage of BrdU+ nuclei over the total 
number of nuclei was calculated and plotted as the 
average of ten images across two technical replicates for 
three independent experiments ± S.E.M (Ghadiali et al., 
2016).   
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5.3 Discussion 
 
In this chapter, heparin and a small library of chemically modified heparin derivatives with 
different levels and patterns of sulfation (HS mimetics), were tested on satellite cell-derived 
myoblasts for their effects on proliferation, differentiation and self-renewal. The process of 
myogenesis is regulated by several heparin-binding growth factors; whilst some growth 
factors promote cell proliferation; such as FGF (Clegg et al., 1987; Schabort et al., 2009; 
Sheehan and Allen, 1999), others promote myogenic differentiation such as IGF (Jennische 
and Hansson, 1987). Since growth factor signalling is heavily affected by the sulfation 
pattern of HS and the structure of HS changes during myogenesis, it was hypothesised that 
HS mimetics displaying various structures might differentially affect myogenesis, further 
elucidating structure-function properties of HS during myogenesis. To investigate this 
hypothesis, satellite cell-derived myoblasts were treated with HS mimetics at differing 
concentrations concomitant with induction to differentiation. Consistent with the hypothesis, 
different effects on myoblast cell number, differentiation, fusion and self-renewal were 
observed between HS mimetic treatments. In general, the effects of the HS mimetics on the 
different stages of myogenesis were structure-specific and concentration-dependent.  
 
The majority of the HS mimetics, at the highest concentration tested (1 µg/ml), produced a 
significant reduction in myoblast differentiation. Oversulfated heparin (HS mimetic 1), was 
the only mimetic that did not reduce myoblast differentiation and produced a significant 
reduction in myoblast cell number. Since there was no noticeable cell detachment or cell 
death in myoblasts treated with HS mimetic 1, it is likely that the reduction in cell number 
was due to cell cycle arrest. Since on the first day in low serum, myoblasts are still dividing, it 
is possible that HS mimetic 1 induces cell cycle arrest more rapidly than serum reduction 
alone or serum reduction and other HS mimetics. This is likely due to the strong inhibitory 
effect of HS mimetic 1 on FGF2 induced proliferation, leading to reduced cell numbers. 
Indeed, myoblasts treated with FGF2 and HS mimetic 1 together, did not produce an 
increase in Erk1/2 phosphorylation and showed a significant reduction in the number of cells 
re-entering the cell cycle. These observations together suggest that HS mimetic 1 leads to a 
reduction in myoblast proliferation by blocking FGF2 signalling. This lends strength to our 
previous findings that the more highly sulfated HS species produced during myogenic 
differentiation is associated with reduced FGF2 induced mitogenic activity. However, it 
cannot be ruled out that oversulfated heparin may affect other signalling pathways, which 
could also contribute to the reduction in myoblast proliferation and this requires further 
investigation. Mimetic 2, on the other hand, which had the largest effect on increasing cell 
number, was found to increase FGF2/Erk1/2 signalling pathway, prolonged FGF2 induced 
Erk1/2 phosphorylation and produced a significant increase in the number of cells re-
entering the cell cycle. This suggests that HS mimetic 2 increases myoblast proliferation in 
low serum by promoting FGF2 signalling.  
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When myoblasts are maintained under differentiating conditions ex vivo, a proportion of 
myoblasts exits the cell cycle and remains in an un-differentiated state and express Pax7. In 
vitro quiescent cells are called “reserve cells” which are Pax7+ Ki-67- negative and represent 
an ex vivo model of satellite cell self-renewal (Yoshida et al., 1998). Since after three days in 
differentiating conditions the number of proliferating (Ki-67+) cells are negligible (Figure 3.7), 
it was reasoned that the level of Pax7 expression was an appropriate predictor of the level of 
reserve-cell generation with the effects of the HS mimetics on cell numbers being limited to 
the cells still completing the cell cycle in the hours following serum withdrawal. Interestingly, 
despite all HS mimetics, with the exception of HS mimetic 1, producing a reduction in 
myoblast differentiation, the effects on the number of Pax7+ bona fide cells were more 
variable. Notably, at 1 µg/ml, on HS mimetics 2 and 4 promoted cell expansion, which alone 
would justify an increase in the proportion of undifferentiated cells. In contrast, HS mimetics 
3 and 7 did not affect cell expansion and reduced differentiation, thus suggesting that HS 
mimetics 3 and 7 might have a direct effect on promoting reserve cell generation. Further 
characterisation of reserve cell generation based on double Pax7/Ki-67 staining is required 
in order to test this hypothesis. This strongly supports the idea that HS-mediated signalling 
events regulate satellite cell fate in a complex manner, simultaneously affecting multiple 
signalling pathways. Furthermore, it lends strength to the argument that the structure-
function activity of HS is not solely reliant on the level of charge since there is no simple 
correlation between the level of sulfation (and thus charge) of the HS mimetic treatment and 
the levels of reserve-cell generation. This implies that there is some structure-function 
redundancy of HS. Indeed, previous findings have shown that non-HS or glycosaminoglycan 
analogues can promote FGF2 signalling, but do not support FGF2 stabilisation (Rudd et al., 
2010), highlighting that HS-mediated promotion of FGF2 signalling is dependent on 
mechanisms other than protein stabilisation.  
 
One explanation for the sustained FGF2 signalling with HS mimetic 2 compared to cells 
treated with FGF2 alone, could be that HS mimetic 2 binds FGF2 in a way that prevents its 
proteolytic degradation by extracellular proteinases (Saksela et al., 1988) which may be in 
turn due to differences in the stabilising interaction between the HS mimetic and FGF2. 
However, previous investigations into the stabilising effects of the HS mimetics on FGF2, 
reported that heparin has the largest stabilising effect on FGF2 followed by oversulfated 
heparin (HS mimetic 1) (Uniewicz et al., 2012). This is further supported by highly sulfated 
fractions of heparin, which bind FGF2 more strongly than less sulfated fractions of heparin 
(Naimy et al., 2011).  Furthermore, the relative stabilising effect of HS mimetic 2 was four 
times lower than that of oversulfated heparin yet had the most significant effect on increasing 
myoblast proliferation compared to non-treated cells (Uniewicz et al., 2010). This suggests 
that there is not a direct correlation between HS-mediated stabilization of FGF2 and FGF2 
induced myoblast proliferation. Therefore, the level of FGF2 stabilization by the HS mimetics 
does not predict HS-mediated FGF2 activity alone. Instead, HS mediated FGF2 activity is 
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reliant on a combination of interactions involving FGF2, HS and the FGF receptor 
(Schlessinger et al., 2000). For example, HS mimetic 2 contains 2- and 6-O-sulfation, which 
is important for supporting FGF2 signalling (Pye et al., 1998) and thus may support 
sustained FGF2 induced Erk1/2 phosphorylation. Indeed, HS mimetic 2 has been reported to 
support FGF2/FGFR1 BaF3 mitogenic activity (Guimond et al., 2006) and thus our data 
further support this finding that HS mimetic 2 promotes FGF2 signalling.  In contrast, the 
large number of sulfate groups on HS mimetic 1, which binds strongly to FGF2 may 
sequester FGF2 away from the FGF receptor leading to reduced FGF2 signalling. 
Alternatively, the more highly sulfated heparin derivative may compete with endogenous HS 
for FGF2 signalling in which the sulfation pattern does not support formation of the HS-
FGF2-FGFR1 ternary complex. A similar phenomenon has previously been reported with a 
highly sulfated heparin mimicking polymer poly(sodium-4-styrenesulfonate) (PSS) (Sangaj et 
al., 2010). Here, the authors report that PSS binds strongly to FGF2 and in turn blocks 
Erk1/2 activation in the C2C12 myoblast cell line promoting myogenic differentiation (Sangaj 
et al., 2010). Since myoblast fusion is heavily influenced by the level of myoblast 
differentiation, it is not surprising that the HS mimetics affect myoblast fusion in a similar 
pattern to that presented in myogenic differentiation. This suggests that HS mediated 
signalling events have a direct role on myogenic differentiation but a less pronounced effect 
on regulating myoblast fusion. However, further work may involve investigating specific HS-
mediated signalling pathways that could modulate myoblast fusion independent on myoblast 
differentiation. Furthermore, from the phenotypes displayed through the treatment with HS 
mimetics, effects on other HS-mediated signalling pathways on myogenesis cannot be 
excluded. However, there is no correlation between the biological activity and the charge 
density alone. Instead, these observations suggest that it is the overall structural 
consequences of a combination of; a) the level of sulfation, b) the position of sulfation and c) 
the conformation of HS structures that are critical for interactions and biological activity. 
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Chapter 6 
 
 
 
 
6 Effect of Fully Synthetic HS Mimetic Clusters on 
Myogenesis 
 
6.1 General Introduction 
 
6.1.1 HS mimetics as therapeutics 
 
In the previous chapter, it was demonstrated that chemically modified heparins differentially 
affect muscle stem cell homeostasis depending on the pattern and level of sulfation. 
Therefore, HS mimetics may represent novel therapeutic entities for muscle wasting 
conditions, where muscle stem cell homeostasis is dysregulated. However, heparin itself is a 
heterogeneous mixture containing polysaccharides of different lengths and structures; 
although modified heparins can have less heterogeneity in sulfation, they are still mixtures 
containing polysaccharides of different lengths. Thus, although modified heparins provide an 
important indication of the structural requirements for a particular HS-mediated function, it 
could be beneficial to produce fully synthetic HS mimetics that maintain the same potency of 
HS or modified heparins as potential therapeutic molecules.  
 
6.1.2 Carbohydrate Chemistry  
 
The synthesis of oligosaccharide-based HS mimetics requires a multifaceted, complex 
process. Since particular techniques are consistently required in the handling of sugars, 
carbohydrate chemistry in itself is a specialised branch of organic chemistry. 
Oligosaccharide synthetic complexity arises from the large numbers of hydroxyl functional 
groups around a sugar, which must be differentiated to attain chemoselectivity and 
regioselectivity. Importantly, the large numbers of hydroxyl groups give rise to a highly 
hydrophilic macromolecule and thus solvent choice can be limited during synthesis, adding 
to the synthetic complexity.  
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Most monosaccharides, such as glucose and galactose, are readily obtained from natural 
sources, which are commonly the starting point for oligosaccharide synthesis. 
Monosaccharides are linked together by the glycosylation reaction (Figure 6.1), leading to 
the formation of a mixture of anomers connected by either 1,2-cis or 1,2-trans linkages. It is 
these linkages that determine the stereochemistry of the oligosaccharide, which is an 
important factor for determining the conformation of a sugar and thus their chemical 
properties. Firstly, one monosaccharide is termed the ‘glycosyl donor x’, which contains a 
leaving group X, at the anomeric position. The lone pair of electrons on the ring oxygen aids 
the departure of X and stabilises the planar intermediate 2. The second monosaccharide is 
termed the glycosyl acceptor 3, which bears a free hydroxyl group that can attack either face 
of the planar intermediate, allowing for the formation of both the equatorial anomer 4 and the 
axial anomer 5. The axial anomer is the more thermodynamically favourable product due to 
hyperconjugation, known as the anomeric effect and hence axial anomers are formed 
preferentially over equatorial anomers. Achieving the correct glycosidic bond 
stereoselectivity is crucial in HS oligosaccharide synthesis but this remains a significant 
challenge. Functional groups adjacent to the anomeric carbon (the site of glycosylation) can 
be employed to direct the stereoselectivity of the glycoside bond. This is termed 
‘neighbouring group participation’ and is a strategy frequently used in HS oligosaccharide 
synthesis.  
 
 
 
 
 
 
 
Figure 6.1 Schematic of glycosylation reactions. General scheme for the glycosylation 
reaction of glycosyl donor 1 and glycosyl acceptor 3 forming a mixture of (compound 4) equatorial 
and axial (compound 5) anomers. The formation of anomers is due to the intermediate 2, which is 
a planar molecule and can be attacked from either side. 
 
 
In addition to achieving stereoselectivity, regioselectivity is also crucial in oligosaccharide 
synthesis. Depending on the position around the ring, and thus the surrounding chemical 
environment, the hydroxyl groups can have different chemical properties. When hydroxyl 
groups have similar chemical properties, the glycosylation reaction can involve multiple 
hydroxyl groups on the glycosyl acceptor. Likewise, in a desired reaction, for example in a 
sulfation reaction, hydroxyl groups can interfere by reacting instead of the functional group 
(FG) required. To overcome this, hydroxyl groups can be chemically shielded with a non-
reactive, protecting group (PG) (Figure 6.2). The desired reaction can then take place at the 
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functional group, without the competing hydroxyl groups. Once the chemical reaction has 
taken place, the protecting group can be removed. In the majority of cases in 
oligosaccharide synthesis, the protection of more than one hydroxyl group is necessary. The 
use of orthogonal protecting groups with different chemical properties allows for selective de-
protection. For HS synthesis, the use of protecting groups is crucial for regioselectivity 
enabling the production of libraries of HS sequences containing different positions of 
sulfation of the multiple hydroxyl groups. Five of the most commonly used protecting groups 
in oligosaccharide synthesis are listed in Table 6.1. 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2 Schematic showing hydroxyl group protection.  Compound 6 contains one 
functional group (FG) for a chemical reaction in which the three free hydroxyl groups are 
competing. Therefore, the remaining three hydroxyl groups are protected with protecting groups 
(PG) in 7 prior to the chemical reaction producing 8. Compound 8 then undergoes chemical de-
protection to produce compound 9 with free hydroxyl groups. 
 
6.1.3 HS synthesis  
 
Although there has been significant progress in the development of strategies for HS 
oligosaccharide synthesis, the synthesis of longer chains of HS sequences remains a multi-
step (more than 50 steps for the synthetic pentasaccharide drug, Arixtra), arduous and costly 
process (Arungundram et al., 2009; Cole et al., 2010; Hung et al., 2012; Lee et al., 2004; 
Noti and Seeberger, 2005; Polat and Wong, 2007; Schwörer et al., 2013). To overcome this, 
chemoenzymatic approaches have been developed (Liu et al., 2010; Xu et al., 2011), which 
use multiple HS biosynthetic enzymes for the synthesis of low molecular weight heparin 
oligosaccharides. However, it is difficult to regulate enzyme activity and specificity in 
chemoenzymatic reactions (Xu et al., 2011) and thus the production of specific and pure HS 
oligosaccharide sequences using chemoenzymatic approaches remains a challenge.  
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Table 6.1 Structures of 5 common protecting groups employed in HS oligosaccharide 
synthesis with their corresponding selective removal conditions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6.1.4 HS Dendrimer Clusters 
 
Recently, a greatly simplified synthetic procedure has been developed for producing a library 
of HS mimetics, which have been found to retain the bioactivity of long chained HS 
oligosaccharide structures. These HS mimetics, termed HS dendrimers, consist of a single 
entity tetravalent glycomimetic containing a core which has been end capped with short 
specific HS sequences. A wide range of dendrimer structures have been readily synthesised 
utilising the same dendritic core and disaccharide-building block, with few steps (Tyler et al 
2015). Owing to the long, flexible dendritic core, bioactivity can be maintained with end-
capped HS sequences as short as disaccharides, which individually would not retain 
bioactivity. All the dendrimers synthesised so far lack anticoagulant activity, making them 
promising therapeutic molecules with potentially few off-target effects (Tyler et al., 2015). 
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6.2 Hypothesis 
 
Since: a) different structures of modified heparins affect myogenesis differently and b) HS 
dendrimers are able retain the bioactivity of longer HS oligosaccharides, it was hypothesised 
that HS-mimicking dendrimers (HS dendritic clusters) would affect myogenesis in a 
structure-dependent manner. 
 
In this chapter it is shown that: 
 
1. The synthesis of a new HS mimetic cluster containing N-sulfation.  
2. Biological activities of the dendrimers produced is only observed at relatively high 
concentrations in bioassays testing myoblast differentiation or Pax7 expression. 
 
6.3 Results 
 
6.3.1 Preliminary Screen of HS dendrimers on Satellite Cell-Derived Primary 
Myoblasts 
6.3.1.1 HS Mimetic Cluster Selection 
 
As a preliminary screen, to test the hypothesis that HS dendritic clusters would affect 
myogenesis, primary satellite cell-derived myoblasts were treated, concomitant with 
induction to differentiation, with a selection of HS dendritic clusters, which had been 
previously synthesised and kindly donated by Dr Olga Zubkova and Prof Peter Tyler 
(Victoria University of Wellington, New Zealand). The synthesis of some of these compounds 
had previously been published (Tyler et al., 2015). Six tetramer dendrimers were selected 
(dendrimers 3, 4, 5, 6, 7 and 8) in which the end-capped saccharide contained at least 6-O-
sulfation since these dendrimers had been found to mimic much longer poly- and oligo-
saccharide chains of natural HS in their inhibition of BACE-1. All 6 dendrimers tested 
consisted of the ‘long-armed’ dendritic core since previous studies had confirmed these to be 
more potent than the corresponding ‘short-armed’ dendritic cores.  Three disaccharide and 
three tetrasaccharide end-capped dendrimers including L-iduronic or D-glucuronic acid 
residues were tested (Figure 6.3 and Table 6.2). 
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Figure 6.3 General structures of HS dendritic clusters tested on myoblast differentiation. 
Tetramer 10 contains iduronic acid (dendrimer 3 and dendrimer 5) or glucuronic acid (dendrimer 
4). 11 contains iduronic acid (dendrimer 6) or glucuronic acid (dendrimer 7 and dendrimer 8). The 
pattern of sulfation of the dendrimers tested is shown in Table 2 where R1/R2 = H or SO3- and R3 = 
Ac or SO3-. 
 
 
Table 6.2. The pattern of sulfation of the HS dendritic clusters tested on myoblast 
differentiation. The structural componenets  of dendrimer 3, 4, 5, 6, 7 and 8 based on the 
teteramer HS clusters 10 and 11 shown in Figure 6.3.  
  
 
 
 
 
 
 
 
Dendrimer HS 
Cluster 
R1 R2 R3 
Position of 
Sulfation 
Uronic Acid 
den 3 10 SO3- Ac H 6S L-iduronic 
den 4 10 SO3- Ac SO3- 2S, 6S D-glucuronic 
den 5 10 SO3- Ac SO3- 2S, 6S L-iduronic 
den 6 11 SO3- SO3- SO3- 2S, 6S, NS L-iduronic 
den 7 11 SO3- Ac H 6S D-glucuronic 
den 8 11 SO3- Ac SO3- 2S, 6S D-glucuronic 
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6.3.1.2 Preliminary Screen Differentiation Assay 
 
The differentiation index was measured in satellite cell-derived primary myoblasts that had 
been treated with the dendritic clusters at 0.1, 1 and 10 µg/ml for 72 hours concomitant with 
induction to differentiation. As seen with the modified heparin HS mimetics from the previous 
chapter, there was a general trend for a reduction in differentiation of myoblasts treated with 
the HS dendritic clusters. From the preliminary screen, the dendritic clusters that appeared 
to have the largest effects on reducing myogenic differentiation were the disaccharide-
capped clusters: dendrimer 3, dendrimer 4 and dendrimer 5 (Figure 6.4). The uronic acid 
residue (L-iduronic acid or D-glucuronic acid) did not appear to have a significant effect on 
myogenesis, since both dendrimer 4 and 5 (which consist of the same disaccharide unit with 
exception of the uronic acid residue) had comparable effects on myogenesis. There did, 
however, appear to be a more significant effect of HS fragment size, since disaccharide-
capped dendrimer 4, produced a reduction in differentiation whereas the same concentration 
of tetrasaccharide-capped dendrimer 5 (1 µg/ml), produced an increase in differentiation 
compared to non-treated cells.  
 
Figure 6.4 Preliminary screen of a selection of HS dendritic clusters for their effects on 
myoblast differentiation. Primary SC-derived myoblasts were cultured for 2 days in growth 
medium and then induced to differentiate for a further 3 days. The differentiation index was 
calculated as the percentage of nuclei in MyHC+ cells (both mono- and multi-nucleated) over the 
total number of nuclei (DAPI+). The average of ten images across two technical replicates ± 
S.E.M. was calculated and plotted normalised to the non-treated cells. 
  
From the preliminary screen of the HS dendritic clusters, there appeared to be a general 
trend for a reduction in myoblast differentiation in satellite cell-derived myoblasts treated with 
the HS dendritic clusters. Therefore, it was hypothesised that the reduction in myoblast 
differentiation could be accompanied by an increase in myoblast expansion. Thus, the 
number of cells present after 72 hours in differentiating conditions was analysed. Dendrimer 
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6 had the most significant effect on increasing cell numbers in differentiating conditions at 
0.1, 1 and 10 µg/ml (Figure 6.5). Dendrimer 3, which also reduced myogenic differentiation, 
produced a significant increase in myoblast cell numbers at 0.1 and 1 µg/ml, although the 
results were not as pronounced. Myoblasts treated with dendrimers 5, 7 or 8 presented no 
differences in myoblast numbers compared with non-treated cells. The most significant 
difference in phenotype appeared to arise from the pattern and level of sulfation, since the 
addition of N-sulfation, in dendrimer 6, appeared to have a marked effect on increasing 
myoblast numbers. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.5 Preliminary screen of a selection of HS dendritic clusters for their effects on 
myoblast differentiation. Primary SC-derived myoblasts were cultured for 2 days in growth 
medium and then induced to differentiate for a further 3 days. The differentiation index was 
calculated as the percentage of nuclei in MyHC+ cells (both mono- and multi-nucleated) over the 
total number of nuclei (DAPI+). The average of ten images across two technical replicates ± 
S.E.M. was calculated and plotted normalised to the non-treated cells. 
 
6.3.2 The Development of an N-sulfated HS Disaccharide Dendrimer Cluster 
 
From the preliminary screen of the HS dendritic clusters tested on myogenic differentiation 
and myoblast cell expansion, dendrimer 6 appeared to have the most significant effects on 
myogenesis. Dendrimer 6 consists of a tetrasaccharide-capped-tetramer made up of 
iduronic acid and glucosamine disaccharide unit containing, N-sulfation, 6-O- and 2-O-
sulfation; this represents the main disaccharide unit of heparin. From the preliminary screen, 
the disaccharide-capped HS clusters appeared to have the most significant effects on 
reducing myogenic differentiation. A dendrimer consisting of disaccharide tetramer is 
synthetically less challenging than a dendrimer consisting of a tetrasaccharide tetramer.  
Thus, we reasoned it would be useful to investigate the properties of a dendrimer consisting 
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of a disaccharide tetramer, with an iduronic acid residue and glucosamine containing N-
sulfation, 6-O- and 2-O-sulfation. Furthermore, we sought to explore the effects of using a 
HS mimetic cluster containing a short arm dendritic core. Such a construct may produce 
similar effects on myogenesis as dendrimer 6, being made up of the same disaccharide unit 
but in disaccharide form and with the shorter-armed dendritic core. Therefore, we aimed to 
synthesise the appropriate target compound designated Den T (Figure 6.6).  
 
 
 
Figure 6.6 Structure of the target compound, Den T. The structure of the desired target 
compound based on a long-armed dendritic core end capped with HS disaccharides consisting of 
glucosamine and iduornic acid containing sulfation at position 2, position 6 and position N 
(highlighted in red). 
6.3.2.1 Disaccharide Building Block 
 
The synthesis of a wide range of the HS structural units can be achieved through just one 
disaccharide building block, designed to contain orthogonal protecting groups on the key 
structural positions (position 2, position 6 and position N), which can be selectively de-
protected and sulfated. The details of the synthesis of a disaccharide building block has 
been previously synthesised and published (Schwörer et al., 2013). β-disaccharide 12 
(Figure 6.7) contains a linker region, which is protected with an Fmoc group and can be 
selectively removed before coupling the disaccharide building block to the dendritic core. 
The disaccharide building block 12 had been previously synthesised (Tyler et al., 2015) and 
was kindly donated to us by Professor Tyler.  
 
 
 
 
 
Figure 6.7 Structure of the disaccharide building block. Disaccharide building block 12 for 
synthesising the target dendrimer   which had been previously synthesised (Dr Olga Zubkova). 
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6.3.2.2 Dendritic Core 
 
The target compound was designed based on the use of the short-armed dendritic core 13 
(Figure 6.8). This dendritic core had been previously synthesised (Tyler et al 2015) and 
kindly donated to us by Professor Tyler.  
 
 
 
 
 
 
Figure 6.8 Structure of the short-armed dendritic core. The short-armed dendritic core 13 
consists of a 4 armed structure which can be end-capped with HS seqeunces via the linker 
region. 13 had been previously synthesised and donated to us. 
 
6.3.2.3 Partial Processing of the Disaccharide 
 
The synthetic process for synthesising a wide range of HS dendrimers has been previously 
published (Tyler et al., 2015). Thus it was hypothesised that the target compound could be 
synthesised following a similar synthetic procedure. Prior to coupling the disaccharide to the 
dendritic core, the disaccharide was partially processed (Figure 6.9). Firstly, the 
chloroacetate group was selectivity removed from the disaccharide building block 12, to 
expose a free hydroxyl group. The disaccharide containing a free hydroxyl group and the N-
Fmoc protected linker region was then isolated as compound 13 at 78% yield. The free 
hydroxyl group was then oxidised to the corresponding carboxylic acid 14, forming the basis 
of the iduronic acid residue. The carboxylic acid group was then re-protected as a methyl 
ester 15 at 66% yield, prior to coupling with the dendritic core. The methyl ester was 
detected by the singlet peak on the 1H NMR spectra at 3.82 ppm representing 3 protons 
(appendix). N-Fmoc was then selectively removed to furnish amine 16 at 80% yield. Fmoc 
benzylic protons were no longer present at 7.76 and 7.59 ppm on the 1H NMR spectra 
(appendix) in amine 16.  
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Figure 6.9 Scheme showing partial processing of disaccharide building block. a) Selective 
de-chloracetylation with DABCO, MeCN/EtOH, 70 °C (Appendix 2.2.1); b) Oxidation of the 
hydroxyl group to a carboxylic acid functional group with TEMPO, BAIB aq MeCN, RT, then c) 
methyl ester re-protection of the carboxylic acid with CH2N2, 0 °C to room temperature (Appendix 
2.2.2) and finally d) N-Fmoc de-protection with piperidine to afford the amine (Appendix 2.2.3). 
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6.3.2.4 Coupling Reaction 
 
After the disaccharide had been partially processed to afford amine 16, it was coupled to the 
dendritic core 13 (Figure 6.10). Since the dendritic core is a tetravalent compound, four 
equivalents of the HS disaccharide 16 were coupled with the dendritic core 13 to afford the 
tetramer clusters after purification chromatography to afford the tetramer cluster 17 at 81 % 
yield which was confirmed by the production of the ion for [C213H252N16O60]+3H m/z 3996.72 
found 3996.8 (Appendix 2.2.4). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.10 Scheme showing the formation of the disaccharide tetramer. Coupling of 
compound 16 to the dendritic core 13 was achieved with DMF, Et3N at room temperature at 81.4 
% yield (Appendix 2.2.4). 
 
6.3.2.5 Selective Sulfation 
 
After successfully coupling the disaccharide to the dendritic core, tetramer cluster 17 was 
then subjected to a series of de-protecting reactions to reveal free hydroxyl groups for 
subsequent sulfation steps. Sulfation reactions are repeatedly used in HS oligosaccharide 
synthesis. Since sulfate groups are highly negatively charged, the presence of multiple 
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sulfate groups produces a highly polar compound. As the compound becomes more polar, 
solvent choices for further chemical reactions become overly limited. Thus, it is easier 
synthetically to sulfate groups as the last synthetic stage in a step-wise manner; this also 
reduces the risk of partial-sulfation reactions. As mentioned previously, the orthogonal 
protecting groups present on the disaccharide unit allow for the selective de-protection and 
sulfation on the key positions: position 6, position 2 and position N (Figure 6.11) on the HS 
disaccharide unit.  
 
 
 
 
 
 
 
 
Figure 6.11 Orthogonally protected disaccharide unit. Diagram depicting the protected 
disaccharide unit (protecting groups highlighted in red) with the corresponding order of sulfation. 
The acetate group at position 6 of glucosamine is removed first, followed by removal of the 
benzoate group at position 2 of iduronic acid and finally the azide group at the N-position of 
glucosamine. The benzoylated groups (highlighted in blue) are removed to afford three free 
hydroxyl groups. 
 
Tetramer cluster 17 was first subjected to acid hydrolysis to selectively remove the O-
acetates to afford the free primary hydroxyl group (position 6) tetramer cluster 18 (59% 
yield), which was then subjected to the initial sulfation of the primary hydroxyl group to 
produce the mono-sulfated disaccharide-capped tetramer 19 (93% yield), revealing 6-O-
sulfation on the glucosamine residue. Tetramer cluster 19 was then subjected to 
saponification, to simultaneously remove i) the methyl ester-protecting group (chemical shift 
at 3.82 ppm) to reveal the carboxylic acid and ii) the benzoate-protecting group to reveal a 
free hydroxyl group at position 2, furnishing 20 (95% yield). The free hydroxyl group was 
then sulfated at position 2 of the iduronic acid residue, to form the di-sulfated disaccharide-
capped tetramer 21 (Figure 6.12).  
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Figure 6.12 Scheme showing selective de-protection and sulfation of the disaccharide 
endcapped tetramer. a) Selective de-O-acetylation with DCM/MeOH/AcCl to afford free primary 
hydroxyl groups (Appendix 2.2.5) b) sulfation of the hydroxyl groups (at posn 6) with SO3.NMe3, 
DMF, H2O, 0 °C to room temperature (Appendix 2.2.7). c) saponification to remove the benzoate 
group and the methyl ester protecting group with NaOH, aq. MeOH, 0 °C to room temperature 
(Appendix 2.2.8). d) sulfation of the hydroxyl groups (position 2) with SO3.NMe3, DMF, 0 °C to 
room temperature (Appendix 2.2.9). Scheme depicts one arm of the tetramer cluster. 
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Hydrogenolysis of 21, furnished the fully de-benzylated amine 22 (80% yield). Finally, 22 
was subjected to selective N-sulfation to yield the desired target dendrimer (Den T); the tri-
sulfated disaccharide capped tetramer (Figure 6.13).  
 
 
Figure 6.13 Scheme showing de-benzylation and selective N-sulfation of the end-capped 
disaccharide. e) Hydrogenolysis of the disaccharide to remove the benzyl groups and reduce the 
azide group to a free amine group with Pd/C/H2 (Appendix 2.2.10) f) Selective N-sulfation was 
achieved with SO3.NMe3, H2O at 0 °C to room temperature to afford the target dendrimer. 
Scheme depicts one arm of the tetramer cluster (Appendix 2.2.11). 
 
However, after the initial purification, the NMR presented two distinct anomeric carbons 
suggesting some impurity was present after chromatography (Figure 6.14). From the 1H 
NMR 65 % of the anomeric proton was identified as the N-sulfated product Den T. Therefore 
the target dendrimer, Den T was subjected to further purification after flash column 
chromatography, which finally afforded 4 mg of the target dendrimer as its sodium salt, of 
sufficient purity (79 %) suitable for testing in biological assays (Figure 6.6).  
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Figure 6.14 Proton NMR of anomeric regions of disaccharide 13 and Den T. (Proton NMR) 
shows chemical shift of anomeric protons of the glucosamine residue (H1 GlcN) and the chemical 
shifts of the anomeric protons of the iduronic acid residue (H1 Ido) for compound 13 (blue), for 
Den T after 1st purification (green) and Den T after the 2nd purification (red). The major anomeric 
product represents 65 % of the total material after the first purification (green). After a second 
purification the major anomeric product of Den T represents 79 % of the total material. 
 
6.3.3 Effects of Dendrimer Den T on Myogenesis 
 
To investigate the effects of the target dendrimer on myogenesis, primary satellite cell-
derived myoblasts were treated with the target dendrimer (Den T), concomitant with 
induction to differentiation. From the preliminary screen, the largest effects on myogenesis 
appeared at the higher concentrations tested and thus, myoblasts were treated with the 
target dendrimer at 1 µg/ml, 10 µg/ml and 100 µg/ml to first investigate the effects on 
myoblast differentiation and cell expansion (Figure 6.16). At the lowest concentration tested 
(1 µg/ml) there were no statistically significant differences in the level of differentiation or cell 
number in treated myoblasts compared to non-treated cells (Figure 6.17). However, 
myoblasts treated with the target dendrimer at 10 µg/ml showed a statistically significant 
increase in cell number, although the level of differentiation remained unchanged. These 
results thus contrast with those observed with den 6 treatment (Figure 6.4 and 6.5). At 100 
µg/ml however, there was no statistically significant differences in cell number compared to 
non-treated cells but a statistically significant reduction in myoblast differentiation. 
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Figure 6.16 Representative images showing the concentration dependent effect of the 
target dendrimer on myoblast differentiation. Primary SC-derived myoblasts were cultured for 
48 h and then induced to differentiate for an additional 72 h. Differentiated cells, both mono- and 
multi-nucleated, were identified via immuno-staining to detect myosin heavy chain (MyHC, 
green). Nuclei are detected with DAPI (blue). The differentiation index was calculated as the 
percentage of nuclei in MyHC+ cells (both mono- and multi-nucleated) over the total number of 
nuclei (DAPI+). The average of ten images across two technical replicates for three independent 
experiments ± S.E.M. is calculated and plotted. Asterisks are p-values for each condition 
compared to non-treated (NT) cells. ** = p < 0.01. Scale bar = 100 µm across all images. 
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Since Den T affected cell numbers and differentiation at the highest concentrations tested 
(10 µg/ml and 100 µg/ml) without affecting cell numbers, it was hypothesised that the level of 
Pax7 expression may also be affected. Satellite cell-derived myoblasts were treated with the 
Den T at 10 µg/ml and 100 µg/ml to test the effects on Pax7 expression (Figure 6.18). At 10 
µg/ml there were no statistically significant differences in the level of non-differentiated cells 
compared to non-treated cells. However, at 100 µg/ml there was a statistically significant 
increase in the proportion of cells expressing Pax7 (Figure 6.18).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.18 Representative images showing the 
concentration dependent effect of the target 
dendrimer on Pax7 expression. Primary satellite cell-
derived myoblasts were cultured for 48 h in growth 
medium and then induced to differentiate for an additional 
72 h. Reserve cells were identified via immunostaining for 
Pax7 (green). Nuclei are detected with the nuclear stain 
DAPI (blue). The percentage of Pax7+ nuclei over the 
total number of nuclei was calculated and plotted as the 
average of ten images across two technical replicates for 
three independent experiments ± S.E.M. Asterisks are p-
values for each condition compared to non-treated (NT) 
cells. ** = p < 0.01. 
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6.4 Discussion 
 
In this chapter, a small library of HS mimetic dendritic clusters, with differing levels and 
patterns of sulfation, were tested on primary myoblasts for their effects on differentiation and 
myoblast expansion. The ability of the HS mimetic clusters to inhibit the BACE-1 protease 
has been reported (Tyler et al., 2015), but thus far, the HS mimetic clusters have not been 
widely investigated in further HS-mediated biological processes. Tetrasaccharide end 
capped-HS mimetic clusters have displayed a similar potency in their ability to inhibit BACE-
1, to the most potent longer saccharide sequences (up to dodecasaccharides) of a similar 
structural sequence (Tyler et al., 2015), suggesting that they could be useful therapeutic 
approaches in other HS-mediated signalling events. Since I have shown in the previous 
chapter (Chapter 5) that HS mimetics differentially affect myogenesis, it was hypothesised 
that HS mimetic clusters might also affect myogenesis depending on their structure. Out of 
the six HS mimetic clusters tested, four appeared to have significant effects on myogenesis. 
Notably, dendrimer 6, consisting of the most common disaccharide unit of heparin, had the 
greatest effect on increasing myoblast cell numbers and also led to a reduction in 
differentiation which corresponds to the same phenotype as myoblasts treated with heparin. 
Dendrimer 3 and dendrimer 5, which are made up of the same disaccharide units of HS 
mimetic 5 and HS mimetic 2 respectively, led to comparable phenotypes on myogenesis 
suggesting that the HS mimetic clusters are able to mimic the longer HS mimetic 
equivalents.  
 
A new HS mimetic cluster, Den T, was synthesised, consisting of the most common 
disaccharide unit of heparin, in which the ‘long-armed’ dendritic core was replaced with a 
‘short-armed’ dendritic core (Tyler et al., 2015) to explore the effects of the dendritic core 
size and its affect on myogenesis. Overall, Den T had less of an effect on both myogenic 
differentiation and myoblast numbers compared to dendrimer 6, suggesting that the 
tetrasaccharide-capped ‘long-armed’ tetramer displays a higher level of potency than the 
disaccharide capped ‘short-armed’ equivalent. It has previously been reported that the HS 
mimetic clusters with the ‘long-armed’ dendritic cores displayed higher potencies than HS 
mimetic clusters with the ‘short-armed’ dendritic core in their ability to inhibit BACE-1 (Tyler 
et al., 2015). Our results support these findings that the size of dendritic core is an important 
factor in determining the biological potency of the HS mimetic cluster, since significant 
effects of Den T on myogenesis were only observed at high concentrations (100 µg/ml). At 
this concentration, the level of myoblast differentiation was reduced, cell number was 
unaffected and there were a significantly higher proportion of cells expressing Pax7.  
 
During ageing, the numbers of quiescent satellite cells expressing Pax7 decrease leading to 
reduced regenerative potential (Brack et al., 2005; Dedkov et al., 2003; Gibson and Schultz, 
1983; Shefer et al., 2006). Thus, it is interesting to speculate that a compound, such as Den 
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T, which leads to an increase in reserve-cell generation, might prove useful as a potential 
therapeutic strategy for muscle wasting during ageing. However, the mechanisms by which 
they function remain unknown. From the previous chapter it was shown that HS mimetics 
modulate myogenesis partly by their ability to support or repress FGF2 signalling affecting 
myoblast proliferation and differentiation. In contrast, it has previously been reported that HS 
mimetic clusters do not support FGF signalling by FGF-1 or FGF-2 via the FGF receptor 1 at 
concentrations up to 10 µg/ml (Tyler et al., 2015). Thus, Den T might be inhibiting FGF 
signalling or alternatively be affecting an alternative-signalling pathway other than FGF2 
signalling, which inhibits differentiation. Den T has not been tested for its effects on FGF2 
signalling and thus cannot yet be ruled out as a target. Therefore, future directions may 
involve studying the signalling pathways that are affected by the HS mimetic clusters during 
myogenesis.  
 
Previous investigations into GAG mimetics, known as regenerating agents (RGTAs), as 
therapeutic targets for muscle injury were undertaken; they were developed to ‘re-model’ the 
extracellular satellite-cell niche and provide a matrix for increased growth factor signalling by 
preventing their proteolysis and promoting angiogenesis, allowing for prolonged muscle 
regeneration (Meddahi et al., 2002b; Rouet et al., 2005). Furthermore, they significantly alter 
the GAG species produced during myogenesis of C2C12 myoblasts (Barbosa et al., 2005), 
suggesting there may be further indirect effects on HS-mediated signalling events. Although 
this has not been explicitly investigated here, it may represent an additional mechanism 
behind the effects observed with dendrimer treatments. However, in an ageing environment, 
increased growth factor signalling may lead to an increase in the number of satellite cells 
breaking quiescence, accelerating satellite-cell depletion and thus reducing their 
regenerative potential further. Moreover, increasing the level of multiple heparin-binding 
growth factor signalling events might lead to many off-target effects. Thus, the HS mimetic 
clusters may present themselves as potential new therapeutic agents with fewer off-target 
effects, since have been found not to support FGF2 signalling, and they do not exhibit 
anticoagulant activity. An additional benefit to the HS mimetic clusters is that their synthesis 
is greatly simplified compared to longer oligosaccharide syntheses. Thus many different 
structures can be synthesised from the same starting materials allowing for easy 
optimisation of highly defined and controllable structures. 
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Chapter 7 
 
7 General Discussion 
 
Heparan sulfate is a dynamic, structurally complex biomolecule that regulates multiple 
biological processes due to its ability to bind numerous proteins and facilitate many growth 
factor signalling pathways (Turnbull et al., 2001). Heparan sulfate proteoglycans constitute a 
key component of the satellite cell niche (Brandan and Gutierrez, 2013; Cornelison et al., 
2001; Cornelison et al., 2004; Pisconti et al., 2010). In skeletal muscle, interactions between 
the satellite cell and the extracellular environment are a critical factor for determining satellite 
cell fate (Barberi et al., 2013; Conboy and Rando, 2002; Le Grand et al., 2009; Shea et al., 
2010; Urciuolo et al., 2013). Satellite cell dysregulation and depletion during ageing is largely 
attributed to the alterations in the extracellular environment, including changes in growth 
factor signalling (Chakkalakal et al., 2012; Yousef et al., 2015). However, the role of the HS 
structural component of the satellite cell niche during myogenesis in the absence of injury or 
during ageing in muscle has been largely unexplored. In this study, we aimed to advance our 
understanding of the HS structural component of the satellite cell niche and its role in 
regulating myogenesis.  
 
We have found that the structure of HS changes during myogenic differentiation and during 
ageing in skeletal muscle, and these changes are associated with altered FGF2 signalling. 
Others have also reported more recently, that the structure of HS is altered during muscle 
regeneration and is associated with altered growth factor signalling (Chevalier et al., 2015), 
further supporting our findings that the structure of HS is a critical signalling component of 
the satellite cell niche in the regulation of myogenesis. This study demonstrates that there is 
an overall increase in the level of HS sulfation during myoblast differentiation, which fails to 
promote FGF2-induced mitogenic activity. One explanation for this could be that the more 
highly sulfated HS sequesters FGF2 away from the cell surface FGF receptor. A further 
explanation is that the increased sulfation is present in patterns not compatible with 
promoting FGF2 signalling. Since FGF2 signalling is a potent inhibitor of myoblast 
differentiation, it is possible to speculate that the more highly sulfated HS from differentiating 
myoblasts indirectly permits myogenic differentiation by preventing FGF2 signalling (Figure 
7.1). In contrast, HS from proliferating myoblasts is associated with an increase in HS-
dependent FGF2 induced mitogenic activity, suggesting that the HS supports formation of 
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the quaternary FGF2-FGFR-HS complex, and thus supports myogenic proliferation whilst 
inhibiting myogenic differentiation (Figure 7.1).  
 
Figure 7.1 Structural Changes in HS During Myoblast Differentiation. a) HS extracted from 
proliferating myoblasts in culture promotes FGF2-induced mitogenic activity thus inhibiting 
myoblast differentiation b) Serum reduction leads to induction of myoblast differentiation. HS 
extracted from differentiated myoblast cultures shows a higher level of sulfation, which does not 
promote FGF2 signalling, thus supporting myoblast differentiation, likely via a number of potential 
mechanisms. 
 
Interestingly, the HS present in uninjured ageing muscle is associated with an increase in 
FGF2 induced mitogenic activity compared to the HS from younger muscle, yet the level of 
HS sulfation in muscle during ageing does not change. Instead, in ageing muscle, there is an 
overall increase in the level of HS 6-O-sulfation compared to the HS from younger muscle. It 
is established that HS 6-O-sulfation is important for supporting FGF2 signalling (Pye et al., 
1998). This study suggests that HS with higher levels of 6-O-sulfation from the ageing 
muscle promotes FGF2-induced mitogenic activity more than HS from younger muscle, 
which partly inhibits FGF2-induced mitogenic activity. A reduction in C2C12 myoblast HS 6-
O-sulfation was also associated with reduced levels of myoblast proliferation further 
supporting our findings that an increase in 6-O-sulfation leads to increased levels of satellite 
cell proliferation. Thus, we speculate that the HS from young muscle, with lower levels of 6-
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O-sulfation, is a contributory factor to maintaining satellite cells in a non-proliferative state 
and thus conserving the quiescent satellite cell pool available for muscle growth and 
regeneration (Figure 7.2). Our findings also support those that demonstrate that 6-O-
sulfation is an important regulator of FGF2 signalling in many biological processes (Ferreras 
et al., 2012; Higginson et al., 2012; Huynh et al., 2012a; Lamanna et al., 2008; Seffouh et 
al., 2013; Sugaya et al., 2008).  
 
A notable result obtained in this study is that FGF2 signalling can be similarly affected with 
distinct structural changes in HS. This supports the case that there is some structural 
redundancy in the ability of HS to support a specific type of growth factor interaction (Catlow 
et al., 2003; Guimond et al., 2009b; Rudd et al., 2010). In this example, our data indicate that 
there is more than one type of structural modification of HS that affects HS-dependent FGF2 
signalling. Structural redundancies in HS likely permit combinations of a wider range of HS-
interactions adding to its structural complexity and functional possibilities. This may be of 
significance in the regulation of muscle stem cell homeostasis where a number of other 
heparin-binding growth factor signalling pathways are involved (Gill et al., 2010; Sheehan 
and Allen, 1999; Shefer and Benayahu, 2012), and thus the difference in HS structural 
composition is likely a reflection of the different functional requirements of HS. In the first 
instance described, the HS analysed was extracted from a largely pure population of 
myoblasts, whereas in the second instance, the HS analysed was extracted from whole 
muscle, which is made up of multiple cell types. The number of muscle-resident fibroblasts 
significantly increase during ageing (Brack et al., 2007). Since the structure of HS is cell-type 
specific, it is possible that an increase in the number of resident fibroblasts leads to an 
altered structure of HS present in the whole muscle. However, the increase in HS 6-O-
sulfation is already apparent in muscles of 1 year-old mice and is comparable to the HS from 
muscles of 2 year-old mice, yet there are significantly more fibroblasts (Brack et al., 2005). 
This suggests that the structure of HS is altered in myoblasts during ageing, since there is 
an increase in HS 6-O-sulfation when there is not considerable fibrosis (Brack et al., 2005). It 
has recently been demonstrated that myogenic progenitor cells (activated satellite cells) 
present in the extracellular matrix surrounding myofibres, inhibit ECM deposition by 
fibrogenic cells (Fry et al., 2017). Thus, it is possible that an altered HS structure in ageing 
myoblasts might also play a role in their interaction with interstitial fibrogenic cells and ECM 
production. It has previously been reported that high levels of HS 6-O-sulfation are present 
in idiopathic pulmonary fibrosis, which is associated with high levels of fibrosis in the lungs 
(Lu et al., 2014). Silencing of HS6ST1 in primary lung fibroblasts in vitro leads to a decrease 
in ECM deposition in response to TGF-β stimulation (Lu et al., 2014). TGF-β is well known to 
promote muscle fibrosis (Border and Noble, 1994; Li et al., 2004) and thus the increase in 6-
O-sulfation in the muscle of aged mice might also contribute to the increase in muscle 
fibrosis ECM deposition that is associated with ageing muscle. However, further studies 
would be required to investigate the precise cell type origin of the structural changes of HS 
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during ageing in skeletal muscle and the effects on neighbouring cells present in the satellite 
cell niche.  
 
 
 
Figure 7.2 The effects of an increase in 6-O-sulfation on myogenesis during ageing. 
Schematic representing the potential effects of an increase in muscle HS 6-O-sulfation during 
ageing; a) the increase in HS 6-O-sulfation in ageing muscle leads to an increase in FGF2 
myoblast proliferation which in turn might contribute to the reduction in SC self-renewal in ageing 
muscle b) an increase in 6-O-sulfation has also been related to increased levels of fibrosis (Lu et 
al., 2014) and thus may play a part in skeletal muscle leading to increased ECM deposition by 
fibrogenic cells (purple cells in Fig 7.2) 
 
 
Furthermore, we have shown that different structures of both chemically modified heparin 
HS mimetics and fully synthetic HS mimetic clusters are capable of modulating myogenesis. 
We have demonstrated that modified heparin HS mimetics differentially affect myogenesis in 
part by differences in their abilities to support FGF2 signalling. Specifically, an increase in 
the level of sulfation using HS mimetic 1 (oversulfated heparin) treatment is associated with 
reduced FGF2 induced myoblast proliferation associated with inhibition of Erk1/2 activation. 
This is consistent with our previous observation that the more highly sulfated HS from 
differentiating myoblasts exhibits reduced FGF2 signalling inhibiting myogenic differentiation 
whilst permitting proliferation. Since it has previously been reported that oversulfated heparin 
binds FGF2 (Uniewicz et al., 2010), we propose that HS mimetic 1 prevents endogenous 
HS-dependent FGF2 signalling by binding to FGF2 and sequestering it away from the cell 
surface FGF receptor (Figure 7.3). HS mimetic 2 (with reduced sulfation; 2S, 6S and NS) 
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treatment, on the other hand, is associated with increased FGF2 induced myoblast 
proliferation associated with sustained Erk1/2 activation (Figure 7.3). Thus we propose that 
HS mimetic 2 supports the formation of the FGF2-FGFR1 quaternary complex, and thus 
exceeds the amount of endogenous HS-dependent FGF2 signalling. In contrast, the HS 
mimetic clusters do not support FGF2 signalling; yet can differentially effect myoblast 
differentiation, expansion and the number of Pax7+ undifferentiated cells (bona fide reserve 
cells) (Figure 7.3). This suggests that the HS mimetic clusters affect myogenesis via 
alternative signalling pathways, which provides avenues for future experiments.  
 
A problem for many cell therapies involving myoblast transplantation to promoted muscle 
repair, is that the majority proliferate whilst a small sub-population of cells divide slowly, 
which contribute more extensively to muscle repair (Beauchamp et al., 1999; Ono et al., 
2012). Thus, it is interesting to consider the use of HS mimetic clusters in cell-based 
therapies for myoblast transplantations. A compound that inhibits differentiation whilst not 
greatly affecting proliferative capacity could be highly beneficial for maintaining satellite cells 
in a resting state prior to transplantation (Briggs and Morgan, 2013). Overall, HS mimetic 
clusters are synthetically accessible and a wide range of structures can be synthesised from 
the same starting materials. They can be produced at a high level of purity and display no 
anticoagulant activity. HS mimetic clusters are thus potential candidates in clinical 
applications because of their ability to mimic longer chains of HS whilst potentially presenting 
fewer off-target effects.  
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Figure 7.3 Summary of effects of HS mimetics on myogenesis. Schematic summarising the 
effects of HS mimetics on myogenesis. a) N-acetylated heparin, (HS mimetic 2), leads to 
prolonged FGF2 induced Erk1/2 activation and increased proliferation b) oversulfated heparin 
(HS mimetic 1) represses FGF2 induced Erk1/2 activation and decreased proliferation and c) a 
newly synthesised tetramer cluster, Den T, leads to a reduction in myoblast differentiation at high 
concentrations although the mechanisms by which it acts, remain unknown.  
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7.1 Future Directions 
 
Overall this study provides a bridge between the satellite cell field and the HS field by 
highlighting the importance of the structure of the HS component in satellite cell regulation 
and in muscle during ageing. This study has also provided an indication of potential novel 
therapeutic strategies for muscle ageing and further implicates HS clusters as easily 
accessible, synthetic HS mimetics. However, this project has also opened up avenues for 
further research questions such as: what regulates the structural changes of HS during 
ageing in muscle? What other signalling pathways are affected by the change in HS during 
myogenesis and in ageing? Can the ageing muscle phenotype be rescued with HS from 
young muscle or HS mimetics? 
 
Understanding how and why the structure of HS is regulated remains a significant challenge 
in the HS field. In this project, we investigated the transcript expression levels of the HS 
biosynthetic and remodelling enzymes in an attempt to elucidate the origin of the structural 
changes in HS observed during ageing. However, the increase in HS 6-O-sulfation in ageing 
muscle did not correspond to the expression levels of the 6-O-sulfation modifying enzymes. 
Therefore, further experiments to evaluate their protein levels and to better understand the 
activity of HS biosynthesis enzymes, and their regulation, is required. Moreover, future 
experiments might involve investigating the effects of increased FGF2 signalling on the 
structure of HS in skeletal muscle. Transgenic mice either overexpressing or with conditional 
knockouts of the HS biosynthetic enzymes might provide further information into the effects 
of specific HS structural modifications on muscle during ageing.  
 
Considering the structural impact of HS sulfation, it has previously been demonstrated that 
an increase in 6-O-sulfation has the least dramatic effect on the structural conformation of 
HS chains. Thus it is interesting that we and others have found that changes in the level of 
6-O-sulfation have a significant biological outcome, suggesting that direct interactions of 6-
O-sulfate groups with protein targets may be crucial. Therefore, future experiments may be 
designed to better understand the structural importance of HS 6-O-modifications on its 
functional activity. Moreover, further investigations would be required to unravel other HS-
dependent signalling pathways that might be affected by the change in structure of HS 
during ageing. For example, investigating the effects of 6-O-sulfation on TGF- β signalling in 
fibrosis in muscle would be important. 
 
Since previous findings have demonstrated that the ageing muscle phenotype can be 
rescued by engrafting old muscle in a young muscle environment (Carlson and Faulkner, 
1989), it is interesting to speculate that HS from young muscle might improve the phenotype 
in ageing muscle. Thus, future experiments could involve in vivo assays treating young mice 
with HS from old muscle and vice versa. In this way we could better elucidate the effects of 
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the structural changes of HS during ageing on the skeletal muscle phenotype. In vitro assays 
could further investigate this by culturing myoblasts lacking endogenous HS in the presence 
of HS from young and aged muscle. To further investigate the effects of the increase in HS 
6-O-sulfation during ageing in muscle, reserve-cell generation assays could be employed to 
explore the effects of structural changes of HS observed during ageing in muscle on satellite 
cell self-renewal. Finally, to validate the hypothesis that a compound that leads to an 
increase in the level of reserve-cell generation could improve the muscle phenotype during 
ageing, Den T could be used in vivo on ageing mice.  
 
7.2 Concluding Remarks 
 
The studies in this thesis have demonstrated that: 
•  myogenic differentiation is associated with an increase in the level of HS sulfation in 
primary myoblasts isolated from young muscles and in the C2C12 myoblast cell line  
• there is a specific increase in HS 6-O-sulfation in skeletal muscle during ageing and 
that this might be a significant contributory factor to satellite cell depletion during 
ageing  
• the HS component of the satellite cell niche is able to modulate myogenesis partly 
through its ability to support HS-dependent FGF2 signalling. 
• successful synthesis of a new HS mimetic cluster, Den T, which may have 
application as a novel therapeutic agent to enhance satellite cell self-renewal 
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Appendix 
 
Appendix 1: RT PCR For SiRNA Knockdown 
 
Appendix 1 Extent of knockdown  Transfection of siRNA against HS6ST1, HS6ST2 and 
HS6ST3 results in knock-down of HS6ST expression by approximately 75%. C2C12 cells were 
transfected with either 60 nM universal control siRNA or with a combined treatment of 20 nM of 
siRNA directed to each one of the three HS6STs (HS6ST1, HS6ST2 and HS6ST3). GAPDH was 
used as a house-keeping gene and the mRNA levels of the three HS6STs and of GAPDH measured 
by qPCR in both transfection conditions. The ΔΔCt method was used to quantify and normalise the 
results which are expressed as percentage of each HS6ST/GAPDH mRNA in the 3xHS6ST siRNA-
transfected cells over the amount of each HS6ST/GAPDH mRNA in the cells transfected with control 
siRNA. One representative of two independent experiments is shown where the results from two 
technical replicates are averaged and plotted ± standard deviation (Ghadiali et al., 2016). 
 
Appendix 2: Effects of HS mimetics on proliferation in high serum conditions  
 
 
 
 
 
 
 
 
 
 
 
Appendix 2: Effects of HS mimetics on myoblast proliferation in high serum conditions. HS 
mimetics differentially effect myoblast cell number. Primary SC-derived myoblasts were cultured 
for 2 days in growth medium and then treated with the HS mimetics snd grown for a further 24 hours 
followed by a BrdU proliferation assay. For each condition shown, the proortion of BrdU+ nuclei was 
measured and the average of ten images across two technical replicates for three independent 
experiments ± S.E.M. plotted.  
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A 2.1 General Chemistry Methods 
Air sensitive reactions were performed under argon. Organic solutions were dried over 
anhydrous MgSO4 and the solvents were evaporated under reduced pressure. Anhydrous and 
chromatography solvents were obtained commercially and used without any further purification.  
 
A 2.1.2 NMR Spectroscopy 
Proton magnetic resonance spectra were recorded on 500 MHz spectrometers at ambient 
temperatures. Chemical shifts (δH) are reported in parts per million (ppm) and are referenced to 
the residual solvent peak (Gottlieb et al., 1997). 1H NMR spectra were measured in CDCl3, 
CD3OD or D2O (HOD, δ 4.79). Carbon magnetic resonance spectra were recorded on 500 MHz 
spectrometers at ambient temperatures. Chemical shits (δC) are reported in parts per million 
(ppm) and are referenced to the residual solvent peak. 13C NMR spectra in CDCl3 (centre line, δ 
77.0), CD3OD (centre line, δ 49.0), D2O (no internal reference, δ1.47 where stated). 
Assignments of 1H and 13C resonances were based on 2D (1H-1H COSY, 1H-13C HSQC) 
experiments. Coupling constants (J) are recorded to the nearest 0.5Hz. Multiplicities are 
abbreviated as s (singlet), d (doublet), t (triplet) or m (multiplet).  
 
A 2.1.3 Analytical Thin Layer Chromatograph (TLC) 
Thin layer chromatography was performed on aluminium sheets coated with 60 F254 silica gel. 
Organic compounds were visualized under UV light or use of a dip of ammonium molybdate (5 
wt%) and cerium(IV) sulfate 4 H2O (0.2 wt%) in aq. H2SO4 (2M), or 0.1% ninhydrin in ethanol. 
 
A 2.1.4 Column Chromatography  
Chromatography (flash column, or an automated system with continuous gradient facility) was 
performed on silica gel (40-63 µm). The crude material was applied to the column by pre-
adsorption onto silica, as appropriate.  
 
A 2.1.4 Mass Spectrometry 
High resolution electrospray mass spectra (ESIHRMS) were recorded on a Q-TOF Tandem 
Mass Spectrometer.  
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A 2.2 Chemical Procedures and Compound Characterisations 
 
A 2.2.1 De-chloroacetylation  
Synthesis of Compound 13 
 
 
 
 
 
 
Compound 13 was prepared from dimer 12:  DABCO (6 equiv. per chloroacetyl group) was 
added to the starting material in dry ethanol/acetonitrile, 5:1 (5 mL for 40 µmol) at room 
temperature. The mixture was heated at 60-70 ⁰C under argon for 2hoursAfter TLC (ethyl 
acetate:petroleum ether, 1:1) indicated the completion of the reaction the reaction was diluted 
with ethyl acetate and washed with 1M aq. HCL and extracted. The organic layer was washed 
with sodium hydrogen carbonate, extracted and then washed with brine and dried over MgSO4. 
Concentrated in vacuo. Hivac o/n. To ensure the N-Fmoc group had not been removed, the 
crude reaction mixture was dissolved in methanol and triethylamine (1.1 equiv.) was added 
followed by FmocCl (1 equiv) at 0 ⁰C. The reaction mixture was stirred for 2 hours at RT until 
completion. The reaction was diluted with chloroform, washed with 1M aq HCL, sodium 
hydrogen carbonate, extracted. The organic layer was then washed with brine and dried over 
MgSO4. Concentrated in vacuo. Chromatography (ethyl acetate:petroleum ether, 1:1) afforded 
product 13 with an unblocked primary hydroxyl group (13, 0.95g, 0.44mmol, 78% yield). TLC 
(ethyl acetate: petroleum ether, 1:9 → 1:1) Rf = 0.52. 1H NMR (500 MHz, CDCl3) δ 8.16-8.13 
(m, 2H, Ar H), 7.77-7.74 (m, 2H, Ar H), 7.42-7.24 (m, 22H, Ar H), 7.17-7.14 (m, 2H, Ar H), 5.15 
(bs, 1H, iH2), 4.98 (s, 1H, iH1), 4.92 (d, J = 11.7 Hz, 1H, Bn-CH), 4.78-4.71 (m, 2H, Bn-CH), 
4.64 (d, J = 1H,) gH1), 4.51 (d, J = 10.9 Hz, 1H, Bn-CH ), 4.43-4.36 (m, 3H, CHFmoc + Bn-CH), 
4.32-4.26 (m, 2H, iH5 + gH6), 4.24-4.19 (m, 1H, CHFmoc), 4.16-4.08 (m, gH6), 4.00-3.95 (m, 
1H, gH5), 3.92-3.87 (m, 1H, CH2), 3.80-3,71 (m, 3H, iH4) 3.68 – 3.63 (m, 1H, gH3),  3.50-3.45 
(m, 1H, linker), 3.38 – 3.32 (m, 1H, gH4), 3.29 (dd, J = 10.2, 3.7 Hz, 1H, gH2), 3.17-3.11 (m, 
1H, linker), 2.02 (s, 3H, OAc), 1.67-1.59 (m, 1H), 1.47-1.22 (11 H). 13C NMR: (126 MHz, CDCl3) 
δ 13C NMR (126 MHz, CDCl3) δ 133.15, 129.81, 128.55, 128.40, 128.27, 128.00, 127.64, 
127.03, 125.02, 98.59 (gC1), 98.43 (iC1), 80.78 (gC3), 77.93 (gC4), 75.10 (iC4), 72.68 (iC3), 
72.15, 70.29 (gC5), 68.87 (iC2), 67.88, 67.25 (iC4), 63.86 (gC2), 63.07, 61.78, 47.35 (Fmoc). 
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A 2.2.2 TEMPO/BAIB Oxidation and Esterification with TMS-diazomethane 
 
Synthesis of Compound 15 
 
 
 
 
 
 
 
 
 
 
 
 
A solution of 13 in acetonitrile (5 mL for 32 µmol) and water (0.9 mL) was treated with TEMPO 
(0.2 equiv.) and BAIB (2.5 equiv. per hydroxyl group) at room temperature for 4-24 hours. After 
TLC (ethyl acetate: petroleum ether, 3:2) indicated the completion of the reaction chloroform 
and water were added. The solution was acidified with diluted HCl, back-extracted with 
chloroform, dried and concentrated. Residue 14, was dissolved in diethyl ether/methanol (3:2) 
and a 2M solution of TMS-diazomethane in hexane (1.5 eq per carboxylate) was added drop-
wise at 0 °C. After completion TLC (toluene : ethyl acetate, 3:2), 0.5 mL acetic acid was added 
to quench the reaction. Solvents were evaporated in vacuo and the residues were purified by 
silica gel chromatography (ethyl acetate : petroleum ether, 1:9 → 2:3) gradient to furnish the 
ester 15 (15, 0.64g, 0.56mmol, 65.8%). TLC (ethyl acetate: petroleum ether, 1:1). Rf = 0.7. 1H 
NMR (500 MHz, CDCl3) δ 8.11 (d, J = 7.2 Hz, 2H, Ar H), 7.76 (d, J = 7.5 Hz, 2H, Ar H), 7.59 (d, 
J = 7.5 Hz, 2H, Ar H), 7.42 – 7.22 (m, 20H, Ar H), 7.16 – 7.12 (m, 2H, Ar H), 5.29 (s, 1H), 5.17 
(s, 1H, iH1), 5.15 (bs, iH2), 4.93 (d, J = 11.5 Hz, 1H, Bn-CH), 4.84 (d, J = 2.2 Hz, 1H, iH5), 4.80 
(d, J = 3.4 Hz, 1H, gH1), 4.76-4.71 (m, 2H, Bn-CH2), 4.54 (d, J = 10.9, 1H, Bn-CH), 4.41-4.38 
(m, 2H, CHFmoc + gH6), (dd, J = 3.2 Hz, 9.1, 1H, gH6), 4.21 (t, J = 6.7 Hz, 1H, CHFmoc), 4.17-
4.15 (m, 2H, iH3 + Bn-CH), 4.10 (m, 1H, iH4), 4.05 (d, J = 10.6 Hz, 1H, Bn-CH), 4.01 (d, J = 
10.0 Hz, 1H, gH5), 3.80 (s, 4H, OMe, linker), 3.57 (dd, J = 18.1, 8.1 Hz, 1H, gH3), 3.55-3.50 (m, 
1H, linker), 3.46 (t, J = 9.1, gH4), 3.20 (dd, J = 3.42, 10.22, 1H, gH2), 3.14-3.12 (m, 2H, linker), 
2.01 (s, 3H, OAc), 1.62-1.58 (m, 2H), 1.46-1.26 (m 10 H). 13C NMR: (126 MHz, CDCl3) δ 
165.58, 156.43, 144.09, 141.37, 137.86, 137.72, 133.27, 130.00, 129.71, 129.06, 128.76, 
128.46, 128.41, 128.35, 128.25, 128.00, 127.91, 127.87, 127.82, 127.68, 127.05, 125.33, 
125.06 (Bn), 119.98 (Bn), 99.57 (gC1), 99.20 (iC1), 80.16 (gC3), 77.47 (gC4), 77.42, 77.16, 
76.91, 76.08 (iC4), 74.91 (Bn-C), 74.76 (Bn-C), 73.45 (iC3), 72.35 (Bn-C), 70.18 (gC5), 68.71, 
68.06 (iC2), 67.47 (iC5), 66.47 (CHFmoc), 63.81 (gC2), 62.41 (gC6), 52.38 (OMe), 47.39, 
40.98, 29.86, 29.72, 29.30, 26.47, 25.83, 21.47, 20.84 (OAc). MS (ESI, positive mode) 
calculated for [C64H68N4O15]+Na m/z 1132.47, found 1132.52. 
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A 2.2.3 Removal of N-Fmoc 
 
 
 
 
 
 
 
Fmoc protected 15 (638 mg, 0.563mmol) was dissolved in dry DMF (15 mL). Piperidine (5 mL) 
was added and stirred at RT for 1.5 hours. The solvents were removed in vacuo and the residue 
was purified by chromatography (ethyl acetate : methanol: aq. ammonia, 4:1:0.05) to furnish 16 
(16, 0.41g, 0.452mmol, 80%). TLC (ethyl acetate : ethanol : water, 3:1:1) Rf = 0.23. 1H NMR 
(500 MHz, CDCl3) δ 8.10 (d, J = 7.2 Hz, 2H, Ar H), 7.39- 7.24 (m, 16, Ar H), 7.14 (d, J = 6.3 Hz, 
2H, Ar H), 5.17 (s, 1H, iH1), 5.12 (s, 1H, iH2), 4.91 (d, J = 11.5 Hz, 1H, Bn-CH), 4.82 (d, J = 2.1 
Hz, 1H, iH5), 4.79 (d, J = 3.5 Hz, 1H, gH1), 4.76 – 4.70 (m, 2H, Bn-CH2), 4.53 (d, J = 10.9 Hz, 
1H, Bn-CH), 4.43-4.38 (m, 1H, gH6), 4.25 (dd, J = 12.3, 3.1 Hz, 1H, gH6), 4.18 – 3.97 (m, 5H, 
Bn-CH2, iH3, iH4, gH5), 3.79-3.75 (m, 4H, linker, O2CH3), 3.59-3.44 (m, 4H, linker, gH3, gH4), 
3.19 (dd, J = 10.2, 3.5 Hz, 1H, gH2), 2.94 – 2.88 (m, 1H, linker). 13C NMR: (126 MHz, CDCl3) δ 
167.95, 167.27, 167.16, 162.98, 135.18, 130.66, 127.42, 127.15, 126.17, 125.87, 125.82, 
125.76, 125.41, 125.31, 125.24, 97.02 (gC1), 96.63 (iC1), 77.58 (gC3), 74.90 (gC4), 74.81 
(iC4), 74.55 (Bn-C), 74.30 (Bn-C), 73.58 (iC3), 72.31 (Bn-C), 72.15, 70.84 (gC5), 69.72 (linker), 
67.59 (iC2), 66.20 (iC5), 65.40 (gC2), 64.81 (gC6),  61.25, 59.82, 50.88 (OMe), 49.77, 48.89, 
39.49 (linker), 30.89, 28.22, 26.84, 24.83, 24.07, 23.41, 18.26 (OAc). 
 
 
A 2.2.4 Coupling with tetra-N-hydroxysuccinimide activated ester 
 
Synthesis of Compound 17 
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A solution of tetra-N-hydroxysuccinimide activated ester 13 (1 eq) in dry DMF (40 mg per 1 mL 
of DMF) was added to the solution of glycoside 16  (4-6 eq.) in dry DMF (100 mg per 1 mL of 
DMF) at room temperature. The reaction mixture was treated with triethylamine (8 eq) and 
stirred at RT for 24 hrs. DMF was removed in vacuo and the residue was purified by flash 
chromatography on silica gel eluting with ethyl acetate followed by ethyl acetate: methanol, 
9:1→3:2 to give tetramer 17 (17, 0.4mg, 0.10mmol, 81.4%). TLC (ethyl acetate : methanol, 9:1). 
Rf = 0.52. 1H NMR (500 MHz, CDCl3) δ 8.11-8.09 (m, 8H, Ar H), 7.39-7.23 (m, 64 H, Ar H), 
7.15-7.13 (m, 8H, Ar H), 5.16 (s, 4H, iH1), 5.13 (s, 4H, iH2), 4.91 (d, J = 11.6 Hz, 4H, Bn-CH), 
4.83 (d, J = 2.2 Hz, 4H, iH5), 4.78 (d, J = 3.5 Hz, 4H, gH1), 4.76 – 4.70 (m, 8H, Bn-CH), 4.53 (d, 
J = 10.9 Hz, 4H, Bn-CH), 4.39 (dd, J = 12.3, 1.9 Hz, 4H, gH6), 4.26 (dd, J = 12.3, 3.1 Hz, 4H, 
gH6), 4.17 – 4.03 (m, 20H, iH4, iH3, Bn-CH, core), 4.02-3.98 (m, 4H, gH5) 3.81 – 3.74 (m, 16H, 
OMe, linker), 3.63- 3.55 (m, 12 H, gH3, linker, core), 3.52-3.45 (m, 8H, gH4 + linker), 3.28 (s, 
4H), 3.21-3.16 (m, 12 H, gH2 + linker), 2.04 (s, 4H), 2.01 (s, 12 H, OAc), 1.61-1.59 (m, 10 H), 
1.46-1.41 (m, 9 H), 1.33-1.24 (m, 48 H). 13C NMR (126 MHz, CDCl3) δ 171.25, 170.53, 169.71, 
165.55, 137.68, 133.25, 129.96, 128.73, 128.43, 128.38, 128.33, 127.97, 127.88, 127.80, 99.56 
(gC1), 99.15 (iC1), 80.13 (gC3), 77.42 (gC4), 76.08 (iC4), 74.87 (Bn-C), 74.73 (Bn-C), 73.36 
(iC3), 72.31 (Bn-C), 70.13 (gC5), 69.04 (core), 68.72 (linker), 68.03 (iC2), 67.40 (iC5), 63.78 
(gC2), 62.36 (gC6), 60.38 (core), 52.35 (OMe), 39.49 (linker), 39.42, 36.86, 29.70, 29.63, 29.34, 
26.78, 25.82, 20.82 (OAc). MS (ESI, positive mode) calculated for [C213H252N16O60]+3H m/z 
3996.72, found 3996.8. 
 
A 2.2.5 Selective De-O-acetylation  
Synthesis of Compound 18 
 
 
 
 
 
Starting material was dissolved in dry dichloromethane (2 mL for 9 µmol) at 0 °C and treated 
with a solution of cold dry methanol (4 mL) containing 80 µL of acetyl chloride. The reaction 
mixture was stirred for 30 min at 0° and then at RT for 24 hours. After TLC (ethyl acetate) 
indicated completion of the reaction dichloromethane was added and the solution was washed 
with water and sodium hydrogen carbonate solution (sat., aq.), dried and concentrated. The 
residue was purified by silica gel chromatography (ethyl acetate : methanol, 9:1) to give fully de-
O-acetylated product  18 (18, 0.23 g, 0.05 mmol, 59.2 % yield). TLC (DCM : methanol : aq 
ammonia, 7:2:0.25) Rf = 0.85. 1H NMR (500 MHz, CDCl3) δ 8.10-8.09 (m, 8H, Ar H), 7.39-7.23 
(m, 64 H, Ar H), 7.15 – 7.11 (m, 8H, Ar H), 5.17 (s, 4H, iH1), 5.12 (s, 4H, iH2), 4.91 (d, J = 
10.0Hz, 4H, Bn-CH), 4.84 (d, J = 2.0 Hz, 4H, iH5), 4.79 (d, J = 3.5 Hz, 1H, gH1), 4.75-4.72 (m, 
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8H, Bn-CH), 4.61 (d, J = 11.0 Hz, 4H, Bn-CH), 4.21 (d, J = 10.8 Hz, 4H, Bn-CH), 4.14-4.09 (m, 
12H, iH3, iH4), 4.06 (d, J = 10.8 Hz, 4H, Bn-CH), 3.94-3.91 (m, 4H, gH5), 3.86 (d, J = 12.0 Hz, 
4H, gH6), 3.80 (s, OMe), 3.78 – 3.75 (m, 4H, linker), 3.71 – 3.66 (m, 4H, gH6), 3.63-3.61 (m, 
8H, core), 3.59 – 3.54 (m, 4H, gH3), 3.53-3.48 (m, 4H, linker), 3.44-3.40 (m, 4H, gH4), 3.20-
3.14 (m, 12H, linker, gH2), 2.04 (s, 7H), 1.64-1.57 (m, 8H), 1.47-1.41 (m, 8H), 1.34-1.24 (m, 
32H). 13C NMR (126 MHz, CDCl3) δ 171.32, 170.08, 165.57, 138.01, 137.79, 137.67, 133.24, 
129.93, 129.62, 128.74, 128.43, 128.33, 127.94, 127.85, 127.74, 99.42 (gC1), 99.25 (iC1), 
79.84 (gC3), 77.86 (gC4), 75.77 (iC4), 74.99 (Bn-C), 74.74 (Bn-C), 73.61(iC3), 72.95 (gC5), 
72.39 (Bn-C), 69.05 (core), 68.72 (linker), 68.26 (iC2), 67.40 (iC5), 63.69 (gC2), 61.62 (gC6), 
60.37, 52.37 (OMe), 39.49 (linker), 36.84, 29.58, 29.31, 26.74, 25.80, 21.01, 14.19. 
 
 
A 2.2.6 General Sulfation Procedure 
Sulfur trioxide trimethylamine complex (5 equivalents. per hydroxyl group) was added to the 
starting materials in dry DMF (3 mL for 50 mg). The mixture was heated at 50-60 ºC under 
argon for 48-72 hours. Methanol (1 mL) was added and the mixture stirred for 15 minutes and 
concentrated in vacuo. Chromatography (DCM : methanol : aq. ammonia, 7:2:0.5) afforded O-
sulfated products. 
 
 
A 2.2.7 Synthesis of Compound 19 
  
 
 
Compound 19 was synthesised from starting material 18 following the general sulfation 
procedure. Chromatography (DCM: methanol: aq. ammonia, 7:2:0.5) afforded the singly O-
sulfated product 19 (19, 120mg, 0.025 mmol, 83.2 % yield). TLC (DCM : methanol : aq 
ammonia, 7:2:0.25) Rf = 0.69. 1H NMR (500 MHz, MeOD) δ 8.05 (d, J = 7.3 Hz, 8H, Ar H), 7.39-
7.20 (m, 64 H, Ar H), 7.11-7.10 (m, 8H, Ar H), 5.13 (s, 4H, iH1), 5.05 (s, 4H, iH2), 4.87-4.82 (m, 
16H, gH1, iH5 , Bn-CH), 4.63 (d, J = 10.3 Hz, 4H, Bn-CH), 4.38 (dd, J = 10.8, 2.2 Hz, 4H, gH6), 
4.30 (d, J = 9.6 Hz, 4H, gH6), 4.22-4.10 (m, 12, BnCH2, iH3, iH4), 4.02-3,91 (m, 8H, gH5 + Ar 
H), 3.82 (s, 12 H, OMe), 3.76-3.72 (m, 4H, linker), 3.74 (H2O), 3.62-3.49 (m, 20 H, gH4, gH3, 
linker, core), 3.32-3.30 (m, 12 H, core), 3.21 (dd, J = 10.2, 3.4 Hz, 4H, gH2), 3.13-3.10 (m, 8H, 
linker), 1.59-1.27 (m, 38 H). 13C NMR (126 MHz, MeOD) δ 172.42, 170.17, 165.48, 138.37, 
138.09, 137.80, 133.14, 129.62, 128.69, 128.14, 128.06, 128.01, 127.88, 127.76, 127.59, 
127.54, 127.22, 127.16, 99.69 (gC1), 99.07 (iC1), 79.75 (gC3), 77.50 (gC4), 75.87 (iC4), 74.63 
(Bn-C), 74.19 (Bn-C), 73.52 (iC3), 71.98 (Bn-C), 70.75 (gC5), 69.31 (core), 68.35 (iC2), 67.36 
(iC5), 65.42 (gC6), 63.56 (gC2), 51.92 (OMe), 39.08 (linker), 36.35, 29.13, 29.08, 26.43, 25.63. 
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A 2.2.8 Saponification  
 
Synthesis of 20 
 
 
 
 
Starting material 19 was dissolved in methanol and water (4/1, v/v, 1.25 mL for 20 mg - 100 mg 
therefore 5ml) containing 2M solution of sodium hydroxyl  (50 L per 1.25 mL of reaction mixture) 
at 0 °C. The reaction mixture was stirred at room temperature for 48-72 hours. After TLC (ethyl 
acetate: ethanol : water, 3:1:1) indicated the completion of the reaction, the volume of the 
solvents was reduced in vacuo. The solution was applied to a column of silica for flash 
chromatography (DCM : methanol : aq. ammonia, 7:2:0.5 → 5:4:1) to furnish the product 20 (20, 
80 mg, 0.02 mmol, 95 % yield). TLC  (DCM : methanol : aq. ammonia, 7:2:0.25) Rf = 0.23. 1H 
NMR (500 MHz, MeOD) δ 7.97 (s, 8H), 7.39-7.26 (m, 52 H), 5.11 (s, 4 H), 4.94 (s, 4 H), 4.75-
4.63 (m, 20 H), 4.31 (bs, 4H), 4.26-4.24 (m, 4 H), 4.19 (bs, 4H), 3.95-3.86 (m, 16 H), 3.74 (bs, 
8H), 3.67-3.58 (m, 20 H), 3.50 (bs, 4H), 3.15-3.12 (m, 12 H), 2.42-2.38 (10 H), 2.01 (s, 8H), 1.94 
(s, 4H), 1.59-1.29 (m, 53H). 13C NMR (126 MHz, MeOD) δ 174.78, 172.61, 171.59, 163.47, 
138.11, 128.02, 127.98, 127.87, 127.48, 127.43, 127.33, 101.38 (gC1), 95.65 (iC1), 80.61 
(gC3), 77.70 (gC4), 74.99 (iC4), 74.61 (Bn-C), 73.54 (Bn-C), 72.81 (iC3), 71.67 (Bn-C), 70.46 
(gC5), 69.24 (core), 68.01 (iC2), 67.35 (iC5), 66.92, 65.69 (gC6), 63.85 (gC2), 60.13, 53.71, 
39.16 (linker), 36.39, 35.56, 30.27, 29.24, 29.09, 26.38, 25.65  
 
A 2.2.9 2nd Sulfation  
 
Synthesis of Compound 21 
 
Compound 21 was synthesised from starting material 20 following the general sulfation 
procedure. Chromatography (DCM: methanol: aq. ammonia, 7:2:0.5) afforded the di-sulfated 
product 21. TLC (ethyl acetate, ethanol: water, 3:1:1) Rf = 0.18. 1H NMR (500 MHz, MeOD) δ 
7.41 – 7.28 (m, 60H), 5.18 (d, J = 3.4 Hz, 4H, gH1), 5.14 (s, 4H, iH1), 4.89 (m, 20 H), 4.66-4.64 
(m, 16 H), 4.48 (bs, 4H), 4.34 (dd, J = 10.7, 2.6 Hz, 4H), 4.25-4.21 (m, 8H), 4.15 (bs, 4H), 3.98 
(d, J = 10.0 Hz, 4H), 3.85-3.81 (m, 4H), 3.61-3.59 (m, 12 H), 3.50-3.45 (m, 8H), 3.35 (s, 3H), 
3.32-3.30 (m, 18H), 3.28 (9H), 3.14-3.11 (m, 8H), 3.02 (s, 1H), 2.88 (304 H), 2.73 (s, 1H), 2.70 
(3H), 2.64 (s, 7H), 2.41-3.37 (m, 10H), 1.66-1.49 (m, 12H), 1.47-1.27 (m, 40 H). 13C NMR (126 
MHz, MeOD) δ 175.64, 173.94, 173.87, 139.83, 139.52, 129.86, 129.48, 129.08, 128.84, 
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100.46 (gC1), 95.80 (iC1), 81.83 (gC3), 79.10 (gC4), 76.17 (iC4), 72.78, 71.80, 71.50, 71.33, 
70.64 (gC5), 69.28, 68.79 (iC2), 68.5, 67.08 (iC5), 65.47 (gC6), 55.24, 52.34, 40.52, 39.76, 
37.80, 30.67, 30.51, 27.93, 27.15.  
 
A 2.2.10 Hydrogenolysis 
 
Synthesis of Compound 22 
 
 
 
 
 
Starting material 21 was dissolved in THF and water (1/1, v/v, 3 mL for 10 mg) containing 
aqueous ammonia solution (10% of reaction mixture) and treated with palladium hydroxide on 
carbon (20% Pd, 5 times the weight of 21). The reaction mixture was stirred for 24-48 hours 
under hydrogen at ambient temperature and pressure. After TLC (ethyl acetate : ethanol : 
water, 2:1:1) indicated the completion of the reaction, the catalyst was filtered off and washed 
with 50% aqueous THF. The solution was concentrated to dryness and chromatography of the 
residue (DCM : methanol : aq. ammonia, 5:4:1) gave the final products as ammonium salts. The 
resulting materials were dissolved in water, passed through a Dowex 50WX8-200 (Na+) resin 
column (8 x 1 cm) and eluted with water. Fractions containing the products were evaporated 
and dried in vacuo to furnish sodium salts of final product 22 (22, 55 mg, 0.0136 mmol, 80.18 % 
yield). TLC (DCM : methanol : aq. ammonia, 7:2:0.25) Rf = 0.1. 1H NMR (500 MHz, D2O) δ 5.48 
(d, J = 3.7 Hz, 4H, gH1), 5.20 (s, 4H, iH5), 4.71 (s, 4H), 4.66 (s, 4H), 4.42-4.39 (m, 10H), 4.32 – 
4.23 (m, 12H), 4.22 (bs, 4H), 4.05-3.99 (m, 8H), 3.99-3.92 (8H), 3.82-3.77 (m, 16H), 3.65-3.6 
(m, 12 H), 3.50 (bs, 2H), 3.46- 3.38 (m, 16H), 3.32 (s, 3H), 3.27-3.20 (m, 54H), 3.15-3.08 (182 
H), 2.93 (bs, 23 H), 2.57-2.48 (m, 16H), 1.79 (solvent), 1.68 (solvent), 1.61 – 1.52 (m, 22 H), 
1.48 – 1.3 (m, 40H). 13C NMR (126 MHz, D2O) 175.18, 174.01, 97.99 (gC1), 92.20 (iC1), 72.84, 
70.78, 70.26, 70.01, 69.27, 68.76, 68.64, 67.61, 66.40, 66.28, 62.93, 54.24, 39.47, 36.40, 
28.46, 28.35, 25.91, 25.02. 
 
 
 
 
 
 
 
 
 
 
 
Appendix                                                                                                                          
 
 
171 
A 2.2.11 Selective N-Sulfation  
 
Synthesis of Target Dendrimer (Den T) 
 
 
 
 
 
Starting material 22 was dissolved in 2.5ml H2O. Treated with sodium carbonate (0.0346 g, 
0.326 mmol) and sulfur trioxide-triethylamine complex  (0.0346 g, 0.181 mmol). The reaction 
mixture was stirred at RT over night. The volume was then reduced volume and poured on top 
of Silica Column and purified with acetonitrile : water : ammonia , 8:1→ 6:2:1. NMR showed 
mixture of 2 products in anomeric region. All fractions were re-collected and subjected to the 
reaction again over night using 7 equivalents per amine group. TLC (acetonitrile:water: aq 
ammonia, 4:2:1.2) Rf = 0.62. 1H NMR (500 MHz, D2O) δ 5.31 (d, J = 3.2 Hz, 4H, gH1, 65%), 
5.20 (s, 4H, iH1, 65%), 5.11 (2.6, iH1, 35 %), 5.04 (d, 2 H), 4.52 (t, J = 14.8 Hz, 3H, iH5), 4.37 
(t, J = 9.6 Hz, 4H), 4.27-4.10 (m, 32H, iH2, iH3), 4.04 (bs, 8H, iH4), 3.78-3.56 (m, 20H, gH3, 
gH4, gH5, gH6), 3.42-3.31 (m, 4H), 3.29-3.23 (gH1), 3.19 (bs, 8H), 3.07 – 3.03 (m, 4H,), 2.98 (t, 
J = 6.8 Hz, 4H), 2.70 (s, 8H), 2.51 – 2.41 (m, 4H), 1.66 – 1.48 (m, 24H), 1.40 – 1.30 (m, 9H). 
13C NMR (126 MHz, D2O) δ 175.00, 174.07, 98.21 (iC1), 97.31 (gC1), 97.009 (g2), 75.39 (iC4), 
74.40 (iC2), 69.96 (gC3), 69.89 (gC6), 69.57 (gC4), 69.29 (gC5), 68.79 (CH2), 68.57, 67.64, 
67.42 (iC3), 67.15 (iC5), 66.64, 66.46, 61.54, 61.42, 57.84, 55.71 (gC2), 55.38, 52.36, 51.12, 
49.33, 48.68, 45.31, 45.02, 43.33, 39.48, 36.46, 29.01, 28.90, 28.50, 28.44, 25.96, 25.30, 
25.04, 24.07. 
Appendix                                                                                                                          
 
 
172 
 
 
 
 
Appendix                                                                                                                          
 
 
173 
 
 
 
 
 
Appendix                                                                                                                          
 
 
174 
 
 
 
 
Appendix                                                                                                                          
 
 
175 
 
 
 
 
Appendix                                                                                                                          
 
 
176 
 
 
 
 
Appendix                                                                                                                          
 
 
177 
 
 
 
 
 
Appendix                                                                                                                          
 
 
178 
 
 
 
 
Appendix                                                                                                                          
 
 
179 
 
 
 
 
 
Appendix                                                                                                                          
 
 
180 
 
 
 
 
 
Appendix                                                                                                                          
 
 
181 
 
 
 
 
 
Appendix                                                                                                                          
 
 
182 
 
 
 
